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Putting on the spectacles of science  
in expectation of finding an answer to everything looked at  
signifies inner blindness. 
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In the 1930’s Ernst Klenk discovered new cell membrane elements in the brain of a 
patient who died from Tay-Sachs disease, a disorder characterized by progressive loss 
of mental abilities that already start at very young age. First Klenk called the elements 
substance X, but later, when he noticed that it concerned a mixture of compounds, he 
changed it into “gangliosides”, believing that they were preferentially localized in the 
ganglia of the brain (Klenk, 1942; Debuch, 1973). Despite the enthusiasm of several 
scientists, it was not before 1963 that the biochemical structure of the first ganglioside 
was elucidated. When the whole family of gangliosides became known, proper 
naming for every separate ganglioside was needed. Therefore in 1964 a nomenclature 
for the different gangliosides was proposed by Lars Svennerholm in the Journal of 
Lipid Research and this is still used today (Svennerholm, 1964). In 1994 a Nobel 
symposium was organized, devoted to gangliosides only. Nowadays not only the 
structures of this diverse class of lipids are known, but also different kinds of 
transgenic mice exist for research objectives, lacking particular combinations of 
gangliosides. Despite the knowledge of the molecular properties of the different 
gangliosides, the biological function of these components, which are mainly present in 
neural membranes (and especially enriched in presynaptic membranes), remain 
obscure. They appear to play a role in many physiological functions, but the 
underlying molecular mechanisms still need to be elucidated. Next to their somewhat 
mysterious physiological functions, gangliosides are involved in the pathophysiology 
of several neurological disorders. They appear to be the initial targets of anti-
ganglioside antibodies in autoimmune diseases like Guillain-Barré syndrome and 
Miller Fisher syndrome, and also play an important role as receptors for a number of 
neurotoxins. This thesis deals with the role of gangliosides and anti-ganglioside 
































The plasma membrane is an external, limiting bilayer between the cell and its 
environment, consisting mostly of lipids and proteins. There are three main classes of 
lipids in cell membranes: glycerol-lipids (e.g. phospholipids), sphingolipids, and 
sterols (e.g. cholesterol) (Breckenbridge et al., 1972). One subgroup of the (glyco) 
sphingolipids is formed by the gangliosides. These are amphipathic compounds 
composed of both sugar and lipid (ceramide) moieties, the latter of which consists of a 
fatty acid and a sphingoid base. Gangliosides have at least 3 sugar molecules, one of 
which must be a sialic acid: N-acetylneuraminic acid (NeuAc) or less commonly N-
glycoloyl-neuraminic acid (NeuGc)
*
, or a NeuAc analogue in which the amine group 
is replaced by OH. The negatively charged sialic acid is the sugar that differentiates 
gangliosides from neutral glycosphingolipids and sulfatides. The structural formula of 









































Figure 1.1. Structure of ganglioside GM2 
 
Gangliosides are located primarily in the outer leaflet of plasma membranes with the 
hydrophobic ceramide inserted into the lipid bilayer and the hydrophilic headgroup 
consisting of neutral sugar molecules and sialic acids protruding into the extracellular 
space (Figure 1.2). In addition, a small proportion of the gangliosides is localized in 
the mitochondria and the endoplasmatic reticulum inside the cell. Gangliosides are 
present in most cell types, but are especially abundant in nerve cells; they comprise up 
to 15% of the total amount of lipid in the vertebrate nervous system (d’Azzo et al., 
2006) and are enriched in presynaptic membranes (Ledeen et al., 1993). 
                                                 
 
* Among mammals, the human species is very unique for the lack of NeuGc in any normal tissue. It is 







Furthermore, gangliosides can also occur in a non-cell associated state in blood 
plasma and the cerebrospinal fluid and a constant exchange between free and 






Figure 1.2. Schematic overview of gangliosides inserted in the phospholipid bilayer of the cell membrane. The 




The biosynthesis of all sphingolipids starts in the endoplasmatic reticulum and 
continues in the Golgi apparatus. Ceramide is the precursor of the sphingolipids. A 
crucial (as well as rate limiting) step in biosynthesis of sphingolipids is its transport 
from the endoplasmatic reticulum to the Golgi apparatus with the aid of the transfer 
protein CERT (Kumagai et al., 2005; Morales et al., 2007). Glycosylation reactions
*
 
take place in the Golgi apparatus and after synthesis is completed, the gangliosides (as 
well as the other glycosphingolipids) reach their final destination in the cell 
membrane through vesicular exocytotic membrane flow (Kolter and Sandhoff, 2006). 
They are inserted in the outer leaflet of the plasma membrane.  
The biosynthesis of the heterogenous family of gangliosides is a stepwise process 
starting with ceramide as core lipid (Figure 1.3). Through addition of 
acetylgalactosamine, galactose, and sialic acid moieties, the different gangliosides are 
formed. These additions are catalyzed by highly specific membrane-bound 
glycosyltransferases. The synthesis of lactosylceramide (LacCer) and the simplest 
gangliosides GM3, GD3 and GT3 occurs in a compartment more proximal in the 
Golgi apparatus than the one in which the synthesis of the complex gangliosides (e.g. 
GM2, GD2 and GD1b) is carried out (Maccioni, 2007; Giraudo and Maccioni, 2003).  
 
                                                 
 





























































Figure 1.3. Simplified scheme of the ganglioside stepwise biosynthesis. Arrows point in the direction of the 
sequential step in the synthesis.  
 
 
Besides anabolic processes, gangliosides also undergo catabolic processes involving a 
number of lysosomal hydrolases (Kolter and Sandhoff, 2005). Together, these 
activities are responsible for the expression of a single ganglioside species. Disruption 
of ganglioside metabolism is associated with several neurodegenerative disorders that 
can be lethal. Gangliosidoses (lysosomal storage disorders) are caused by impaired 
catabolism due to a genetic mutation in a degrading enzyme (Brunetti-Pierri and 
Scaglia, 2008; Paw et al., 1989; Kolter and Sandhoff, 1998; Kolter and Sandhoff, 
2006; Buccoliero et al., 2004) and in Huntington’s disease an imbalance in 
ganglioside metabolism is thought to be a pathological factor (Desplats et al., 2007). 
Infantile-onset symptomatic epilepsy syndrome is the first described disease in the 
anabolic pathway of gangliosides. It is caused by a loss-of-function mutation in 
GM3synthase (Simpson et al., 2004). Ganglioside compositions in the cell 
membranes can differ between animal species, even within the mammalian group 
(Saito and Sugiyama, 2001). 
 
Function  
In addition to their role as surface markers in the outer leaflet of cell membranes, 
gangliosides are thought to have multiple other biological functions. As gangliosides 
carry one or more negative charges in their headgroup, they can contribute 
significantly to the surface charge of the cell. Gangliosides can therefore modulate 
ion-interactions of proteins, in particular with protons and Ca
2+
-ions, and can affect 
functioning of voltage-gated ion-channels in the membrane (Wang et al., 1999a; 
Wang et al., 1999b; Wang et al., 1996; Slomiany et al., 1992; Hayashi et al., 1984; 
Duan et al., 2006; Tanaka et al., 1997).  
In general, gangliosides play a role in both inter- and intracellular signalling processes 
(Allende and Proia, 2002; Buccoliero and Futerman, 2003; Hashiramoto et al., 2006; 









homeostasis (Ledeen and Wu, 2006a; Ledeen and Wu, 2006b; Ginzburg et al., 2008).
 
Wu and colleagues (2004) showed an impaired regulation of Ca
2+
 in cultured 
cerebellar granule neurons from mice that only express gangliosides GM3 and GD3. 
In the presence of a depolarizing concentration K
+
, these cells showed persistent 
elevation of intracellular Ca
2+ 
leading to apoptosis and cell destruction. Gangliosides 
also play a role in the immune system (inhibition of cellular immune responses), 
temperature adaptation (Kappel et al., 2000), cell maintenance and repair, and 
apoptosis (Hakomori, 2002; d’Azzo et al., 2006; Malisan and Testi, 2002). It was for 
example found that GM3 act as a modulator of neuronal cell death, and that 
accumulation of GD3 can alter mitochondrial function and thereby induce cell death 
in a caspase-dependent manner (Sohn et al., 2006; De Maria et al., 1997; Morales et 
al., 2007).  
More specialized roles for gangliosides are amyloid β protein binding (which is a key 
pathological hallmark in Alzheimer’s disease (Lin et al., 2008; Peters et al., 2009))
 
and spermatogenesis and testosterone transport (Sandhoff et al., 2005). Furthermore, 
gangliosides can act as receptors for viruses, bacterial toxins (e.g. GM1 for cholera 
toxin and GQ1b for botulinum toxin) (Baldwin et al., 2007; Kozaki et al., 1998; Wu et 
al., 2007; Hansson et al., 1977; Fishman, 1982), and mammalian adhesion molecules, 
and have also been thought to be the autoimmune targets in immune-mediated 
neuropathies (e.g. the Guillain-Barré syndrome, see below). They also play a role in 
tumor growth (Choi et al., 2008; Hettmer et al., 2005), diabetes (especially the C-
series gangliosides) (Saito et al., 1999; Gillard et al., 1989)
 
and neurodegenerative 
diseases (Saito et al., 2007; Barrier et al., 2007, Lin et al., 2008).  
Since gangliosides are so abundant in neuronal tissue, they are believed to be 
important factors in neuron-specific functions. For example it was found that external 
addition of GQ1b to the rat brain improved spatial learning and memory of the 
animal, possibly by modulation of NMDA receptors in hippocampal neurons (Jung et 
al., 2008). Ganglioside compositions change during life span (Svennerholm et al., 
1997; Ngamukote et al., 2007), therefore gangliosides are thought to play a role in 
neural development, brain maturation and (at later age) maintenance and regeneration 
(Itoh et al., 2001; Wu et al., 2007; Desplats et al., 2007; Yamashita et al., 2005; 
Lehmann et al., 2007; Valaperta et al., 2007; Susuki et al., 2007b; Izumi et al., 1993). 
The gangliosides GM3 and GD3 were found to be relatively abundant in the early 
embryonic brain but decrease rapidly in later stages (Ngamukote et al., 2007). The 
function of this variable ganglioside expression during embryogenesis is quite elusive, 
as it was also found that mice with a cell-specific deletion for the Ugcg gene in the 
brain, thereby not expressing any gangliosides (and their precursors) in the brain, do 
not develop neural defects till after birth. These mice are born indistinguishable from 
their wildtype littermates, which at least suggests that gangliosides are not essential 
during embryonic ontogenesis of the nervous system (Jenneman et al., 2005). GD3 
though, is thought to be a modulator of the ageing process, as its expression was 
found to increase again during the process of normal ageing (Malisan and Testi, 
2002). And experimental results showed that ganglioside 9-O-acetyl GD3
*
 is re-
expressed during periods of regeneration after a sciatic nerve axon had been crushed 
(Ribeiro-Resende et al., 2007). Gangliosides are also known to be receptors for 
myelin-associated glycoprotein (MAG), an enhancer of axon-myelin stability, but also 
                                                 
 
* 9-O-Acetyl GD3 is a derivative of GD3 with an acetyl group attached to position 9 of the terminal 







a potent inhibitor of axonal regeneration (after injury) (Yang et al., 1996; Cao et al., 
2007; Vyas et al., 2002). Especially GT1b, GD1a and GQ1bα appear to be potent 
support molecules for MAG, while GD3 does not bind (Yang et al., 1996; Schnaar 
and Lopez, 2009).  
In addition to age-dependent change of ganglioside compositions, differences in 
ganglioside expression can also be found at different sites in the body (Gong et al., 
2002). For example, GQ1b gangliosides are especially abundant in the ocular nerves 
while GM1 is more expressed in the ventral than in the dorsal roots, and GT1a more 
in the lower than the upper cranial nerves (Hughes and Cornblath, 2005).  
Furthermore gangliosides show subcellular concentration in lipid rafts in the 
membrane, also called microdomains. These are small regions enriched in cholesterol 
and sphingolipids that exhibit compartmentalized cellular processes (Asano et al., 
2009; Sonnino et al., 2007; Crespo et al., 2004; Prinetti et al., 2009; Hakomori, 2002; 
Fujita et al., 2007). Within lipid rafts in the presynaptic membrane, important proteins 
of the neurotransmitter release machinery co-localize with gangliosides (Salaün et al., 
2004; Lang et al., 2001; Taverna et al., 2004), which implies that gangliosides 
participate in neurotransmitter exocytosis. Several studies have shown that application 
of exogenous gangliosides indeed influences synaptic transmission; e.g. in brain slice 
preparations the addition of GM1 or GQ1b was found to enhance nerve potentiation 
(Ramirez et al., 1990; Egorushkina et al., 1993; Wieraszko and Seifert, 1985; Furuse 
et al., 1998) and a change in ganglioside pattern through reduction of bound sialic 
acids, resulted in a decrease of cholinergic transmission efficiency, i.e. abolishment of 
evoked potentials (Wieraszko and Seifert, 1984). Tanaka and colleagues (1997) 
showed that bath-applied GM1 and GQ1b increase K
+
-evoked neurotransmitter 





-ions are important players in the process of neurotransmitter 
release and in addition to Ca
2+
 channel modulation gangliosides are also able to 
directly bind these ions (Rahmann et al., 1992). These in vitro results suggest a 
modulating role in neurotransmitter release. The synthesis and levels of the 
neurotransmitter itself however, were not found to be affected by exogenous 





Structure and function 
Motor neurons in the brain stem and the spinal cord give rise to axons that branch 
intramuscularly to provide peripheral single nerve terminals at each muscle fibre. The 
motor neuron and the muscle fibres it innervates together form a motor unit (Figure 
1.4). A muscle fibre can be innervated by one motor neuron only, except for the 
extraocular muscle fibres, which can be innervated by axons from multiple motor 
neurons. The neuromuscular junction (NMJ) is a specialized chemical synapse where 
transmission of information takes place between the axon of a motor neuron and a 
skeletal muscle fibre. A very short distance separating the motor nerve from the 
striated muscle characterizes the place where transmission of the impulse from nerve 
to muscle can occur. The presynaptic and postsynaptic membranes remain separated 







by the non-myelinating terminal Schwann cells (Sanes and Lichtman, 1999). The 




Figure 1.4. Scanning electron micrograph of two NMJs in the sternothyroid muscle of the Chinese hamster  
The intramuscular nerve produces side branches, which terminate in motor end-plates on the muscle nerve surface. 
Picture is used with approval of Dr. Desaki.  
 
 
The NMJ contains many highly specialized sites, both pre- and postsynaptic, that are 
differentiated for organisation and mediation of neurotransmission. In vertebrate 
NMJs the neurotransmitter is acetylcholine (ACh), which is synthesized in the cytosol 
of the nerve endings from acetyl coenzyme A and choline by the enzyme choline 
acetyltransferase. A single nerve terminal has approximately 200,000 synaptic 
vesicles, each containing ACh. Under controlled conditions fusion of these vesicles 
with the presynaptic membrane results in transmitter release into the synaptic cleft. 
The released transmitter diffuses in about 0.5 ms across the extracellular synaptic 
space and binds to nicotinic ACh receptors (nAChRs) on the postsynaptic cell. After 
activation of the nAChRs the neurotransmitter is catabolized by acetylcholinesterase 
in the extracellular synaptic space.  
 
The arrangement of synaptic vesicles in the nerve terminal constitutes at least two 
different pools: a readily releasable pool (RRP) near the actives zones and storage 
pools more upstream in the nerve terminal. At rest, the RRP contains about 20% of 
the vesicles present in the nerve terminal (Richards et al., 2003; Petrov et al., 2008). 
Prior to exocytosis a process called docking takes place, when the synaptic vesicles 
move into active zones extremely close to the membrane. This is followed by 
priming: the formation of the so-called SNARE complex, which includes 
synaptobrevin at the vesicle membrane, and SNAP25 and syntaxin at the cell 
membrane. Also located in the active zones are the voltage-gated Ca
2+









 channel in the mammalian NMJs is the P/Q-type or Cav2.1-type 
channel (Urbano et al., 2008)), mediating calcium influx in response to a presynaptic 
impulse. By binding to synaptotagmin, which is a synaptic vesicle surface protein, 
calcium stimulates the formation of a fusion pore between a vesicle and the 
presynaptic membrane, leading to the release of neurotransmitter into the synaptic 
cleft (Hua et al., 2007; Figure 1.5). After the fusion event has taken place, new 
synaptic vesicles are formed by endocytosis and they are refilled with 
neurotransmitter in the nerve terminal. This constant turnover of vesicles requires 
energy which is provided by the numerous mitochondria present in the nerve terminal 

















Figure 1.5. Neurotransmitter release at the motor nerve terminal 
 
The postsynaptic membrane is specialized to respond adequately to the released 
neurotransmitter. It contains a high concentration of nAChRs, which are ligand-gated 
ion channels. They predominantly accumulate at the endplates where lipid rafts play 
an important role in regulating AChR clustering. The clustering is, amongst others, 
agrin, muscle-specific kinase, and rapsyn dependent (Zhu et al., 2006; Lin et al., 2001; 




 channel. When activated through binding 
of ACh it opens and allows for a relative large influx of Na
+
-ions and a smaller flow 
outwards of K
+
-ions, the net influx of positivity leading to a depolarization of the 
muscle membrane. These changes in electric properties of the membrane are termed 
"end plate potential" (EPP). If the EPP is sufficiently large, a muscle fibre action 
potential is triggered by opening of the voltage-gated Na
+
 channels, leading to 
contraction of the muscle. The total charge of an EPP required to produce an action 
potential, has to overcome a threshold value. During normal activity the released 
amount of neurotransmitter is abundantly greater than the required threshold, which 
allows a safety margin for more stressful situations and ensures the NMJ to be a very 








Electrophysiological NMJ Analysis  
The nAChR opening-induced changes in postsynaptic muscle cell membrane potential 
can be measured in vitro with intracellular recordings using a microelectrode (Figure 
1.6). A miniature endplate potential (MEPP) represents the release of a single vesicle 
of neurotransmitter from the presynaptic nerve terminal into the synaptic cleft, 
resulting in the depolarization of the postsynaptic muscle membrane by about 1 mV. 
MEPPs appear spontaneously with a frequency of ~1 per second in the mouse 
diaphragm muscle. The amount of neurotransmitter in a vesicle constitutes a basic 
unit, called a quantum (about 6,000 to 10,000 molecules of ACh). A second type of 
depolarization is the endplate potential (EPP), which represents the release of ACh of 
several vesicles upon stimulation of the nerve, and is actually a summation of the 
released MEPPs that would have been induced by the individual quanta. Features of 
both MEPP and EPP can vary, depending on several factors like species, muscle type 
and age. Example traces are shown in Figure 1.6. The amplitudes of EPPs and MEPPs 
can be used to calculate the amount of quanta that is released upon a single 
stimulation of the nerve, the quantal content (QC). To calculate the QC at each NMJ 
the following formulas are used: 
 
First the amplitudes are adjusted to a standard resting potential of -75 mV: 
(M)EPPn = (M)EPP m * ((Vstd – V ACh) / Vm ) 
(M)EPPn: normalized amplitude  
(M)EPPm: the amplitude as measured  
Vstd: the standard resting membrane potential (-75 mV by choice)  
VACh: the reversal potential for the ACh induced current, which is 0 mV at the NMJ, 
according to Magleby and Stevens (1972). 
Vm: the resting membrane potential as measured 
 
The McLachlan and Martin (1981) equation is then used to correct for the non-linear 
summation (i.e. the non-linear relationship between endplate current and potential as a 
result of a reduced driving force when additional depolarization is added due to AChR 
openings by release of additional ACh quanta):  
EPPc = EPPn / (1- (0.8 * EPPn / Vstd))   
EPPc: calculated EPP amplitude 
EPPn: normalized EPP amplitude 
0.8 is a factor dependent on the duration of transmitter action relative to the 
membrane time constant (McLachlan and Martin, 1980). This number accounts for 
mice muscle only (e.g. for frogs it’s 0.55).  
Vstd: 75mV is again chosen as the standard resting membrane potential  
 
Finally the QC can be calculated as: QC = EPPc / MEPPn 
 
The EPP would normally cause an action potential, causing the muscle fibre to 
contract. A selective skeletal muscle sodium channel blocker, μ-conotoxin GIIIB, can 
be used to eliminate muscle action potentials, which allows microelectrode 
measurement inside the muscle fibre. This toxin is a peptide isolated from the venom 





















Figure 1.6. Measurement at the NMJ  
Top scheme of motor endplate is adapted from O’Hanlon et al. (2002) and shows the micro-electrode (on the right) 
inserted into the muscle fibre. This way, alterations in the membrane potential of the muscle fibre can be recorded. 
These alterations are the result of ACh molecules that have been released from the motor nerve terminal 
(spontaneously or evoked) and bound to postsynaptic receptors. Below, examples traces of the three signals that 
can be measured at the NMJ are shown: The membrane potential baseline is -75 mV. Successful transmission 
results in a muscle action potential. When a selective muscle sodium channel blocker is applied (μ-conotoxin 
GIIIB), the action potential is reduced to an EPP. A MEPP is the result of the spontaneous release of a quantum 
ACh from a single vesicle of ACh.    
▲ Indicate moment of stimulation 
 
 
The dissected mouse diaphragm muscle with phrenic nerve attached is a most suitable 
preparation for muscle-nerve synapse analyses. It is a flat muscle that can be pinned 
out on a silicon rubber-lined base of a petri dish. It is only 10 fibres thick which 
makes it very accessible for the ~1 μm tip of the glass microelectrode. Furthermore 
the phrenic nerve is very well defined in the NMJ regions, which makes it easy to find 
the points of interest, and the nerve can be dissected over more than a centimetre, 
which is long enough to place it over a bipolar stimulation electrode.  
In addition to intracellular measurements it is also possible to visually assess the 
muscle nerve preparation and score twitching of the individual muscle fibres when the 










Ganglioside-mediated NMJ pathophysiology  
 
Toxins 
The NMJ, unlike most parts of the nervous system, is accessible to factors circulating 
in the blood. This can be a disadvantage when for example botulinum neurotoxin 
enters the body. This toxin is produced by Clostridia bacteria and can disable the 
exocytotic machinery at the motor nerve terminal through cleavage of one of the 
molecules involved in the SNARE-complex (each serotype of the toxin cleaves a 
specific protein). The cleavage results in blockage of the release of ACh from the 
motor nerve terminal and leads to paralysis of the muscle (Dolly and Aoki, 2006; 
Brunger and Rummel, 2009). It was already shown in the 1980’s that Clostridium 
botulinum neurotoxin interacts with gangliosides (Kitamura et al., 1980; Hayes, 1979) 
and later research indicated that this toxin enters the motor nerve terminal through 
receptor mediated endocytosis with gangliosides in the role of the receptor (Bullens et 
al., 2002; Yowler and Schengrund, 2004; Verderio et al., 2006). Also for tetanus toxin 
it is since long recognized that gangliosides act as a receptor (Halpern and Loftus, 
1993). This other member of the Clostridial neurotoxin family enters the NMJ and 
then travels to the spinal cord by retrograde axonal transport. Tetanus blocks the 
release of glycine or γ-aminobutyric acid from inhibitory neurons, which results in 
spastic paralyis (Middlebrook and Dorland, 1984; Brunger and Rummel, 2009).  
Another neurotoxin that has the NMJ as target site is α-latrotoxin (αLTx). αLTx is the 
active component of the Black Widow spider venom and can form non-selective pores 
within the nerve membrane. These pores allow free passage of ions and small 
molecules. Due to an increasing concentration of calcium inside the cell, massive 
uncontrolled exocytosis of neurotransmitter takes place. This massive quantal release 
of ACh can be measured as an enormous increase in MEPP frequency and is visible 
by twitching of the affected muscle fibres. As with the Clostridia bacteria toxins, 
αLTx finally leads to muscle paralysis (Hu et al., 2006; Peterson, 2006). 
 
Anti-ganglioside antibodies 
As described above, gangliosides are abundant in neuronal tissue and they are 
especially enriched at NMJs. In in vitro studies using mouse muscle-nerve 
preparations it was shown that murine monoclonal anti-ganglioside antibodies were 
able to bind presynaptic gangliosides at the NMJ (Paparounas et al., 1999; Plomp et 
al., 1999). It was reported that the events following the antibody-binding closely 
resembled the effects of αLTx, as an increase in MEPP frequency was observed. Also 
serum from patients with Miller Fisher syndrome (see below), which contains high 
titres of anti-GQ1b antibodies, was found to induce an increase in spontaneous ACh 
release when added to an ex vivo mouse diaphragm (Bullens et al., 2000; Jacobs et al., 
2002). As with the neurotoxin, the final result was a blockade of transmission and 
muscle paralysis, but in contrast to αLTx the antibodies depended on the activation of 
the complement cascade to achieve this. Complement depositions were found at 
NMJs of the mouse tissue preparations used in these incubation studies (Jacobs et al., 
2002; Goodyear et al., 1999; Plomp et al., 1999; Halstead et al., 2004; Goodfellow et 
al., 2005). And this complement-dependency was further confirmed in an ex vivo 
assay in the mouse NMJ, with complement component C5-deficient serum: the 
exogenous applied anti-ganglioside antibodies were not able to induce the αLTx-like 







first component of the membrane attack complex (MAC; C5b-C9), which is a pore 
forming molecule. 
Based on experimental studies in mice, the following neuropathophysiological 
mechanism has been suggested: the anti-ganglioside antibodies bind gangliosides in 
the presynaptic membrane, leading to induction of the innate immune response. The 
activated complement system culminates into the formation of MAC. This final 
component of the complement system is able to cause lysis of the nerve cell through 
the formation of pores in the membrane. Ca
2+
-ions can then freely move into the cell 
and trigger the release mechanism of ACh in an unregulated way. This finally results 
in an exhaustion of neurotransmitter in the distal end of the nerve and leads to 
impairment of communication between nerve and muscle (i.e. transmission block), 
which causes paralysis of the muscle (Rinaldi and Willison, 2008; Willison and 
Plomp, 2008). This pathological process and the involvement of complement in anti-
ganglioside antibody-mediated NMJ pathophysiology is extensively reviewed and 
discussed in chapter 3.1. 
In addition to complement-activation, other factors of the immune system can be 
activated by bound anti-ganglioside antibodies, e.g. T cells (Csurhes et al., 2005), or 
more in general leukocytes, can be recruited. This can lead to lymphocyte and 
macrophage infiltrations in and around the NMJ and contributes to inflammation of 
the nerve cell (Van Sorge et al., 2007a; Van Sorge et al., 2007b). On top of the 
destructing effects of anti-ganglioside antibodies to the nerve terminal, it is also 
shown that these antibodies can play an inhibiting role in axonal regeneration 
(Lehmann et al., 2007). This could indicate a limitation for recovery of injured axons.  
Several studies have claimed that anti-ganglioside antibodies were also able to inhibit 
voltage-dependent Ca
2+
-channels, as was observed in rat Purkinje cells (Nakatani et 
al., 2009), PC12 cells (Nakatani et al., 2007a; Nakatani et al., 2007b), and at mouse 
diaphragms NMJs (Buchwald et al., 2007; Ortiz et al., 2001). The effects were 
reversible, and it was therefore hypothesized that muscle weakness induced by anti-
ganglioside antibodies can be independent of complement-involvement and might be 
directly caused by a dysfunction of Ca
2+
-channels in the NMJ. This impaired impulse 
conduction leads to little structural change and has potential for rapid recovery. 
Another pathophysiological action of anti-ganglioside antibodies was found after a 
two week continued passive transfer of anti-GM2 IgM to mouse NMJs. Again no 
complement deposition could be observed, and no NMJ lesions or block of 
neurotransmission were encountered. But morphology showed nerve terminal growth 
and retraction changes, and with electrophysiology, a significant reduction in evoked 
neurotransmitter release was found (Santafé et al., 2005). These observations suggest 
that in addition to the complement-mediated nerve damage induced by anti-
ganglioside antibodies, other complement-independent actions of anti-ganglioside 
antibodies can also play a role in nerve-terminal pathophysiology (Santafé et al., 
2008).  
Furthermore, though outside the scope of this thesis, other molecules than 
gangliosides at the NMJ are also known to act as target sites in antibody-mediated 
autoimmune diseases. Examples are the postsynaptic AChRs (or muscle-specific 
tyrosine kinases) in myasthenia gravis (Gilhus, 2009), presynaptic voltage-gated Ca
2+
-
channels in Lambert-Eaton myasthenic syndrome (Motomura et al., 1997; Lennon et 
al., 1995), and presynaptic voltage-gated K
+
-channels in Isaac’s syndrome (Arimura 









Guillain-Barré syndrome and Miller Fisher syndrome 
 
Clinical symptoms 
In 1916 three French neurologists, Georges Guillain, Jean-Alexandre Barré, and 
André Strohl, reported two cases of acute areflexic paralysis in soldiers that 
spontaneously recovered. In addition to the clinical symptoms, laboratory findings 
showed increased protein concentration in the cerebrospinal fluid with a normal white 
blood cell count (Guillain et al., 1916). Although several clinical cases were already 
described in the 19
th
 century (Brody et al., 1994) and although it was Strohl who 
performed the electrophysiological tests on the soldiers, the combination of features 
became known as the Guillain-Barré syndrome (GBS) (Pritchard and Hughes, 2004).  
GBS is a post-infectious peripheral neuropathy that causes acute neuromuscular 
failure. GBS is recognized as a group of conditions with diverse pathology and 
pathogenesis, but all types present with (sub)acute neuropathy, defined as a 
progressive onset of limb weakness. This is self-limited and reaches its nadir within 
two to four weeks. In severe cases, paralysis involves the nerves feeding the 
brainstem, and patients may lose the ability to swallow or even breathe. Respiratory 
failure is the most severe complication of GBS, and mechanical ventilation is required 
in 20 to 30% of the patients (Durand et al., 2006). 
Although it is a disease with a self-limiting nature, it takes weeks to months to recover 
(partially) and there still is a considerable mortality (5-10%) from this disorder. The 
overall worldwide incidence of GBS is estimated at 1.1 to 1.8 per 100,000/year, with 
lower rates in children and an increase in incidence after the age of 50 (McGrogan et 
al., 2008). For The Netherlands this comes down to about 200 people per year that are 
diagnosed with GBS. Slightly more males are affected than females, which is unusual 
for an autoimmune disease. 
GBS has highly variable clinical forms, of which the incidences are not equally 
distributed geographically (Shafqat et al., 2006; Cheng et al., 2006; Willison and 
Yuki, 2002). There are at least five subtypes: 
 Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most 
common form of GBS in Western countries. The site of action appears to be the 
myelin sheath and the Schwann cells of sensory and motor nerves (Hafer-Macko 
et al., 1996a).  
 Acute motor axonal neuropathy (AMAN) is a pure motor form of GBS and occurs 
with higher frequency in elderly people (Leung, 2008). The site of action is the 
nerve axolemmal membrane (Hafer-Macko et al., 1996b). 
 Acute motor-sensory axonal neuropathy (AMSAN) is characterized by early 
axonal degeneration of both motor and sensory fibres. AMAN and AMSAN were 
first described in 1986 as one axonal variant of GBS by Feasby and colleagues 
(1986). 
 Recurrent GBS or chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP) is a chronic condition, distinguished from GBS by its temporal pattern and 
its potential for clinical relapse (Csurhes et al., 2005).
 
 Miller Fisher syndrome (MFS) is a related condition, commonly thought to be a 
variant of GBS. In contrast to the generalized and often severe limb, respiratory 
and axial weakness, and sensory loss that occur in the other subtypes of GBS, the 
manifestations of MFS are restricted to limb ataxia, tendon reflex loss, and 
extraocular muscle paralysis. MFS accounts for 5-10% of the GBS cases and has a 







It is unclear whether Bickerstaff’s brainstem encephalitis (BBE) is a distinct disease 
or a subtype of MFS (Paparounas, 2004). BBE is characterized by ataxia, 
opthalmoplegia, and disturbance of consciousness. Ito and colleagues (2008) postulate 
that BBE and MFS are not distinct from each other clinically, anatomically, or 
aetiologically, and therefore these two conditions represent the same autoimmune 
disease with variable involvement of the peripheral nervous system (PNS) and the 
central nervous system (CNS). Because of clinical and aetiological overlap, there are 
more conditions considered as subtypes of GBS, e.g. pharyngeal-cervical-brachial 
weakness and acute ophthalmoparesis (Willison and Yuki, 2002; Nagashima et al., 
2007; Tatsumoto et al., 2006; Manganelli et al., 2009; Notturno et al., 2008; Mori et 
al., 2001). 
GBS typically has a three phase course: the progressive phase delineates the onset of 
symptoms (pain, numbness, paraesthesia and/or weakness in the limbs) leading to a 
peak-illness within 2-4 weeks. This is followed by a variable steady plateau phase, 
after which the final phase of recovery starts (Hughes and Cornblath, 2005). In a 
study from Forsberg and colleagues (2008)
 
the experiences of patients during the 
initial phase of GBS were examined. The onset of the disease is characterized by a 
frightening rapid paralysis and deterioration of the body. Although the onset can be 
fast, the recovery tends to take several weeks to months, which means an extensive 
time of hospitalization, often followed by a further rehabilitation program. Patients 
therefore suffer severely, not only physically, but also mentally. In addition, it is 
reported that the long-term impact of GBS appears to reduce the quality of life, with 
persistent fatigue as one of the most disabling symptoms (Garssen et al., 2007; 
Rudolph et al., 2008; Rekand et al., 2009). 
 
Anti-ganglioside antibodies  
In about half of the GBS patients, elevated titres of anti-ganglioside antibodies are 
found in the acute phase serum and in MFS patients antibodies are found in even more 
than 90% of the cases (Lange et al., 2006; Willison et al., 1993; Van Doorn et al., 
2008; Hafer-Macko et al., 1996b). The antibodies found in MFS patients are mostly 
anti-GQ1b antibodies. For the other clinical variants of GBS it is not possible to 
match a certain antibody to a certain subtype, although there are some combinations 
that occur more frequently. AMAN for example is associated with anti-GD1a and 
anti-GM1 IgG antibodies (Lopez et al., 2008; Yuki, 2007a; Matà et al., 2006). Kaida 
and colleagues (2004b) found “antibody-negative” GBS sera that did react with the 
gangliosides GD1a and GD1b in a complex form, but not with either ganglioside 
alone. Gangliosides along with other components as cholesterol are known to form 
lipid rafts in cell membranes, in which the carbohydrate portions of two different 
gangliosides may form a new conformational epitope. Kaida also found that the 
presence of antibodies against GD1a/GD1b and/or GD1b/GT1b complexes was (on 
the short term) significantly associated with a severe course of the disease and a 
requirement for mechanical ventilation (Kaida et al., 2007). 
Clinical findings suggest that the concentration of particular gangliosides in the 
targeted membrane might determine the vulnerability to specific antibodies, as is 
clearly seen in MFS where predominantly the oculomotor nerves, which are rich in 
GQ1b gangliosides, are the most severely affected (Chiba et al., 1997; Chiba et al., 
1993). A related mechanism seems present in genetically manipulated mice that lack 
part of the ganglioside family, but over-express the remaining ones. They show 
increasing vulnerability for anti-ganglioside antibodies, with binding specificity to 







The anti-ganglioside antibodies are able to induce experimental pathogenic effects, as 
was described in the previous section, and therefore are likely to cause the clinical 
symptoms seen in GBS. It should be pointed out however that these antibodies are not 
found in all patients, so their pathogenic role remains somewhat speculative and it 
cannot completely be excluded that the presence of antibodies is a secondary 
phenomenon. On the other hand, also the presence of anti-ganglioside antibodies does 
not necessarily result in the development of GBS. This was found in rabbits that were 
passively immunized with anti-GM1 antibodies and only a subset of the animals 
developed AMAN (Van Sorge et al., 2007a). Also, some healthy human subjects may 
have anti-ganglioside antibodies in their plasma (Prendergast et al., 2004). 
 
Molecular mimicry 
About two third of the GBS patients, report an antecedent infectious disease, most of 
which are respiratory tract and gastrointestinal infections (Cheng et al., 2002; Yuki, 
2001). A preceding infection with Campylobacter jejuni or cytomegalovirus (CMV) 
can be linked to GBS and therefore molecular mimicry and a cross-reactive immune 
response are thought to play a crucial part in the pathogenesis of the disease (Yuki, 
1997; Taboada et al., 2007; Yuki, 2007a; Yuki, 2007b).  Molecular mimicry refers to 
a structural resemblance of host-tissue and pathogens, leading to a dual recognition by 
a T- or B-cell receptor, and is therefore one of the proposed initiating factors in GBS 
(Bach, 2005; Albert and Inman, 1999). The pathogens that are found in GBS patients 
are mostly C. jejuni (associated with anti-GM1 and (cross-reactive) GQ1b antibodies) 
and CMV (associated with anti-GM2 antibodies) (Winer et al., 1988; Furiya et al., 
2008). Furthermore, Mycoplasma pneumoniae, Haemophilus influenzae and Epstein-
Barr virus can be the culprit and there are also case studies that describe a possible 
association between Legionella pneumophila or Rickettsia prowazekii (causing 
typhus) and GBS (Akyildiz et al., 2008; Lee et al., 2008; Yu et al., 2006). For C. 
jejuni it has been established that it has lipopolysaccharides
*
 (LPS) epitopes that 
mimic certain gangliosides (Winer, 2008; Godschalk et al., 2007; Figure 1.7). Jacobs 
and colleagues (1996) showed an association with anti-GM1 antibodies in GBS 
patients and a preceding C. jejuni infection. Other studies (Moran et al., 2005; Ang et 
al., 2000) showed that the sera of rabbits that where immunized with GM1-mimicking 
C. jejuni lipooligosaccharides
†
 (LOS) contained high titres of anti-LOS antibodies that 
where able to bind gangliosides in the peripheral nerve. Similar results were obtained 
in mice immunized with GT1a/GD3-like C. jejuni LPS (Goodyear et al., 1999). Perera 
and colleagues (2007) demonstrated in mice that only the gangliosides mimicking 
molecules of C. jejuni, and no other microbial cell components were required for the 
production of anti-ganglioside antibodies. It was also shown that the sialic acid 
residues of the C. jejuni LOS are essential for the ganglioside mimicry induction of 
GBS. A wildtype C. jejuni strain lost its pathological activity (i.e. triggering GBS) 
after a mutation that erased this crucial epitope (Xiang et al., 2006). 
However, careful judgement is required because not all strains of the same pathogenic 
microbe can be linked to GBS (Godschalk et al., 2004) and the presence of a 
                                                 
 
* Lipopolysaccharides (LPS) are major components of most gram-negative bacterial outer membranes. 
They are composed of three regions: a lipid A component, a core of oligosaccharides, and an O-chain 
of repeating oligosaccharide units.  







molecular mimicry site, is not necessarily related to the development of GBS as 




Figure 1.7. Picture of identical structure GM1 and the outer core of C. jejuni LOS  
KDO: 3-deoxy-D-manno-2-octulosonic acid (picture is based on: Moran and Prendergast, 2001)  
 
 
A study by Nachamkin and colleagues (2008) showed the presence of components in 
influenza vaccines that can induce anti-GM1 antibodies in mice. Several studies have 
examined the risk of a GBS outbreak after immunization programs (Haber et al., 
2004; Lasky et al., 1998). However, no epidemiological evidence has been found for 
an increased vaccine-associated risk of GBS.  
 
Complement involvement 
The pathophysiological effects of anti-ganglioside antibodies are most likely to be 
complement-mediated, although some experimental results suggest complement-
independent effects as well (see previous section). In nerve biopsies of GBS patients 
complement depositions have been found (Hafer-Macko et al., 1996a; Hafer-Macko et 
al., 1996b) and it was reported that elevated levels of anti-GM1 ganglioside antibodies 
by themselves do not cause nerve damage (Ilyas and Chen, 2007). In vitro studies in 
mice muscle-nerve preparations showed that complement was needed to obtain a 
pathologic effect of the anti-ganglioside antibodies at the NMJ (Jacobs et al., 2002; 
Goodyear et al., 1999; Plomp et al., 1999; Halstead et al., 2004; Goodfellow et al., 
2005).  
The complement system is part of the innate immune response against pathogens 
(Walport, 2001; Kawano, 2000). The activation of complement encompasses a 
cascade of enzymatically stimulated actions which involve splicing and binding of 
components (Figure 1.8). There are three pathways in the complement system, which 
all culminate into the formation of component C5, which is (when cleaved into C5a 











Figure 1.8. Scheme of complement cascade  
The classical pathway is mainly activated by antibody-antigen binding. The lectin pathway starts with the binding 
of mannose-binding lectin (MBL) to carbohydrate surfaces and subsequent binding of MBL-associated serine 
proteases (MASPs). The alternative pathway is triggered by bacterial or viral surface components (for review see 
Walport, 2001).  
 
 
Each component of the cascade has an inflammatory or cytotoxic function. For 
example the anaphylactic fragments C3a and C5a recruit and activate phagocytes and 
C4b and C3b label targets for phagocyte uptake by binding to them. MAC is able to 
cause cell lysis by disrupting cell membrane integrity.  
It was found in mice muscle-nerve preparations that application of complement 
component C6-deficient serum following incubation with anti-ganglioside antibodies 
did not lead to neuropathophysiological damage. Although the complement system 
was initially triggered by the antibodies, the inability to create MAC protected the 
integrity of the membrane (Halstead et al., 2004). This further suggests that GBS is 
complement-mediated and that MAC is a necessary component for the proposed 
pathophysiological effects in this disease. Besides in GBS, the complement system is 
important in a number of other autoimmune and neurodegenerative diseases. 
Therefore, it is a very interesting target for therapeutics. Naturally occurring inhibitors 
are already present in the bloodstream and on cell membranes (the complement 
system is potentially very harmful and therefore it is extremely well-regulated) (Van 
Beek et al., 2005). Recently, many compounds have been discovered or developed for 
use as pharmacological complement inhibitor (Ricklin and Lambris, 2007). Chapters 







for their ability to block the neuropathophysiological effects of anti-ganglioside 
antibodies at the mouse NMJ.  
 
Genetic predisposition 
The reason why a certain pathogen can induce the development of an autoimmune 
disease still needs to be elucidated. For example, the number of infections with C. 
jejuni in The Netherlands is estimated at 100,000 per year (Havelaar, 2002), while 
less than 200 persons per year are diagnosed with GBS. This raises the question about 
a possible (genetic) predisposition of the host, or a specific feature of the C. jejuni 
strain. An example of the latter could be that cst-II polymorphism in C. jejuni is 
closely related to autoantibody reactivity as well as to the neurological presentation of 
GBS (Koga et al., 2005; Godschalk et al., 2007; Yuki, 2007b). And polymorphisms in 
host CD1E and CD1A genes
*
 were found to be associated with susceptibility to GBS 
in one study (Caporale et al., 2006), though this could not be confirmed in a larger 
study (Kuijf et al., 2008). In addition, the occurrence of GBS within families might 
also indicate a role for genetic predisposition factors (Geleijns et al., 2004). Thus, 
gene polymorphisms may be determinants of susceptibility for and severity of clinical 
neuropathies (Godschalk et al., 2004; Geleijns et al., 2007). 
 
Treatment 
Treatment of GBS consists of either intravenous administration of large amounts of 
human immunoglobulin (IVIg) or plasma exchange. Both treatments shorten the time 
of recovery and limit the peak symptoms (Lunn and Willison, 2009; Winer, 2008). 
They are equally efficient and IVIg treatment has become standard in the last few 
years (Van Doorn et al., 2008; Hughes et al., 2007). Around 10% of the patients still 
dies from respiratory failure, pulmonary emboli, or co-infection and around 20% has 
residual disability. Although the disease has an immunological aetiology, steroids are 
ineffective (which is unusual), and can even slow down recovery (Winer, 2008; 
Hughes et al., 2007). 
High-dose IVIg may have multiple sites of action, such as interference with T-cells 
and B-cells, cytokine inhibition, and neutralization and catabolism of (auto-) 
antibodies to gangliosides, thereby preventing complement activation and subsequent 
pathophysiological effects (Stangel and Pul, 2006; Jacobs et al., 2003). Plasma 
exchange may act by removing immune complexes, cytokines, complement, and 
autoantibodies from the patient’s plasma. Although both treatments ameliorate the 
symptoms and possibly shorten the time of recovery in most patients, these therapies 
are not perfect yet. Plasma exchange is a difficult procedure requiring specially 
trained staff and it is associated with adverse effects leading to discontinuation of the 
therapy in 10 – 14 % of cases in various trials (Shahar, 2006; Raphaël et al., 2002; 
Hughes et al., 2007). IVIg is a blood product from many donors (at least 1000) and 
carries the risk of containing unknown pathogenic factors. Also IVIg can lead to 
adverse effects during treatments, though in controlled trials less complications were 
found in patients treated with IVIg than in patients treated with plasma exchange 
(Hughes et al., 2006). Both therapies are extremely expensive, and therefore more 
effective, safer and cheaper therapies are required (Hughes et al., 2006; Hughes et al., 
2007).  
 
                                                 
 









Ganglioside knockout mice 
Genetically modified mice are powerful tools for investigating fundamental and 
neurophysiological roles of gangliosides. Several mouse models are engineered in 
which one or more of the ganglioside synthase genes are disrupted. This eliminates 
the gangliosides downstream in the biosynthesis pathway (Figure 1.9). The remaining 
ones are generally upregulated (Takamiya et al., 1996; Okada et al., 2002; Liu et al., 
1999). Therefore the total amount of gangliosides (at least in whole brain) in these 
knockout mice is at the same level as in their wildtype littermates (Kawai et al., 2001; 
Chiavegatto et al., 2000).  
In 1996 a first ganglioside null-mutant mice was generated, by deleting the gene for 
β1,4-N-acetylgalactosaminyltransferase (GalNAc-T or GM2synthase), which is an 
essential enzyme in the ganglioside biosynthesis. The GM2synthase-knockout 
(GM2s-KO) mice only express the simple series of gangliosides and lack all the 
complex gangliosides, since these are synthesized via the eliminated enzyme 
(Takamiya et al., 1996). Though males are infertile due to an impaired transportation 
of testosterone (Sandhoff et al., 2005), the mice otherwise seem healthy at young age. 
At older age however, neurodegenerative changes become apparent and mice display 
whole body tremor and catalepsy. They also show deficits in balance, reflexes, muscle 
strength and motor coordination and these functional impairments are of progressive 
nature (Chiavegatto et al., 2000; Ma et al., 2003; Sheikh et al., 1999; Sugiura et al., 
2005). Furthermore it was reported that the loss of complex gangliosides results in 
disrupted paranodal junctions near the nodes of Ranvier and in an impaired integrity 
of the axonal membrane (Susuki et al., 2007a). Although the pathological effects 
become more prominent with age, lifespan is normal (Takamiya et al., 1996).  
The b-and c-series gangliosides carry a pair of α2,8-linked sialic acids on the internal 
galactose of the gangliotetraosyl core. GD3synthase knockout (GD3s-KO) mice have 
a disrupted Siat8a gene which encodes for the enzyme (α2,8sialyltransferase) that is 
responsible for the addition of the second sialic acid. These knockout mice are only 
able to express the O- and a-series gangliosides. The mice are viable and both male 
and female are fertile. They display no apparent neurological phenotype. A role for b- 
and c-series gangliosides in neuronal repair mechanisms was suggested from axotomy 
studies where it was found that GD3s-KO mice had reduced regeneration of 
hypoglossal nerves (Handa et al., 2005; Okada et al., 2002).  
By crossbreeding the above mutants, GM2*GD3synthases double knockout (dKO) 
mice were created. These mice express only ganglioside GM3 and its precursors and, 
surprisingly, are still viable. Two independent lines have been published and both 
lines show a spontaneous adult lethal phenotype (Kawai et al., 2001; Inoue et al., 
2002). One strain is susceptible to lethal audiogenic seizures, which might explain this 
sudden death phenotype (Kawai et al., 2001). In the other strain, refractory skin 
lesions on the face were reported at or after 25 weeks of age. It was suggested to be 
the result of over-scratching due to a reduced sensory function (Inoue et al., 2002). 
Furthermore peripheral nerve degeneration was observed in relatively young mice 
(Inoue et al., 2002).  
Another mutant is the GM3synthase knockout mouse that only expresses the O-series 







abnormalities. They do show however a heightened sensitivity to insulin, and 
therefore need to be on a diet (Yamashita et al., 2003; Sandhoff et al., 2005). 
A second combination of gene disruption has lead to the GM2*GM3synthases double 
knockout mice, which are not able to express the ganglio-series at all. These mice 
express increased amounts of the biosynthetic precursor, lactosylceramide, and still 
express the three other glycosphingolipid series, i.e. the lacto-series, the neolacto-
series, and the globo-series. Mice are viable, but soon after birth neurodegeneration is 
observed and the mice develop hind limb weakness, ataxia, and tremors. These 
abnormalities become more severe with age and the maximal life span is only about 3 
months (Yamashita et al., 2005).   
Finally, also a mouse has been generated with a disrupted glucosylceramide synthase 
gene (Ugcg), which eliminates the major synthesis pathway of glycosphingolipids. So 
these mice do not just lack the gangliosides, but also their precursor lactosylceramide 
and all the other glycosphingolipid series as well. Homozygosity for this gene 
disruption is embryonically lethal, showing intense apoptosis in the ectodermal layer 
in gastrulation stage embryos, indicating indispensability of glycosphingolipids for 
embryonic development (Yamashita et al., 2002). Specific neuronal disruption of the 
Ugcg gene did not impair embryonic development. However, all mice died within 3 
weeks after birth from severe neurodegeneration. They had structural defects in the 
peripheral nerves and in the cerebellum. This indicates sphingolipid requirement for 
neural maturation and maintenance, and excludes a role for gangliosides in early 















































































Figure 1.9. Simplified biosynthetic scheme of the gangliosides and their precursors: the names in the 
grey squares represent key genes that can be knocked out to block synthesis downstream from that 
point (GalNAc-T: GM2synthase).  
 
For the experiments described in this thesis, only the first three types of mutant mice 
described above were used. In addition, through in vitro treatment of the nerve tissues 
with neuramindase (breaking down certain classes of gangliosides) or cholera toxin B-
subunit (blocking GM1 ganglioside) it was possible to even further manipulate the 









Animal models of GBS 
For GBS and its variants, so far no perfect in vivo animal model exist that mimics all 
features of the disease. However, there are some partial models for research (Meyer 
Zu Hörste et al., 2008). In 2001, a rabbit model for AMAN was established, in which 
GM1 or bovine brain ganglioside is subcutaneously administered for 2 to 3 weeks 
during which the animals develop limb weakness. The disease shows an acute onset 
and is monophasic. Wallerian degeneration without demyelination, together with 
macrophage recruitment to the axons and IgG deposition on root nerves are 
pathological findings in this model, consistent with human AMAN (Yuki et al., 2001; 
Susuki et al., 2003; Phongsisay et al., 2008; Susuki et al., 2007b). Experimental 
autoimmune neuritis (EAN) in rats is a preclinical model of AIDP. Rats are 
immunized with bovine proteins from PNS (e.g. myelin) in combination with 
complete Freund’s adjuvant. They develop severe motor deficits, associated with 
demyelination and neural degeneration. EAN is monophasic and indications for 
allodynia in the pre-onset phase were found, a feature which also can be seen in GBS 
patients (Mangano et al., 2008; Luongo et al., 2008; Sarkey et al., 2007; Cosi and 
Versino, 2006). 
Immunization of mice with anti-GD1a antibodies in combination with a sciatic nerve 
crush model was used to directly study ganglioside involvement in axonal 
regeneration, which may be an important recovery factor in GBS. The antibodies 
where found to inhibit regeneration (Lehmann et al., 2007). Furthermore, in rabbits it 
was found that C. jejuni LPS from GBS patients induced anti-GM1 IgG (Ang et al., 
2000). However, in both these mouse and rabbit models no clinical signs of GBS (i.e. 
paralysis) were observed. In chapter 6 a newly generated mouse model is described, in 
which mice were passively immunized with anti-GQ1b antibodies and received 
additional human complement through intraperitoneal injection. Acute-onset 
respiratory paralysis was observed in this model (Halstead et al., 2008). 
 
 
Aims and outlines of this thesis 
 
The first objective of this thesis was to characterize the contribution of specific 
ganglioside subsets compositions to neurotransmitter release at the NMJ; second, to 
further elucidate the pathophysiological role of anti-ganglioside antibodies at the 
NMJ; and third, to generate an in vivo mouse model for GBS and to study the 
therapeutic potency of (experimental) complement inhibitors.  
 
Chapters 2 and 3 focus on the physiological and the pathophysiological roles of 
gangliosides at the NMJ, respectively: 
 
Chapters 2.1 and 2.2 describe the studies into the roles of gangliosides in synaptic 
function at the NMJ in ganglioside-knockout mice. Chapter 2.1 focuses on the GD3s-
KO mouse, expressing only the O- and a-series gangliosides, as well as on the 
GM2*GD3s-dKO mouse, lacking all gangliosides except GM3. In chapter 2.2, 
synaptic transmission at NMJs of aged GM2s-KO and GD3s-KO mice is studied in 
detail. Old GM2s-KO mice develop motor coordination defects and the question 







Chapter 2.3 describes a study on the in vitro effect of neuraminidase treatment on 
NMJ function of the dKO mouse. Neuraminidase removes the sialic acid from the 
single ganglioside left (GM3), so that no gangliosides remain. This enabled us to 
study the effect of acute, total ganglioside absence on synaptic transmission. 
 
With our increasing knowledge of GBS and its clinical variants, the research now 
focuses on the involvement of the complement system in the neuropathophysiological 
features of the disease. Chapter 3.1 outlines the role of complement and complement 
mediators in motor nerve terminal injury. In chapters 3.2 and 3.3, the involvement of 
complement in GBS was used to explore new inhibiting therapeutics: a newly 
developed neuropathic in vivo mouse model for MFS was used to test a humanized 
monoclonal antibody and, furthermore, a tick saliva protein was tested in the in vitro 
model. Both compounds block the complement cascade at the level of C5. In our 
mouse models the tested therapeutics were able to prevent complement-mediated 
pathophysiological activities and thereby also prevented structural damage of the 
NMJ.  
In sera of part of the GBS patients, antibodies have been found which target a 
complex of two gangliosides, but not the individual species. In chapter 3.4 the ability 
of such sera to induce complement-mediated NMJ damage was explored.  
Anti-GM1 ganglioside antibodies show highly inconsistent abilities for binding at 
neuronal membranes and inducing pathogenic effects. This can be attributed to the 
fact that GM1 in the live membrane is cryptic for a proportion of the anti-GM1 
ganglioside antibodies due to a masking effect of neighbouring gangliosides. In 
chapter 3.5 it is explored how the level of complexity of ganglioside membrane 
topology accounts for inter-antibody variability in their experimental neuro-
pathophysiological effects. 
 








































Neuromuscular synaptic function in mice 
lacking major subsets of gangliosides 
 
 
Femke M.P. Zitman a,b, Boyan Todorov c,                   
Bart C. Jacobs d, Jan J. Verschuuren a, Keiko 
Furukawa e, Koichi Furukawa e, Hugh J. Willison f    





Departments of aNeurology and bMolecular Cell Biology – Group 
Neurophysiology, and cHuman Genetics, Leiden University Medical Centre, 
PO Box 9600, NL-2300 RC Leiden, The Netherlands. 
dDepartments of Neurology and Immunology, Erasmus MC, 's-Gravendijkwal 
230, 3015 CE Rotterdam, The Netherlands. 
eDepartment of Biochemistry II, Nagoya University Graduate School of 
Medicine, Nagoya, Japan. 
fDivison of Clinical Neurosciences, Glasgow Biomedical Research Centre, 













Gangliosides are a family of sialylated glycosphingolipids enriched in the outer leaflet 
of cell neuronal membranes, in particular at synapses. Therefore, they have been 
hypothesized to play a functional role in synaptic transmission. We have measured in 
detail the electrophysiological parameters of synaptic transmission at the 
neuromuscular junction (NMJ) ex vivo of a GD3synthase knockout mouse, expressing 
only the O- and a-series gangliosides, as well as of a GM2*GD3synthase double-
knockout (dKO) mouse, lacking all gangliosides except GM3. No major synaptic 
deficits were found in either null-mutant. However, some extra degree of rundown of 
acetylcholine release at high intensity use was present at the dKO NMJ and a 
temperature-specific increase in acetylcholine release at 35 C was observed in 
GD3synthase knockout NMJs, compared to wildtype. These results indicate that 
synaptic transmission at the NMJ is not crucially dependent on the particular presence 
of most ganglioside family members and remains largely intact in the sole presence of 
GM3 ganglioside. Rather, presynaptic gangliosides appear to play a modulating role 
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Neuronal membranes contain high levels of gangliosides (Ledeen, 1985), which are a 
diverse family of sialylated glycosphingolipids (Figure 2.1; Svennerholm, 1994; 
Ngamukote et al., 2007). Complex gangliosides GM1, GD1a, GD1b and GT1b are the 
major species in central and peripheral nervous tissue (Tettamanti et al., 1973; Gong 
et al., 2002). Simple gangliosides (e.g. GM3 and GD3) are relatively abundant in early 
embryonic brain but decrease rapidly in later stages (Ngamukote et al., 2007). 
Gangliosides are components of membrane lipid rafts and are thought to play roles in 
modulation of membrane-bound enzymes, ion-channel kinetics, cell-adhesion, 
neuritogenesis, cell-signaling and membrane stability and maintenance (Yates and 
Rampersaud, 1998; Hakomori, 2003; Hashiramoto et al., 2006; Sohn et al., 2006; 
Ledeen and Wu, 2006b; Sonnino et al., 2007; Susuki et al., 2007b; Wu et al., 2007). 
Importantly, gangliosides are involved in neurological disease. Anti-ganglioside 
antibodies have been shown in the Guillain-Barré syndrome (GBS) (Willison and 
Yuki, 2002; Ang et al., 2004), where anti-GM1 antibodies are mainly associated with 
motor variants of the disease and anti-GQ1b antibodies with the Miller Fisher 
syndrome variant (Willison and Yuki, 2002; Ang et al., 2004). Ganglioside 
metabolism is disturbed in an infantile epilepsy syndrome (Simpson et al., 2004), in 
Sandhoff’s disease (Liu et al., 1999), and possibly in Huntington's disease
 
(Desplats et 
al., 2007) and multiple sclerosis (Marconi et al., 2006). Gangliosides can also function 
as cell surface receptors for microbial toxins (Fishman, 1982; Bullens et al., 2002). 
Gangliosides contain negatively charged sialic acid residues that contribute to the 





homeostasis as well as voltage-gated ion-channel functioning. In addition, they 
influence membrane viscosity in a temperature-dependent way and thereby indirectly 
modulate ion-channel activities (Kappel et al., 2000). Gangliosides in the vicinity of 
ion-channels or -pumps may directly influence their kinetics and function (Wang et 
al., 1999a; Ledeen and Wu, 2006a). Furthermore, they may influence intracellular 
Ca
2+
 homeostasis (Wu et al., 2005). Recent functional studies using anti-ganglioside 
antibodies suggest a relationship between gangliosides and voltage-gated Ca
2+
 
channels (Ortiz et al., 2001; Santafé et al., 2005; Nakatani et al., 2007b). 
In the light of their known effects on ion-channels and their particular abundance in 
synaptic regions, gangliosides are thought to play a role in neurotransmitter release, 
which is critically dependent on presynaptic ion-channel function (Wieraszko and 
Seifert, 1985; Ramirez et al., 1990; Egorushkina et al., 1993; Takamiya et al., 1996; 
Tanaka et al., 1997; Furuse et al., 1998; Ando et al., 1998; Meir et al., 1999; 
Chiavegatto et al., 2000; Bullens et al., 2002; Hakomori, 2003; Proia, 2003). Several 
important proteins of the release machinery co-localize with gangliosides within lipid 
rafts (Chamberlain et al., 2001; Lang et al., 2001; Taverna et al., 2004; Salaün et al., 
2004). 
β1,4-GalNAc-transferase (EC 2.4.1.92) knockout (GM2s-KO) mice lack complex 
gangliosides (Figure 2.1; Takamiya et al., 1996; Sheikh et al., 1999) and develop 
sensory and motor coordination defects upon ageing (Chiavegatto et al., 2000; 
Sugiura et al., 2005). Previously we investigated synaptic transmission in young 
GM2s-KO mice at NMJs ex vivo (Bullens et al., 2002). Surprisingly, we found that 







temperature. However, reduced release was found at 17 C, suggesting that complex 
gangliosides are involved in temperature-stabilization of synaptic transmission. 
Two additional ganglioside-deficient mice have been generated: 1) a GD3synthase 
knockout (GD3s-KO) mouse (Okada et al., 2002), which lacks the gene coding for 
α2,8-sialyltransferase (EC 2.4.99.8) and only expresses the O- and a-series 
gangliosides and 2) a GM2*GD3synthase double knockout (dKO) mouse (Kawai et 
al., 2001; Inoue et al., 2002), which lacks the genes coding for both β1,4-GalNAc-
transferase and α2,8-sialyltransferase, thereby only expressing GM3 ganglioside 
(Figure 2.1). GD3s-KO mice are viable and fertile and show no overt phenotype, 
while dKO mice display sudden death starting from about 7-12 weeks of age. Here, 
we studied the roles of specific ganglioside subsets in neurotransmission by 






Figure 2.1. Synthesis of the ganglioside family  
Ganglioside nomenclature is according to Svennerholm (Svennerholm, 1994). Membranes of wildtype 
mice contain all the gangliosides. GD3s-KO mice lack the GD3s gene, which results in the absence of 
all the gangliosides within the dashed rectangle (b- and c-series). dKO mice lack both the GM2synthase 
(GalNAc-T) and the GD3synthase genes, leaving expression of only GM3 and its precursor 
lactosylceramide (LacCer), shown within the continuous rectangle. NeuAc: neuraminic acid (or sialic 
acid); GalNAc-T: N-acetylgalactosamine transferase; GD3s: GD3synthase. Arrows represent the 
stepwise biosynthesis through glycosyltransferases. 






Material and methods 
 
Mice 
We used male and female GD3s-KO mice (Okada et al., 2002) for experiments. To 
generate the dKO mice, homozygous female GM2s-KO mice (Takamiya et al., 1996) 
were crossbred with male homozygous GD3s-KO mice. Their double heterozygous 
progeny was then intercrossed to generate homozygous dKO mice. Genotyping was 
performed as described (Takamiya et al., 1996; Inoue et al., 2002). Male and female 
dKO mice were used in the experiments. Wildtype (WT) mice were used as controls. 
The mice were 6-13 weeks of age. Body weights of WT, GD3s-KO and dKO mice 
used were 20.3  1.0, 21.1  0.8 and 21.5  0.8 g, respectively. All animal 
experiments were carried out according to Dutch law and Leiden University 
guidelines and the USA National institute of Health recommendations for the humane 
use of animals. All efforts were made to minimize the number of animals used and 
their suffering. 
 
In vivo neuromuscular function tests 
The inverted screen hanging test was used to assess fatigability of limb muscles as 
described before (Kaja et al., 2007a). The test ended upon falling or completing the 
maximum hanging time which was set at 300 s.  
Muscle strength was assessed using a grip strength meter (type 303500, Technical and 
Scientific Equipment GmbH) and essentially performed as described (Kaja et al., 
2007a). As grip strength the peak force value was taken of a pull measured by the grip 
strength meter. Each trial consisted of at least 10 pullings and the averaged value was 
used for statistical analysis. Values were normalized to the body weights of mice. 
Respiratory rate and volume were assessed with non-invasive whole-body 
plethysmography (RM-80, Columbus Instruments). The signal was digitized using a 
Digidata 1440A interface (Axon Instruments/Molecular Devices) and analyzed with 
the event detection feature of Clampfit 9.2 (Axon Instruments/Molecular Devices). 
 
In vitro electrophysiology at the NMJ 
Mice were killed by CO2 asphyxiation. Left and right hemi-diaphragms were 
dissected with their phrenic nerve attached and mounted in standard Ringer’s medium 
(119 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, 23 mM 
NaHCO3, 11 mM glucose, pH 7.4) at room temperature, pre-gassed with 95% O2 / 5% 
CO2. 
Intracellular recordings of miniature endplate potentials (MEPPs) and endplate 
potentials (EPPs) in the NMJ were made using a glass micro-electrode (10-20 MΩ, 
filled with 3 M KCl) connected to a Geneclamp 500B (Axon Instruments/Molecular 
Devices) for amplifying and filtering (10 kHz low-pass) of the signal. The signal was 
digitized using a Digidata 1322A interface (Axon Instruments/Molecular Devices) 
and analyzed using Clampfit 9.2 (Axon Instruments/Molecular Devices) and Mini 
Analysis 6.0.3 (Synaptosoft). Muscle action potentials were eliminated by using the 
selectively skeletal muscle Na
+
 channel blocker, μ-conotoxin GIIIB (3 μM) (Scientific 
Marketing Associates). To record EPPs, the phrenic nerve was stimulated at multiple 
frequencies using a bipolar platinum electrode. The mean EPP and MEPP amplitudes 
at each NMJ were normalized to -75 mV, with the reversal potential for ACh-induced 
current assumed to be 0 mV (Magleby and Stevens, 1972). In order to calculate the 







rate (0.3 Hz) stimulation was corrected for non-linear summation (McLachlan and 
Martin, 1980) and the normalized and corrected mean EPP amplitude was divided by 
the normalized mean MEPP amplitude (calculated from at least 40 MEPPs sampled). 
The quantal content is the number of ACh quanta that is released upon a single nerve 
impulse.  
MEPPs were also recorded after addition of hypertonic medium (0.5 M sucrose 
Ringer's medium), in order to estimate the pool of ACh vesicles ready for immediate 
release (Stevens and Tsujimoto, 1995; Varoqueaux et al., 2005). In some experiments 
we tested the effect on EPPs and MEPPS of 200 nM of the Cav2.1 Ca
2+
 blocker ω-
agatoxin-IVA (Scientific Marketing Associates) and 10 µM of the Cav1 blocker 
nifedipine (Sigma-Aldrich). 
Temperature of the bath medium was controlled using a Peltier device placed around 
the recording bath and adjusted by varying the DC output of a power supply (Delta 
Elektronika). A miniature probe connected to a digital thermometer was used to 
monitor the temperature. Bath temperature was held at 24-26 °C, unless stated 
otherwise. 
Electrophysiological data are presented as group mean ± SEM of the mean muscle 
values calculated from the mean NMJ values. At least 10 NMJs were sampled per 
muscle per experimental condition. 
 
Statistical analysis 
Statistical differences between group means were analyzed with an unpaired Student’s 






In vivo neuromuscular tests 
Neuromuscular synapse dysfunction may lead to respiration difficulties that are 
detectable in whole-body plethysmography (Halstead et al., 2008). Upon such 
assessment we found in both the GD3s-KO and dKO mice a lower respiration rate 
than in WT mice (WT 424 ± 20; GD3s-KO 298 ± 10; dKO 307 ± 14 min
-1
; n=8-20 
mice, p<0.01; Figure 2.2A, C). The positive peak amplitude of the measured signal, 
reflecting tidal volume, was ~35% increased in dKO mice (WT 12.2 ± 0.7; GD3s-KO 
12.2 ± 0.4; dKO 16.4 ± 0.6 mV; p<0.01; Figure 2.2B, C). When the signals were 
normalized to body weight this difference became somewhat smaller but remained 
statistically significant (WT 0.65 ± 0.03; GD3s-KO 0.59 ± 0.02; dKO 0.77 ± 0.03 mV 
per g body weight; p<0.01 dKO vs. GD3 and p<0.05 dKO vs. WT). Figure 2.2C 
shows typical examples of respiration traces recorded. 
GD3s-KO mice showed no overt neuromuscular phenotype. In 6 of the 14 dKO mice 
used, however, we observed symptoms of weakness and/or uncoordinated movement 
(especially of hind legs). Although grip strength testing indicated normal muscle 
strength in dKO mice (~6 g/g body weight for each strain; p=0.30, n=7-20 mice; 
Figure 2.2D), they performed worse on the inverted mesh (hanging times: WT 300 ± 
0; GD3-KO 277 ± 16; dKO 178 ± 28 s; p<0.05, n=5-20 mice; Figure 2.2E). 
Symptomatic dKO mice had shorter (p<0.05) hanging times (111  39 s) than non-






symptomatic dKO mice (228  30 s), but did not differ from each other with respect 







Figure 2.2. In vivo assessment of neuromuscular functioning 
Mouse respiration was characterized with non-invasive plethysmography (n= 8-20). A. Respiration 
frequency was ~40% higher in WT mice than in the other two groups. B. The positive peak of the 
plethysmography signal (reflecting tidal volume) was ~35% higher in dKO mice, compared with WT 
and GD3s-KO. C. Typical examples of respiration traces recorded. D. Grip strength was averaged for 
ten trials and normalized to the body weights of the mice; all groups pulled ~6 g per gram bodyweight 
(n=7-20). E. Hanging times in the inverted screen test. A maximum hanging time of 300 s was chosen. 




Normal basic synaptic electrophysiology in GD3s-KO and dKO mice 
Spontaneous uniquantal transmitter release was measured at the diaphragm NMJ. No 
statistically significant differences were found between genotype groups in MEPP 
amplitude (~0.9 mV; p=0.43, Figure 2.3A, E) and MEPP frequency (~1.3 s
-1
; p=0.10, 
Figure 2.3B). The 0.3 Hz nerve stimulation-evoked transmitter release resulted in 







delay between nerve stimulus and start of the EPP was somewhat longer in dKO 
preparations (WT 1.74 ± 0.09; GD3s-KO 1.84 ± 0.05; dKO 2.16 ± 0.11 ms; p<0.05 
dKO vs. WT). Quantal content was calculated and appeared not statistically 
significantly different between groups although there was a tendency towards 
reduction in the dKO NMJ (WT 47.0 ± 2.7; GD3s-KO 46.1 ± 1.9; dKO 40.3 ± 1.0; 





Figure 2.3. Basic ACh release parameters at the NMJ 
Ex vivo electrophysiological measurements at NMJs of phrenic nerve-diaphragm preparations were 
performed at 24-26 °C in standard Ringer's medium. Each genotype group consisted of at least 5 mice. 
A. Uniquantal size measured as MEPP amplitude. B. Spontaneous uniquantal ACh release measured as 
MEPP frequency. C. EPP amplitude at 0.3 Hz stimulation. D. Calculated quantal content of EPP at 0.3 
Hz nerve stimulation. E. Typical examples of MEPP recordings. F. Typical examples of EPP 
recordings. No statistically significant differences between genotypes were observed. 






ACh release at the NMJ is almost completely mediated by Ca
2+
 flux through Cav2.1 
(P/Q-type) channels. We probed for compensatory contribution of non Cav2.1 
channels by determining the effect of 200  nM ω-agatoxin-IVA (Cav2.1 blocker) and 
10 µM nifedipine (Cav1 blocker) on 0.3 Hz evoked ACh release at both dKO and 
GD3s-KO NMJs. ω-Agatoxin readily reduced the quantal content by 95% at NMJs of 
both genotypes (from 28.4 ± 1.6 to 1.4 ± 0.3 in the dKO and from 44.1 ± 4.8 to 2.1 ± 
0.5 in the GD3s-KO; one hemi-diaphragm preparation each, 10-15 NMJs sampled per 
condition), indicating an almost complete dependence on Cav2.1, identical to the 
reductions we observe routinely at WT NMJs (Kaja et al., 2007a). This seems to rule 
out any compensatory contribution by other types of Cav channels. The Cav1 (L-type) 
channel blocker nifedipine was without effect on the quantal content measured at 
dKO and GD3s-KO NMJs, excluding compensation by Cav1 channels. The quantal 
content values were 29.9 ± 2.6 before and 31.3 ± 0.3 after nifedipine in the dKO and 
44.1 ± 4.8 before and 44.1 ± 4.1 after nifedipine in the GD3s-KO (one hemi-
diaphragm preparation each, 10-15 NMJs sampled per condition). 
 
No change in hypertonic shock-induced ACh release 
Hypertonic medium (0.5 M sucrose Ringer's) elevated MEPP frequencies to equal 
levels in the three genotype groups (~48 s
-1
; p=0.48, n=3-6; Figure 2.4). These results 
suggest an unchanged size of the readily releasable ACh vesicle pool at the NMJ of 









Figure 2.4. Hypertonic medium-evoked 
ACh release  
MEPP frequency in hypertonic medium (0.5 
mM sucrose Ringer's). No statistically 
significant differences between genotypes 




More pronounced ACh release rundown at dKO NMJs at high rate nerve 
stimulation 
Some effects of ganglioside composition on transmitter release may only come about 
at high intensity use of the synapse, stressing the exocytotic molecular machinery. 
We, therefore, measured EPPs during 1 s high-rate (40 Hz) nerve stimulation trains, 
which is the approximate physiological firing frequency. At dKO NMJs a modest but 
statistically highly significant increase in EPP rundown was observed, compared with 





expressed as percentage of the first EPP in the train) were: WT 81.2 ± 0.9; GD3s-KO 
83.0 ± 0.8; dKO 75.7 ± 0.8% (p<0.01, n=11-12 mice; Figure 2.5A). At 3 Hz no such 
difference was encountered. The rundown level in all groups was ~83% (p=0.15). In a 
separate experimental series on dKO NMJs we explored the behaviour of ACh release 







EPPs ran down to a 5-7% lower level than WT at all stimulation frequencies (p<0.01; 
Figure 2.5B). Examples of typical EPP rundown traces are shown in Figure 2.5C.  
 
Temperature-dependent changes in transmitter release parameters 
We explored a possible temperature-dependent functioning of gangliosides by 
performing synaptic electrophysiological measurements at 17, 20, 30, and 35 °C in a 
separate series of experiments (Figure 2.6). No major differences between GD3s-KO, 
dKO and WT NMJs in the temperature-dependency of synaptic transmission 
parameters (MEPP amplitude and frequency, EPP amplitude and quantal content) 
were observed within this temperature range, other than a somewhat increased MEPP 
amplitude at GD3s-KO NMJs at 17 C (~30%, p<0.05; Figure 2.6A) and an increase 
of quantal content in GD3s-KO NMJs (~40%, p<0.05), compared with WT, at 35 C 
(Figure 2.6D). The rundown of EPPs at 40 Hz stimulation at dKO NMJs was more 
pronounced than in GD3s-KO and WT, over the whole temperature range, although 
only statistically significantly at 25 C (as described above), 30 and 35 C test 
temperatures (p<0.05; Figure 2.6E). Because the extent of this extra EPP rundown 
was similar (~25%) at the several temperatures, it can be concluded that the three 
genotype groups show a similar temperature-dependency for this parameter. The 3 Hz 
EPP rundown at both dKO and GD3s-KO NMJs were not statistically significantly 
different from WT at all tested temperatures, although there was a tendency of 
increased rundown at dKO NMJs. At 17 and 30 C, 3 Hz EPP rundown at dKO NMJs 
was somewhat more pronounced than at GD3s-KO NMJs (p<0.05; Figure 2.6F). 
  
Influence of external Ca
2+
 concentrations on transmitter release 
Besides our basic measurements in 2 mM extracellular Ca
2+
, low (0.2 mM) as well as 
high (5 mM) Ca
2+
 extracellular medium was applied to explore the Ca
2+
-dependency 
of synaptic transmission in the GD3s-KO and dKO mice. MEPP amplitude was ~0.83 
mV for each strain at each Ca
2+
 concentration (Figure 2.7A). MEPP frequency (Figure 
2.7B), EPP amplitude (Figure 2.7C) and quantal content (Figure 2.7D) in WT NMJs 
were, as expected, steeply dependent on Ca
2+
. However, we observed no different 
values of these parameters at GD3s-KO and dKO NMJs, compared to WT, at all Ca
2+
 
concentrations, showing unaltered Ca
2+
-sensitivity of these parameters. As observed 
at 2 mM Ca
2+
, the 40 Hz EPP rundown level at dKO NMJs in the presence of 5 mM 
Ca
2+
 (71.3%) was lower than that in WT (79.8%) and GD3s-KO (78.4%) (Figure 
2.7E; p<0.01). At low Ca
2+
 and 40 Hz stimulation, WT EPPs were potentiated to a 
plateau level of ~150% of the first EPP. GD3s-KO and dKO NMJs showed similar 
EPP potentiation (p=0.83, Figure 2.7E). Example traces of the EPP profiles at 40 Hz  
stimulation at 0.2 mM Ca
2+
 are shown in Figure 2.7F. EPPs at dKO NMJs at 3 Hz 
stimulation at 5 mM Ca
2+
, but not at 0.2 and 2 mM, showed a slightly lower EPP 
rundown level (79.5%) than at WT (84.8%) and GD3s-KO (85.1%) NMJs (Figure 
2.7G, p<0.01). We assessed 25 ms paired-pulse facilitation by comparing the first and 
second EPP of 40 Hz trains, but found no statistically significant differences between 
GD3s-KO, dKO and WT NMJs at any of the Ca
2+
 concentrations tested (Figure 
2.7H). 
 









Figure 2.5. Evoked ACh release at high rate stimulation frequencies 
A. Mean EPP rundown profile at 40 Hz stimulation. Each EPP in the trains is expressed as percentage 
of the first EPP. dKO EPPs ran down more pronouncedly than WT and GD3s-KO EPPs (#p<0.01; 
n=11-12). B. Rundown level is expressed as the ratio of the mean amplitude of the plateau phase of the 
train (21st-35th EPP) and the amplitude of the first EPP and was measured at several stimulation 
frequencies for WT and dKO mice. dKO NMJs displayed lower rundown levels at all frequencies but 3 
Hz (**p<0.01, n=7-12). C. Typical traces of EPP amplitude rundown profiles at 40 and 70 Hz 












Figure 2.6. Temperature-dependency of ACh release parameters 
Electrophysiological measurement of ACh release at diaphragm NMJs at different bath temperatures. 
Each genotype group consisted of 4-6 mice. A. MEPP amplitude at GD3s-KO NMJs was higher than at 
WT and dKO NMJs at 17 °C. B. No statistically significant differences between genotypes in 
spontaneous ACh release measured as MEPP frequency at all temperatures. C. Differences between 
genotypes in evoked EPP amplitude at 0.3 Hz nerve stimulation were found only at 17 and 35 °C 
(##p<0.01 for GD3s-KO vs. dKO and *p<0.05 for WT vs. GD3s-KO, respectively). D. The quantal 
content at GD3s-KO NMJs was higher than WT, only at 35 C (*p<0.05). E. dKO mice have lower 
rundown levels than GD3s-KO and WT mice at >20 C. EPP rundown level is expressed as the ratio of 
the mean amplitude of the plateau phase of the train (21st-35th EPP) and the amplitude of the first EPP 
at 40 Hz stimulation (* p<0.05; ** p<0.01). F. dKO and GD3s-KO EPP rundown level at 3 Hz 
stimulation did not differ from WT at all measured temperatures. Between each other they differed in 
this parameter at 17 and 30 °C (#p<0.05). 
 











-dependency of ACh release parameters 
Electrophysiological measurement of ACh release at diaphragm NMJs at different extracellular Ca2+ 
concentrations. Each genotype group consisted of 4-6 mice. No differences between genotypes in Ca2+-
dependency were found for (A) MEPP amplitude, (B) spontaneous uniquantal ACh release, measured 
as MEPP frequency, (C) evoked EPP amplitude at 0.3 Hz nerve stimulation and (D) calculated quantal 
content of EPP at 0.3 Hz nerve stimulation. E. Rundown level of EPPs is expressed as the ratio of the 
mean amplitude of the plateau phase of the train (21st-35th EPP) and the amplitude of the first EPP at 40 
Hz stimulation. At 2 and 5 mM Ca2+ concentrations we found a lower rundown level at dKO NMJs, 
compared with WT and GD3s-KO NMJs. F. Typical examples of EPP profiles at 40 Hz stimulation in 
0.2 mM Ca2+ medium. G. EPP rundown level at 3 Hz stimulation shows a slight, but statistically 
significant, increase of the rundown at dKO NMJs at 5 mM Ca2+, compared with WT and GD3s-KO. 










We studied the effects of changed ganglioside profiles in neuronal membranes on 
synaptic transmission by characterizing NMJ function in GD3s-KO mice, lacking b- 
and c-series gangliosides, and in dKO mice, lacking all ganglioside types except GM3 
(Figure 2.1). However, we found no major synaptic deficits in both null-mutants. This 
is quite surprising, in view of studies suggesting a synaptic role for gangliosides on 
the basis of exogenous ganglioside application (Tanaka et al., 1997; Ando et al., 
1998), as well as the reported co-localization in lipid rafts of gangliosides and proteins 
important for neuroexocytosis (Chamberlain et al., 2001; Lang et al., 2001; Taverna et 
al., 2004; Salaün et al., 2004). The only changes we observed were some extra degree 
of rundown of transmitter release at high intensity use at the dKO NMJ and a 
temperature-specific increase in quantal content at 35 C in GD3s-KO NMJs, 
compared with WT. These results indicate that synaptic transmission at the NMJ is 
not crucially dependent on any particular ganglioside and remains largely intact in the 
sole presence of GM3 ganglioside. 
 
In vivo neuromuscular analysis 
We have performed some orienting in vivo characterization of neuromuscular function 
of the GD3s-KO and dKO mice. Previously we showed that severe paralysis of mouse 
diaphragm muscle leads to reduced respiration rate and tidal volume in whole-body 
plethysmography (Halstead et al., 2008). Although we here observed some reduction 
in respiration rate in both GD3s-KO and dKO mice, tidal volume was not reduced (in 
fact, there was ~35% increase in the dKO), making severe diaphragm paralysis highly 
unlikely. Therefore, these changes in respiration patterns probably have a central 
(possibly synaptic) origin. The reduced hanging time of dKO mice in the inverted 
mesh test is at least not due to initial forelimb muscle weakness because grip strength 
testing appeared normal. Although most likely due to central dysfunction, it cannot be 
excluded that the reduced inverted mesh performance has a fatigue component due to 
increased rundown of transmitter release at the NMJ (see below). 
 
Basic synaptic transmission 
In standard physiological medium at 25 C the variations in ganglioside composition 
at GD3s-KO and dKO NMJs did not seriously limit synaptic function. The rate of 
uniquantal ACh release, measured as MEPP frequency, was not different from the 
WT control NMJs. Uniquantal size, measured as MEPP amplitude, as well as the 
amount of ACh released upon 0.3 Hz nerve stimulation was similar in the three 
genotypes. These unchanged synaptic function parameters at GD3s-KO and dKO 
NMJs show that at 0.3 Hz stimulation there is a normal invasion of the nerve impulse 
into the presynaptic nerve ending and a normal translation of this depolarization into 







channels involved in these processes is not impeded by either the loss of b- and c-
series gangliosides or by the loss of all gangliosides except GM3. Some degree of ion-
channel dysfunction may be present in the dKO phrenic nerve, because we observed 
~25% longer delay between nerve stimulus and postsynaptic response in dKO 
preparations, compared with WT. Although we have not investigated whether this 
effect is either due to extra synaptic delay or to slower axonal action potential 
conduction, the observation that GM1 and GD1a are necessary for stability and ion-
channel composition of motor nerve nodes of Ranvier (Susuki et al., 2007b) favours 






the latter possibility. Our experiments with specific Cav2.1 and Cav1 Ca
2+
 channel 
blockers indicated no compensatory contribution by non-Cav2.1 Ca
2+
 channels to ACh 
release at both dKO and GD3s-KO NMJs. 
Previously we demonstrated a redundancy for the set of complex gangliosides (i.e. the 
gangliosides from all series with more than two non-sialic acid sugar residues; Figure 
2.1) by finding unaltered basic synaptic function at NMJs of GM2s-KO mice (Bullens 
et al., 2002). Our present results in dKO and GD3s-KO mice, in combination with this 
previous study, show that the sole presence of GM3 ganglioside is sufficient to 
support neurotransmitter release at the NMJ. GM3 is upregulated in dKO whole 
brains (Kawai et al., 2001) and such an accumulation may also take place at the 
presynaptic motoneuronal membrane, possibly enhancing compensatory effects of 
GM3 in supporting neurotransmitter release upon absence of all other types of 
gangliosides. Alternatively, gangliosides might not influence the function of ion-
channels and/or other membrane factors at mouse presynaptic nerve terminal at all. In 
other organisms, like Drosophila melanogaster, functional synapses exist in spite of 
the inability to produce gangliosides (Roth et al., 1992; Chen et al., 2007a). This 
shows that gangliosides are not a general prerequisite for synaptic function. However, 
such absence of a biological role for gangliosides in mammals is rather unlikely in 
view of the presence of such a highly organized ganglioside synthesis system and, 
furthermore, the demonstrated severe neurodegeneration in transgenic mice lacking 
all gangliosides including GM3 (Yamashita et al., 2005) and the severe neurological 
symptoms in human babies with loss-of-function mutated GM3synthase (Simpson et 
al., 2004). Therefore, it would be of interest to investigate synaptic transmission in 
GM3synthase null-mutant mice.  
 
Increased rundown of high-rate transmitter release at dKO synapses 
We observed a more pronounced rundown of high rate (30-70 Hz) nerve stimulation-
evoked ACh release at dKO NMJs (EPP rundown plateau levels, expressed as 
percentage of the first EPP in the trains, were ~6% lower than WT). In contrast, 
GD3s-KO NMJs showed a 40 Hz rundown level comparable to the WT control. This 
more pronounced rundown of ACh release at dKO NMJs is, however, not to be 
expected to negatively impact on successful synaptic transmission. From the mean 
dKO EPP amplitude of 24 mV and the published safety factor for the mouse NMJ of 
at least 2.4 (Wood and Slater, 2001) it can be calculated that EPPs of more than 10 
mV will result in successful transmission. Even at maximal rundown (to a plateau 
level of ~66% of their initial value, at 70 Hz stimulation), dKO EPPs would remain 
~16 mV, i.e. large enough to trigger an action potential in the muscle fibre. This could 
explain the absence of overt muscle weakness in the dKO mice. However, it cannot be 
excluded that a more pronounced EPP rundown underlies the worse performance of 
dKO mice on the inverted mesh, which tests for fatigue on the longer duration scale 
(minutes). It may be that the extra EPP rundown in dKO mice became more 
prominent upon such long-duration and high-intensity use, resulting in subthreshold 
EPPs. 
Rundown of neurotransmitter release is presumably depending on a combination of 
the inactivation characteristics of presynaptic Ca
2+
 channels and the size and 
replenishment rate of the pool of releasable ACh vesicles. At least the pool size in 
dKO motor nerve terminals seems not reduced because MEPP frequency after 
addition of hypertonic medium, being a measure for pool size (Stevens and 
Tsujimoto, 1995; Varoqueaux et al., 2005), was not reduced compared with WT. The 









concentrations tested here. Previously, we analyzed synaptic function at NMJs of 
GM2s-KO mice and found some extra rundown of EPP amplitude during high 
frequency stimulation in particular at 30-35 C and at a high extracellular Ca
2+
 
concentration (Bullens et al., 2002). However, GD3s-KO NMJs did not show extra 
EPP rundown at any condition. This suggests a role for the O- and/or a-series 
gangliosides in transmitter release at high frequency nerve stimulation, which could 
be supported by the finding that in particular GM1 ganglioside influences cellular 
Ca
2+
 membrane flux and homeostasis (Wu et al., 2004), including stimulation of Ca
2+
 
influx in some cell types (Wu et al., 1990). If GM1 would promote Ca
2+
 influx at the 
motor nerve terminal through slowing down Ca
2+
 channel inactivation this could 
explain the extra EPP rundown in the dKO NMJs where GM1 is absent. Ion-channel 
kinetics have been shown to be influenced by gangliosides, either through an 
electrical effect of the negative charges on their head groups or by an indirect 




Gangliosides have been hypothesized to play a role in thermal stabilization of the 
neuronal membrane, including adaptation of ion-channel function (Rahmann et al., 
1998). We observed a slight tendency of the quantal content at dKO and GD3s-KO 
NMJs to increase with increasing temperature. At 35 C this resulted in statistically 
significantly higher level (~40%) at GD3s-KO NMJs, compared with the WT level 
which itself remained more or less equal at all temperatures tested. On the basis of 
this observation it can be hypothesized that gangliosides inhibit transmitter release, 





 channels. The negative charges on 
extracellular sialic acid residues of gangliosides contribute to membrane surface 
charge and may thus influence voltage-dependent properties of ion-channels (Green 
and Andersen, 1991). For instance, it has recently been shown that removal of sialic 
acid from the extracellular neuronal membrane by neuraminidase treatment shifts the 
activation- and inactivation-voltage of Na
+
 channels (Isaev et al., 2007), although it 
remains unclear whether removal of sialic acid from either the surrounding 
gangliosides or the ion-channel protein itself is causing this effect. The tendency for 
increased quantal content at 35 C at dKO compared with WT NMJs indicates that the 
presence of GM3 alone is not sufficient to keep quantal content at WT level. This may 
be related to the relatively low level of sialylation of GM3 (only a single sialic acid 
residue) as compared with other types of gangliosides, because this degree influences 
the specific effects of gangliosides on ion-channel function (Kappel et al., 2000). An 
alternative explanation for the tendency of an increase of quantal content at GD3s-KO 
and dKO NMJs at the higher temperatures tested could be an increased Ca
2+
 
availability. Gangliosides have temperature-dependent Ca
2+
 binding sites of which the 
amount is positively associated with the extent of sialylation (Rahmann et al., 1998). 
Therefore, loss of sialic acid density in the vicinity of presynaptic voltage-gated Ca
2+
 
channels could lead to less adequate Ca
2+
 buffering and thus to increased ACh release. 
Such an effect seems to occur rather specifically at temperatures around 35 C, 
because in our Ca
2+
 variation experiments at 25 C all GD3s and dKO synaptic 












In conclusion, our results show that most types of gangliosides are not crucially 
important for synaptic transmission at the mouse NMJ but, rather, have a role in 
temperature- and use-dependent fine-tuning of transmitter release level. It remains to 
be directly shown whether the remaining (and possibly upregulated) presence of the 
simple ganglioside GM3 at dKO membranes explains the partial redundancy of all 
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Gangliosides are sialylated glycosphingolipids that are present in high density on 
neuronal membranes, especially at synapses, where they are assumed to play 
functional or modulating roles. Mice lacking GM2synthase express only the simple 
gangliosides GD3 and GM3 and develop progressive motor behaviour deficits upon 
ageing, apparently due to failing complex ganglioside-dependent maintenance and/or 
repair processes or, alternatively, toxic GM3/GD3 accumulation. We investigated the 
function of neuromuscular junctions (NMJs) of aged (>9 months-old) GM2synthase 
null-mutant mice, because synaptic dysfunction might develop with age and could 
potentially contribute to the late-onset motor phenotype. In addition, we studied NMJs 
of old mice lacking GD3synthase (expressing only O- and a-series gangliosides), 
which do not show an overt neurological phenotype but may develop subclinical 
synaptic deficits. Detailed electrophysiological analyses showed subtle changes in 
presynaptic neurotransmitter release. Acetylcholine release at 40 Hz nerve stimulation 
at aged GM2synthase null-mutant NMJs ran down slightly more pronounced than at 
wildtype NMJs, and spontaneous acetylcholine release rate at GD3synthase null-
mutant NMJs was somewhat higher than at wildtype, selectively at 25 ºC bath 
temperature. Interestingly, we observed faster kinetics of postsynaptic 
electrophysiological responses at aged GD3synthase null-mutant NMJs, not 
previously seen by us at NMJs of young GD3synthase null-mutants or other types of 
(aged or young) ganglioside-deficient mice. These kinetic changes might reflect a 
change in postsynaptic acetylcholine receptor behaviour. Our data indicate that it is 
highly unlikely that transmission failure at NMJs contributes to the progressive motor 
defects of aged GM2synthase null-mutants and that, despite some kinetic changes of 
synaptic signals, neuromuscular transmission remains successful in aged 
GD3synthase null-mutant mice. Apparently, mutual redundancy of the different 
gangliosides in supporting presynaptic function, as observed previously by us in 
young mice, remains adequate upon ageing or, alternatively, gangliosides have only 
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Gangliosides are sialic acid-containing glycosphingolipids (Ledeen, 1985) that are 
enriched in neuronal membranes and, therefore, are thought to have neuron-specific 
functions, e.g. in modulation of membrane-bound enzymes and ion-channels, cell-
adhesion, neuritogenesis and membrane stability (Hakomori, 2003; Hashiramoto et 
al., 2006; Ledeen and Wu, 2006a; Salazar et al., 2004; Sohn et al., 2006; Susuki et al., 
2007b; Wu et al., 2007; Yates and Rampersaud, 1998). Furthermore, anti-ganglioside 
autoimmunity and ganglioside turnover deficits cause neurological disorders (Ang et 
al., 2004; Maegawa et al., 2006; Simpson et al., 2004; Willison and Yuki, 2002). 
Gangliosides may be particularly important in synaptic function because they 1) show 
high expression at synapses (Ando et al., 2004; Waki et al., 1994); 2) co-localize with 
neuroexocytotic proteins (Chamberlain et al., 2001; Lang et al., 2001; Salaün et al., 
2004; Taverna et al., 2004) and 3) influence neurotransmitter release and synaptic 
plasticity when applied exogenously (Ando et al., 1998; Egorushkina et al., 1993; 
Furuse et al., 1998; Ramirez et al., 1990; Tanaka et al., 1997; Wieraszko and Seifert, 
1985). In spite of this, we recently showed near-normal synapse function at 
neuromuscular junctions (NMJs) of mice lacking either complex gangliosides, b/c-
series gangliosides or all gangliosides except GM3 (Figure 2.8) (Bullens et al., 2002; 
Zitman et al., 2008), suggesting neurotransmission was supported by GM3 alone or, 
alternatively, is ganglioside-independent.  
One reason for this ganglioside redundancy could be the relatively young age (5-15 
weeks) of the mice we investigated. Specific neuronal ganglioside levels vary during 
embryogenesis but also in postnatal phases, especially during ageing (Ando, 1983; 
Aydin et al., 2000; Malisan and Testi, 2002; Ngamukote et al., 2007; Svennerholm et 
al., 1989; Yamamoto et al., 2008). Gangliosides seem to become increasingly 
important upon ageing, as late-onset and progressive histological and behavioural 
abnormalities develop in both GM2synthase knockout (GM2s-KO) mice and 
compound null-mutant mice lacking GM2- and GD3synthase. Young GM2-KO mice 
(~3 months) show no phenotype (although they have histological signs of peripheral 
nerve degeneration (Sheikh et al., 1999), worsening upon ageing (Sugiura et al., 
2005)). Eventually, starting at 8-16 months of age, these mice develop motor deficits, 
i.e. abnormalities in gait (Chiavegatto et al., 2000; Sugiura et al., 2005), balance, 
coordination, rearing and locomotion, whole-body tremor and catalepsy (Chiavegatto 
et al., 2000). The exact sequence of the development of these disturbances and the 
potential correlated neurodegenerative sites (i.e. sensory nerves, motor nerves or 
CNS) are not known yet. Spinal cord synaptic rearrangements occur in >10 weeks-old 
mice (Sugiura et al., 2005). Young GD3synthase knockout (GD3s-KO) mice have no 
phenotype (Kawai et al., 2001; Okada et al., 2002) but show impaired nerve 
regeneration (Okada et al., 2002). To our knowledge, they have not been studied at 
old age. Compound null-mutant mice are born normal but show sudden death (~50% 
survival at three (Kawai et al., 2001) or six months (Inoue et al., 2002), depending on 
strain) and get skin lesions at >6 months of age, presumably due to sensory nerve 
impairment (Inoue et al., 2002). Thus, these late-onset and progressive phenotypes 
may be due to a lack of the particular ganglioside sub-sets in these null-mutants. 
Alternatively, they might be caused by accumulation of the remaining ganglioside 
sub-sets, amounting to neurotoxic levels during ageing. Brains of GM2s-KO mice 
accumulate GM3 and GD3 ganglioside (Kawai et al., 2001; Takamiya et al., 1996), 







Okada et al., 2002) and possibly also O-series gangliosides. Brains of compound null-
mutants have increased GM3 expression (Inoue et al., 2002; Kawai et al., 2001). Our 
previous studies on pathophysiological effects of anti-ganglioside antibodies suggest 
that similar ganglioside accumulations also take place at NMJ motor nerve terminals 
of these mutants (Bullens et al., 2002; Goodfellow et al., 2005). The exact time course 
of these ganglioside accumulations in brain and NMJ are not known. 
In view of these progressive behavioural and histological deficits, possibly involving 
progressive synaptic dysfunction due to either chronic lack of ganglioside subsets or 
toxic overexpression of the remaining subsets, we here investigated neurotransmission 














































Figure 2.8 Gangliosides synthesis scheme 
Ganglioside nomenclature is according to Svennerholm (Svennerholm, 1994). Membranes of wildtype 
mice contain all gangliosides. GM2s-KO mice lack complex gangliosides (light gray rectangle); GD3s-
KO mice lack b- and c-series gangliosides (dark grey rectangle). 
 
Material and methods 
 
Mice 
GM2s-KO and GDs3-KO mice were bred and genotyped as described by Inoue and 
colleagues (2002). Both male and female homozygous KO and wildtype (WT) 
littermates were used at ages older than 9 months (range 9.5-17 months). Upon visual 




Synaptic function in aged ganglioside-deficient mice 
 
 
Introduction section), as described (Chiavegatto et al., 2000; Sugiura et al., 2005). The 
aged GD3s-KO mice showed no overt neurological phenotype. The body weight of 
the aged GD3s-KO mice was higher than that of the aged WT and GM2s-KO mice 
(47.1 ± 1.8, 41.5 ± 1.5 and 36.6 ± 1.4 g, respectively; p<0.01). Muscle strength was 
assesses with a grip strength meter as described before (Zitman et al., 2008). All 
animal experiments were carried out according to Dutch law and Leiden University 
guidelines. 
 
In vitro electrophysiology 
Mice were killed by CO2 asphyxiation. Left and right hemi-diaphragms were 
dissected with their phrenic nerve attached and mounted in standard Ringer’s medium 
(119 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, 23 mM 
NaHCO3, 11 mM glucose, pH 7.4) at room temperature, pre-gassed with 95% O2 / 5% 
CO2.  
Intracellular recordings of miniature endplate potentials (MEPPs) and endplate 
potentials (EPPs) in the NMJ were made using a glass micro-electrode (10-20 MΩ, 
filled with 3 M KCl) connected to a Geneclamp 500B (Axon Instruments / Molecular 
Devices) for amplifying and filtering (10 kHz low-pass, 1 Hz high-pass) of the signal. 
Signals were digitized and analyzed using a Digidata 1322A digitizer, Clampex 9, 
Clampfit 9 (Axon instruments) and Mini Analysis 6.0.3 (Synaptosoft). At least 10 
NMJs were sampled per muscle per experimental condition and at least 30 EPPs 
















Figure 2.9. Grip strength measurements 
Grip strength was averaged for 10 trials (n=6-8 
mice). A. Pulling force normalized to the body 
weights of each mouse; all groups pulled ~3 g/g 
bodyweight.  
B. Absolute pulling values show increased grip 
strength in GD3s-KO vs. WT mice (p<0.05), 




Muscle action potentials were eliminated by incubation with 3 μM of the selective 
skeletal muscle Na+-channel blocker, μ-conotoxin GIIIB (Scientific Marketing 







supramaximal rectangular pulses of 0.1 ms width at 0.3, 3 and 40 Hz, using a bipolar 
stimulation electrode. The mean EPP and MEPP amplitudes at each NMJ were 
normalized to a standard resting membrane -75 mV, with the reversal potential for 
acetylcholine (ACh)-induced current assumed to be 0 mV (Magleby and Stevens, 
1972) and using the following formula: (M)EPPnormalized = (M)EPP × ((-75-
Vreversal)/Vm), where Vreversal is the reversal potential for ACh and Vm is the measured 
resting membrane potential. In order to calculate the quantal content (i.e. the number 
of ACh quanta that are released upon a single nerve impulse), the normalized mean 
amplitude of EPPs evoked at low rate (0.3 Hz) were corrected for non-linear 
summation using the following formula: EPPcorrected = EPP/(1-f(EPP/75)), with f set to 
0.8 (McLachlan and Martin, 1980). The normalized and corrected mean EPP at each 
NMJ  amplitude was divided by the normalized mean MEPP amplitude to obtain the 
quantal content value. Temperature of the bath medium was controlled using a Peltier 
device placed around the recording bath and adjusted by varying the DC output of a 
power supply (Delta Elektronika). A miniature probe connected to a digital 
thermometer was used to monitor temperature, which was held at 24-26 °C, unless 
stated otherwise. 
MEPPs were also recorded after addition of hypertonic medium (0.5 M sucrose 
Ringer's medium), in order to estimate the pool of ACh vesicles ready for immediate 
release (Stevens and Tsujimoto, 1995; Varoqueaux et al., 2005). In some experiments 
we varied the concentrations of extracellular K+ and Ca2+ by adding the appropriate 
amounts of KCl and CaCl2, respectively, to the Ringer’s medium. 
 
Statistical analysis 
Data are presented as group mean ± SEM of the mean muscle values calculated from 
the mean NMJ values. Statistical differences were analyzed with an unpaired 





In vivo assessment of muscle strength 
Grip strength testing showed similar muscle power of WT, GM2s-KO and GD3s-KO 
mice, when normalized for body weight (~3 g/g; p= 0.13; Figure 2.9A). The absolute 
force delivered by GD3s-KO mice was ~20% higher than that delivered by WT mice 
(p<0.05; Figure 2.9B), paralleling the higher body weight of this mutant.  
 
Spontaneous and evoked ACh release parameters 
First we measured synaptic signals at NMJs under our standard conditions (2 mM 
extracellular Ca2+, 25 °C). Each genotype group consisted of 6-11 mice. Spontaneous 
uniquantal transmitter release, measured as MEPP frequency, was 43% larger in 
GD3s-KO than in WT NMJs (1.91 ± 0.23 and 1.34 ± 0.09 s-1, respectively, p<0.05; 
Figure 2.10A). GM2s-KO MEPP frequency was 1.42 ± 0.11 s-1 and did not differ 
statistically significantly from the other genotype groups. MEPP amplitude in the 
GD3s-KO NMJ was ~25% larger than in WT or GM2s-KO (0.79 ± 0.05; 0.63 ± 0.03; 
0.65 ± 0.02 mV, respectively; p<0.05; Figure 2.10B, C). In addition, we found a 
~30% shorter 10-90% rise time of MEPPs in the GD3s-KO mice, as compared to 
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p<0.01) as well as a ~25% smaller halfwidth (2.29 ± 0.08, 2.92 ± 0.23 and 3.06 ± 0.15 
ms, respectively, p<0.05). The amplitudes of EPPs evoked by 0.3 Hz stimulation were 
22-24 mV for all groups (p=0.22; Figure 2.10D, E). The calculated quantal contents 
of 0.3 Hz EPPs were of similar value (~48) at all three genotype NMJs (p=0.23; 
Figure 2.10F). However, the 10-90% rise time of GD3s-KO EPPs was shorter than 
that of WT and GM2s-KO (0.81 ± 0.05, 1.13 ± 0.07 and 1.11 ± 0.05 ms, respectively; 
p<0.01; Figure 2.10G). Similarly, the width of the EPPs at 50% of their amplitude 
was smaller in GD3s-KO than WT, but not GM2s-KO NMJs (2.93 ± 0.11, 3.89 ± 0.14 
and 3.49 ± 0.28 ms, respectively; p<0.05 GD3s-KO vs. WT; Figure 2.10H). Example 
traces are shown in Figure 2.10E. These kinetic differences were not observed 
previously in NMJs of younger GD3s-KO mice (Zitman et al., 2008). Upon high rate 
(40 Hz) stimulation, GM2s-KO EPPs ran down to a slightly, but statistically 
significantly (p<0.05), lower plateau level than the WT EPPs did (79.5 ± 1.0 and 83.2 
± 0.9% of the first EPP in the train, respectively; Figure 2.11). GD3s-KO EPPs ran 
down to 82.1 ± 0.8%. Within the tested groups of old GM2s- and GD3s-KO mice we 
observed no clear correlation between the age of individual mice (which ranged from 
9.5 to 17 months) and the parameters that had shown statistically significant change 
compared with the WT group on group-average level (data not shown). 
 
Hypertonic shock- and K+-induced ACh release 
Upon incubation of nerve-muscle preparations in hypertonic (0.5 M sucrose) Ringer’s 
medium, MEPP frequency increased to similar levels of 50-60 s-1 for all groups (n=6 
mice; p=0.16; Figure 2.12A). Cultured GM2s-KO neurons have been shown to 
degenerate upon K+-induced depolarization, caused by an underlying impairment of 
cellular Ca2+ regulation (Wu et al., 2001). In order to investigate possible effects at the 
GM2s-KO NMJ, we measured MEPP frequency in extracellular K+ concentrations 
varying from 4.5 to 30 mM and compared it to WT NMJs (n=3-7 mice per condition 
per genotype). As expected, the MEPP frequency steeply rose with increasing K+ 
concentration, but we found no statistically significant differences between the 
genotypes (Figure 2.12B). 
 
Temperature-dependency of ACh release parameters 
Gangliosides may be involved in thermal adaptation of neuronal membrane function 
(Rahmann et al., 1998). We, therefore, performed synaptic electrophysiological 
measurements in a further series of experiments at 17, 20, 30, and 35 °C (Figure 
2.13). Each aged genotype group consisted of 4-5 mice. At all temperatures tested, the 
MEPP amplitude at GD3s-KO NMJs tended to be somewhat higher at GD3s-KO 
NMJs than at GM2s-KO and WT NMJs, although this was only statistically 
significantly at 25 °C, as described above (Figure 2.13A; p<0.01). The temperature-
dependence of spontaneous ACh release rate, i.e. MEPP frequency, seemed roughly 
similar at WT, GM2s-KO and GD3s-KO NMJs, although at the low end of the tested 
temperature range the MEPP frequency at WT NMJs was somewhat higher, compared 
to GM2s-KO (Figure 2.13B; p<0.05). The amplitudes of EPPs evoked by 0.3 Hz 
nerve stimulation amplitudes tended to be somewhat higher at GD3s-KO NMJs at 
every temperature tested, although this reached no statistical significance (Figure 
2.13C). No differences in the calculated quantal contents were observed at any 
temperature tested (Figure 2.13D). Rise times and halfwidths of GD3s-KO EPPs were 
consistently shorter than that of WT and GM2s-KO EPPs, but showed no different 














Figure 2.10. Basic synaptic parameters at the NMJ 
In vitro intracellular electrophysiological measurements at 25 °C in diaphragm-phrenic nerve 
preparations: each group consisted of at least 6 mice; at least 10 NMJs were sampled per muscle.  
A. MEPP frequency was higher in the GD3s-KO NMJs compared to WT. B. MEPP amplitude was 
larger at GD3s-KO NMJs. C. Typical traces of MEPPs. D. EPP amplitude was similar at each 
genotype. E. EPP example traces for WT, GM2s-KO and GD3s-KO mice. Black triangles indicate 
moment of phrenic nerve stimulation. F. Calculated quantal content at 0.3 Hz nerve stimulation was 
similar across genotypes. G. GD3s-KO mice exhibit significantly shorter 10-90% rise time. H. EPP 
halfwidth at GD3s-KO NMJs was shorter than at WT. 
*p<0.05, **p<0.01 





Figure 2.11. High-rate nerve stimulation-evoked ACh release is reduced at GM2s-KO NMJs 
A. EPP amplitude rundown profiles at 40 Hz nerve stimulation (n=6-11 mice per group). Each EPP 
amplitude is expressed as percentage of the amplitude of the first EPP. EPPs at GM2s-KO NMJs 
showed increased rundown, compared to WT (# p<0.05). B. EPP rundown level (the mean amplitude 
of the 21st -35th  EPP, expressed as percentage of the amplitude of the first EPP in the train, was lower 
at GM2s-KO NMJs, compared to WT (* p<0.05). C. Typical 40 Hz nerve stimulation EPP trains.  
 
 
No differences were observed between genotypes in rundown of EPPs at 3 Hz 
stimulation rate (Figure 2.13G), while at 40 Hz the WT EPPs ran down slightly less 
pronounced than at ganglioside-deficient NMJs, albeit only statistically significantly 
at 25 °C (p<0.05, vs. GM2s-KO) and 35 °C (p<0.05, vs. both GD3s-KO and GM2s-
KO; Figure 2.13H). 
 
Ca2+-dependency of ACh release parameters 
Gangliosides have been suggested to play a role in the membrane flux of Ca2+ and its 
cellular homeostasis (Ledeen and Wu, 2006a; Rahmann et al., 1998; Wu et al., 2001). 
Therefore, we explored synaptic transmission at NMJs from muscle preparations 
incubated at low (0.2 mM) and high (5 mM) extracellular Ca2+, at 25 °C bath 
temperature. Genotypes showed no differences in MEPP amplitude at either 0.2 or 5 
mM Ca2+ concentration (Figure 2.14), whereas at 2 mM Ca2+ it was somewhat higher 
at the GD3s-KO NMJ (see above). As expected, in view of the well-known 
dependence of neurotransmitter release on extracellular Ca2+, MEPP frequency, EPP 
amplitude and quantal content of WT NMJs steeply depended on Ca2+. No different 
Ca2+-dependency of these parameters was observed at GM2s-KO NMJs. However, 
the dependency of GD3s-KO NMJs seemed less steep, as we found increased ACh 
release at 0.2 mM Ca2+, compared to WT and GM2s-KO NMJs (Figure 2.14B-D). 
EPP rundown levels at 40 Hz stimulation were not statistically significantly different 







somewhat at 2 mM Ca2+, see above. Paired-pulse facilitation at 25 ms stimulation 
interval was not different between genotypes at any of the Ca2+ concentrations tested. 
Its values, expressed as percentage increase of the second EPP, compared to the first, 
were about 25, 2.5 and -0.5% at 0.2, 2, and 5 mM Ca2+, respectively, for all 
genotypes. As observed at 2 mM Ca2+ (see above), the rise time and halfwidth of 
EPPs were shorter at GD3s-KO than at WT and GM2s-KO NMJs at both 0.2 and 5 
mM Ca2+ (although only statistically significantly at 5 mM Ca2+, Figure 2.14F, G). 















Figure 2.12 Hypertonic shock- and K+-
induced ACh release is unchanged 
A. The levels of ACh release induced by 
hypertonic medium (0.5 mM sucrose Ringer's 
medium) were not different between genotypes 
(n=6 mice).   
B. No differences in K+-MEPP frequency 
concentration-effect relationship between 







We performed a detailed electrophysiological characterization of ACh release 
parameters at NMJs of aged GM2s-KO and GD3s-KO mice. This included high- and 
low-rate nerve stimulation-evoked release, spontaneous release and the release evoked 
by hypertonic medium or elevated extracellular K+. However, neuromuscular synaptic 
transmission of both the aged null-mutant mice showed remarkably little change 
compared with the WT controls. From the evoked release parameters under standard 
conditions (25 °C, 2 mM extracellular Ca2+), only the ACh release at 40 Hz nerve 
stimulation at aged GM2s-KO NMJs was found to be running down more 
pronouncedly than at WT NMJs. However, the extent of this difference was only 
small (EPPs ran down to a plateau level of 79.5% of the first EPP, compared to 83.2% 
at WT NMJs). In view of the presence of a large safety factor in neuromuscular 
transmission (Wood and Slater, 2001), such a small reduction will most likely not 




Synaptic function in aged ganglioside-deficient mice 
 
 
testing the aged GM2s-KO mice with a grip strength meter, where they pulled equal 
forces as WT controls. Thus, the motor coordination defects observed in aged GM2s-
KO mice (Chiavegatto et al., 2000; Sugiura et al., 2005), and also observed by us in 
the mice used here, do not contain a muscle weakness component due to 
neuromuscular transmission failure. Therefore, they are likely attributable to 
progressive dysfunction of the peripheral sensory or proximal motor nerves and/or 
possibly the CNS, caused by chronic lack of complex gangliosides or, alternatively, 
by upregulation of GM3 and GD3 ganglioside to toxic levels. Neurotransmission at 
central synapses has no safety factor and, consequently, small changes in transmitter 
release as observed here at the NMJ already may have pronounced effects on neuronal 
network function in the CNS. 
Earlier we have also observed some extra rundown of high-rate EPPs at NMJs of 
young GM2s-KO mice, but only at higher bath temperatures (30-35°C) tested and at 
high (5 mM) extracellular Ca2+ concentration (Bullens et al., 2002). Furthermore, 
GM2*GD3synthase compound null-mutant NMJs showed some degree of extra EPP 
rundown, at all temperature and Ca2+ conditions tested (Zitman et al., 2008). 
However, at GD3s-KO NMJs, either from young or aged mice, we never observed 
extra EPP rundown compared with WT, except for the 35 °C temperature condition at 
aged NMJs. Together these data suggest that O- and/or a-series gangliosides may 
support the fine-tuning of high-rate transmitter release. In particular, GM1 ganglioside 
may be important, because it has been shown to influence cellular Ca2+ membrane 
flux and homeostasis (Wu et al., 2004; Wu et al., 1990). Perhaps this involves 
inhibition of voltage-gated Ca2+-channel inactivation, one important factor in high-
rate transmitter release. Another relevant factor, the size of the pool of synaptic 
vesicles ready for release, is not likely to be influenced by gangliosides, because we 
did not find differences between genotypes when we assessed for this parameter with 
hypertonic stimulation (Stevens and Tsujimoto, 1995; Varoqueaux et al., 2005), either 
here at aged NMJs or previously in younger ones (Zitman et al., 2008). The less steep 
relationship between extracellular Ca2+ and evoked ACh release observed at NMJs of 
old GD3s-KO mice (and seen previously in young ones) may also be due to altered 
Ca2+ buffering or membrane flux, possibly resulting from a progressive increase in 
GM1 density due to accumulation of O- and/or a-series gangliosides (Handa et al., 
2005; Okada et al., 2002). This may also explain the higher MEPP frequency at 
GD3s-KO NMJs in 0.2 and 2 mM extracellular Ca2+. 
At aged GD3s-KO NMJs we observed decreased rise times and halfwidths of both 
EPPs and MEPPs, not previously seen at NMJs of young GD3s-KO or any of the 
other ganglioside-deficient mice. These kinetic changes may reflect a change in the 
behaviour of postsynaptic ACh receptors (AChRs). Gangliosides are present in the 
vicinity of AChRs (Pato et al., 2008) and can interact with the protein, as shown for 
AChR-rich membrane from Torpedo marmorata (Mantipragada et al., 2003). 
Accumulation of O- and/or a-series gangliosides may occur at muscle membranes of 
GD3s-KO mice, as it does at neuronal membranes (Handa et al., 2005; Okada et al., 
2002), and progressiveness of this process may lead to the observed age-specific 
changes in EPP kinetics. EPP rise time and halfwidth are highly temperature-
dependent parameters (Figure 2.13E, F) and the progressive accumulation of O- 
and/or a-series gangliosides may induce a shift in this dependency by progressively 
altering the membrane fluidity and charge density in the vicinity of the AChRs in a 
similar way that gangliosides have been shown to influence artificial voltage-gated 










Figure 2.13. Effect of temperature on synaptic transmission 
Electrophysiological analysis of ACh release at diaphragm NMJs at different bath temperatures. Each 
genotype group consisted of 4-5 mice. A. MEPP amplitude at GD3s-KO mice was larger than at 
GM2s-KO and WT NMJs, only at 25 °C. B. Spontaneous ACh release, measured as MEPP frequency, 
was lower at GM2s-KO than WT NMJs at 17 °C (p<0.05), and higher at GD3s-KO compared with WT 
NMJs at 25 °C. C. No differences in temperature-dependency between genotypes of EPP amplitude at 
0.3 Hz nerve stimulation. D. The temperature-dependency of quantal content at 0.3 Hz nerve 
stimulation was similar across genotypes. E. GD3s-KO NMJs showed equal reductions of rise time at 
all temperatures tested. F. Halfwidths of EPPs at GD3s-KO NMJs were shorter than at WT and GM2s-
KO NMJs at temperatures >20 °C. G. No changes in temperature-dependency of EPP amplitude 
rundown level at 3 Hz stimulation. H. EPP amplitude rundown level at 40Hz nerve stimulation. GM2s-
KO rundown was somewhat more pronounced than WT at 25 °C and GD3s-KO rundown was more 
pronounced than WT at 35 °C. 
* p<0.05, ** p<0.01, WT vs. GM2s-KO and GD3s-KO; † p<0.05, GD3s-KO vs. GM2s-KO; # p<0.05, 










Figure 2.14. Effect of extracellular Ca2+ concentration on synaptic transmission 
Electrophysiological measurements were performed in Ringer’s medium at 25 °C containing either 0.2, 
2 or 5 mM Ca2+; n=6-11 mice per group. A. MEPP amplitude at GD3s-KO NMJs was larger than at 
GD3s-KO and WT NMJs at 2 mM Ca2+. B. Spontaneous ACh release, measured as MEPP frequency, 
was higher at GD3s-KO NMJs compared with the other genotypes at 0.2 mM Ca2+ and higher than WT 
at 2 mM Ca2+. C. EPP amplitude was increased at GD3s-KO NMJs at low Ca2+ conditions and was 
lower than WT in high Ca2+. D. Quantal content at 0.3 Hz nerve stimulation in 0.2 mM Ca2+ was higher 
at GD3s-KO NMJs. E. EPP rundown level was only somewhat lower for GM2s-KO in 2 mM Ca2+. F. 
GD3s-KO mice exhibit smaller EPP rise times at 2 and 5 mM Ca2+. G. Similarly, halfwidths of GD3s-
KO EPPs were reduced 
* p<0.05, ** p<0.01, WT vs. GM2s-KO and GD3s-KO; † p<0.05, †† p<0.01, GD3s-KO vs. GM2s-









The small increase in MEPP amplitude at aged GD3s-KO, specifically at 25 °C and 
not observed at young GD3s-KO NMJs, may possibly have followed from an 
influence by gangliosides on ion permeation through AChRs (Barrantes, 1989), 
progressively changing due to O- and/or a-series gangliosides accumulation. 
Alternatively, the increased MEPP amplitude may be due to reduced activity of 
cholinesterase in the synaptic cleft, inhibiting ACh breakdown. However, in that case 
one would expect an accompanying MEPP and EPP broadening (due to a prolonged 
action of ACh, as shown in many electrophysiological experiments using 
cholinesterase inhibitors, see e.g. Fiekers, 1985; Maselli and Leung, 1993), but this 
was not found here. Instead, we observed faster MEPPs and EPPs. These might have 
resulted from increased cholinesterase activity, but this would in turn be expected to 
be associated with reduced amplitude, which was not the case. Furthermore, to our 
knowledge, no direct relationship between gangliosides and cholinesterase has been 
reported in the literature. These considerations make changes in cholinesterase 
activity a more distant possibility. A further alternative explanation for changes of 
(M)EPP kinetics may be that O- and/or a-series accumulation influenced the passive 
electrical characteristics of muscle membrane (i.e. reduced capacitance and increased 
input resistance). A presynaptic explanation for the changed EPP and MEPP kinetics 
and quantal size (e.g. increased filling of ACh vesicles) is less likely because 
gangliosides have been reported to lack effect on ACh synthesis (Tanaka et al., 1997). 
On the basis of the only relatively small magnitude of the observed kinetic changes of 
the EPPs and MEPPs in aged GD3s-KO mice, and the EPP amplitude being 
somewhat increased compared with WT, it is not to be expected that successful 
neuromuscular transmission is endangered. Absence of muscle weakness in grip 
strength measurements and the observed absence of any overt neurological symptoms 
in the aged GD3s-KO mice are in agreement with this view.  
GM2s-KO cerebellar neurons have been shown to degenerate when cultured under 
K+-induced depolarization, caused by an underlying impairment of cellular Ca2+ 
regulation (Wu et al., 2001). We tested in acute experiments whether a similar effect 
occurs at aged GM2s-KO motor nerve terminals by measuring the increase in MEPP 
frequency evoked by increased extracellular K+ concentrations. However, no 
differences were observed between GM2s-KO and WT NMJs, indicating no major 
differences between aged GM2s-KO and WT motor nerve terminals in influx or 
intracellular buffering of Ca2+. 
In conclusion, the investigated aged ganglioside-deficient mice show remarkable little 
change in presynaptic neuromuscular function, compared with age-matched WT 
controls. Apparently, the mutual redundancy of the different gangliosides in 
supporting synaptic function, as observed in young mice (Zitman et al., 2008), 
remains adequate even upon ageing, when there is likely an increased demand for 
(gangliosides-dependent) maintenance and repair processes. Alternatively, 
gangliosides may have relatively little direct impact on neuromuscular synaptic 
function, even at old age. The observation of fast EPP and MEPP kinetics at GD3s-
KO NMJs is interesting and indicates a role for O- and/or a-series gangliosides in 
AChR function, which deserves more detailed study. Finally, in view of the only 
slightly reduced 40 Hz nerve stimulation-evoked ACh release at NMJs of aged GM2s-
KO mice, it is highly unlikely that NMJ dysfunction contributes to the age-related 
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Neuronal membrane gangliosides, forming a large family of sialylated 
glycosphingolipids, have been hypothesized to play important roles in synaptic 
transmission. We studied the ex vivo electrophysiological function of neuromuscular 
junctions of GM2/GD2synthase*GD3synthase compound null-mutant mice after 
acute removal of GM3, the only remaining ganglioside in this mouse, by in vitro 
treatment with neuraminidase. We found 16% enhancement of the acetylcholine 
release per nerve impulse at low-rate (0.3 Hz) nerve stimulation. Conversely, the 
treatment reduced the acetylcholine release evoked by high-rate (40 Hz) nerve 
stimulation. Also, 25 ms paired-pulse facilitation of endplate potentials was reduced 
by the neuraminidase-treatment. These effects may indicate a modest modulatory 
influence of the negative electrical charges carried by the sialic acid molecules of 
gangliosides on the function of presynaptic Cav2.1 channels, affecting the magnitude 
and kinetics of the Ca
2+
 influx that induces neurotransmitter release from the motor 
nerve terminal. Our results show that gangliosides are to some extent involved in 
neurotransmission at the neuromuscular junction, but that their presence is not an 
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Gangliosides are glycosphingolipids carrying one or more sialic acid residues. This 
family of amphipathic molecules resides in the outer layer of cell membranes and is 
especially enriched in presynaptic nerve endings (Schwarz and Futerman, 1996; for 
review, see Plomp and Willison, 2009). Hence, gangliosides have been hypothesized 
to play important roles in synaptic transmission, possibly through affecting 
presynaptic voltage-gated ion-channels, Ca
2+
 homeostasis and/or surface charge. 
However, at the neuromuscular junction (NMJ) of transgenic mice lacking major 
subsets of gangliosides (Figure 2.15), we have previously shown that presence of the 
complete family of gangliosides is not strictly required for functional synaptic 
transmission. Electrophysiological measurement of acetylcholine (ACh) release at 
NMJs of GM2synthase knockout (GM2s-KO), GD3synthase knockout (GD3s-KO), 
or compound null-mutant mice lacking both GM2- and GD3synthase (dKO), showed 
only subtle changes and no failure of synaptic transmission was observed (Bullens et 
al., 2002; Zitman et al., 2008; Zitman et al., 2009). This suggests a fine-tuning role for 
gangliosides in transmitter release, rather than their presence being an absolute 
requirement. Alternatively, the different types of gangliosides might act mutually 
compensatory in supporting transmitter release. Such a compensatory action of GM3 
ganglioside might explain the redundancy we found for the other gangliosides, 
because in all three investigated transgenic strains at least this ganglioside remains 
present in the neural membrane (Figure 2.15), most likely at highly accumulated level 
(Inoue et al., 2002). We here acutely removed the sialic acid component of this only 
remaining ganglioside at dKO NMJs, thereby creating a ganglioside-free nerve 
terminal, and studied the effect on transmitter release.  
Male and female dKO mice (Inoue et al., 2002; Zitman et al., 2008) were used in the 
experiments, at ~11 weeks of age and 22.9 ± 1.1 g body weight. Mice were killed by 
CO2 asphyxiation. Left and right hemi-diaphragms with phrenic nerves were dissected 
and pinned out in Ringer’s medium (119 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM 
MgSO4, 1mM NaH2PO4, 23 mM NaHCO3, 11 mM glucose, pH 7.4), pre-gassed with 
95% O2/5% CO2. Animal experiments were carried out according to Dutch law and 
Leiden University guidelines. 
dKO phrenic nerve hemi-diaphragm preparations (6 left and 4 right hemi-diaphragms 
from n=10 dKO mice) were treated with 2 units neuraminidase type V from 
Clostridium perfringens (Sigma-Aldrich) in 1 ml Ringer’s medium for 1 h at 32 °C. 
This disrupts GM3 by cleaving the α2,3-link between the sialic acid and galactose 
molecule (Perillo et al., 1994). We used tissue from dKO mice because neuraminidase 
treatment of wildtype tissue will not induce complete ganglioside ablation due to the 
inability of the neuraminidase to desialylate GM1 (Perillo et al., 1994). The 
contralateral hemi-diaphragm from each mouse was incubated as a control in Ringer's 
medium only. Preparations were then rinsed in Ringer’s medium for 10 min. 
Subsequently, μ-conotoxin-GIIIB (3 μM; Scientific Marketing Associates) was added 
to block voltage-gated Na
+
 channels on the muscle membrane in order to prevent 
muscle action potentials and contraction. ACh release at NMJs at room temperature 
(20-22 °C) was assessed using an intracellular electrophysiological method, as 
described before (Zitman et al., 2008), recording endplate potentials (EPPs, the 
postsynaptic responses resulting from nerve action potential-evoked ACh release 
following supramaximal stimulation of the phrenic nerve) and miniature EPPs 
(MEPPs, the responses resulting from spontaneous uniquantal release). The quantal 
content (i.e. the number of ACh quanta released per nerve impulse) was calculated 
from EPP and MEPP amplitudes (Zitman et al., 2008). Ten NMJs were sampled per 







per NMJ. Data are expressed as group mean ± SEM (n=10 mice) of the mean muscle 
values calculated from the mean NMJ values. Statistical significance of differences 








































































Figure 2.15. Ganglioside synthesis scheme with indication of the subsets lacking in GM2s-KO and GD3s-KO 
mice. dKO mice only express GM3. 
 
The disruption of GM3 at the dKO NMJ by neuraminidase caused a 16% increase of 
quantal content at 0.3 Hz nerve stimulation (control 42.3 ± 2.1 and neuraminidase-
treated 49.1 ± 1.6; p<0.05; Figure 2.16A). Spontaneous uniquantal ACh release, 
measured as MEPP frequency, showed a tendency of increase in the neuraminidase-
treated NMJs, but this was not statistically significant (p=0.28, Figure 2.16B). During 
high rate (40 Hz) nerve stimulation, ACh release at neuraminidase-treated dKO NMJs 
became more depressed than that at control dKO NMJs. The rundown level of EPPs 




 EPP, expressed as percentage of 
the first EPP of the train) at NMJs in neuraminidase-treated tissue was 67.3 ± 1.5%, 
compared to 72.1 ± 0.7% at NMJs of untreated dKO muscles (p<0.05; Figure 2.16C-
E). For comparison, EPP rundown level at wildtype NMJs under comparable 
experimental conditions in our previous study was 80.9 ± 1.2% (Zitman et al., 2008). 
Furthermore, the increase of the second EPP of the 40 Hz evoked train, compared to 
the first EPP (i.e. 25 ms paired-pulse facilitation), was lower in the neuraminidase-
treated group (3.35 ± 0.66% at control vs. 0.32 ± 0.50% at neuraminidase-treated 
dKO NMJs; p<0.01; Figure 2.16F). 








Figure 2.16 Electrophysiological measurement of ACh release at diaphragm NMJs of dKO mice (n=10) to assess 
the effect of neuraminidase (N'ase). Controls were sham-incubated without neuraminidase. For comparison, the 
values of synaptic parameters obtained at wildtype NMJ (without neuraminidase treatment) in our previous study 
(Zitman et al., 2008), have been added to the panels (gray bars, n=4 mice). Data are expressed as group means ± 
SEM (bars) and hemi-diaphragm pairs from individual mice (gray dots with connecting line). A. Quantal content at 
0.3 Hz nerve stimulation increased 16% (p<0.05) by the neuraminidase treatment. B. MEPP frequency showed an 
increase, but this was not statistically significant (p=0.28). C. Rundown level of EPPs upon 40 Hz nerve 
stimulation was more pronounced (p<0.05). D. Mean EPP amplitude profiles during 40 Hz nerve stimulation. E. 
Representative examples of 40 Hz EPPs at control and neuraminidase-treated NMJs. F. Paired-pulse (25 ms) 
facilitation became smaller (p<0.01). *p<0.05; **p<0.01; n.s.: not statistically significant. 
 
These results show that acute absence of all gangliosides by in vitro disruption of 
GM3, the only remaining type of ganglioside at dKO NMJs, at the one hand increases 
presynaptic neurotransmitter release by enhancing the amount of ACh released per 
nerve impulse but, on the other hand, reduces release by causing a more pronounced 
rundown during high-rate stimulation. It is yet unclear how gangliosides affect ACh 







charges carried by sialic acid molecules of gangliosides on the presynaptic Cav2.1 
channels that mediate neurotransmitter release at the NMJ (Kaja et al., 2007b). This 
type of channel has been shown to co-localize with gangliosides in lipid rafts 
(Taverna et al., 2004), which may facilitate interaction. Furthermore, experiments 
using anti-ganglioside antibodies suggest a relationship between gangliosides and 
Cav2.1 channels (Nakatani et al., 2009; Ortiz et al., 2001). Cav2.1 channel behaviour 
is one important determinant of EPP rundown level at high intensity use of NMJs 
(Kaja et al., 2005). Another indication for possible modulation of Cav2.1 channels by 
gangliosides is the reduction of 25 ms paired-pulse facilitation, because this 
phenomenon of short term synaptic plasticity is highly dependent on intraterminal 
accumulation of Ca
2+
, mainly determined by influx levels and intracellular buffering 
capacity. Increased Ca
2+
 influx following neuraminidase treatment has also been 
shown in cardiac myocytes, possibly through opening of “leak” channels (Marengo et 
al., 1998). Alternatively, the sialic acids of gangliosides adjacent to presynaptic 
Cav2.1 channels at the motor nerve terminal might act to locally sequester 
extracellular Ca
2+
, making it available upon high intensity use of the synapse in order 
to enable sustained transmitter release. 
Although we are not aware of any sialylated proteins important for presynaptic 
transmitter release at mouse NMJs, we cannot completely exclude that (part) of the 
effects of neuraminidase treatment on synaptic transmission at the dKO NMJs was 
due to desialylation of such putative sialoproteins. Sialic acid removal from 
hippocampal voltage-gated Na
+
 channels has been shown to increase action potential 
firing threshold (Isaev et al., 2007). However, such an effect occurring in phrenic 
nerves of our nerve-muscle preparations would be irrelevant because of the 
supramaximal stimulation we applied.  
In view of the rather modest magnitude of the effects of total ganglioside ablation on 
ACh release, in combination with the increased initial quantal content, compensating 
for the reduced release at high rate stimulation, it is not to be expected that successful 
neuromuscular transmission becomes endangered. Synaptic transmission at the NMJ 
has a large safety factor (Wood and Slater, 2001), and in line with this we observed a 
sustained tetanic muscle contraction upon 40 Hz nerve stimulation when visually 
inspecting dKO hemi-diaphragms directly after the neuraminidase treatment. 
In conclusion, we show that gangliosides play a role in transmitter release at the NMJ, 
albeit a rather modest one. Although an indispensable role for gangliosides in 
neurotransmission was hypothesized previously, they apparently are not absolutely 
required. The almost normal ACh release levels observed earlier at NMJs of GM2s-
KO, GD3s-KO and dKO mice (Bullens et al., 2002; Zitman et al., 2008; Zitman et al., 
2009) are likely due to compensatory effects of the remaining subsets of gangliosides, 
or GM3 ganglioside alone, respectively. It must be noted that we here studied synaptic 
effects of acute ablation of the last remaining ganglioside at dKO NMJs and that it 
cannot be excluded that long-term overall ganglioside deficiency has more severe 
synaptic effects. Such effects may underlie the severe neurodegenerative symptoms 
and premature death of transgenic mice lacking both GM2synthase and GM3synthase, 
which have permanently blocked in vivo synthesis of all gangliosides (Yamashita et 
al., 2005). In humans it was found that a lack of synthesis of the major gangliosides, 
due to an autosomal recessive truncation mutation in the SIAT9 gene that encodes 
GM3-synthase, resulted in infantile-onset epilepsy associated with developmental 
stagnation and blindness (Simpson et al., 2004). The affected children show distorted 
reflexes and one case of startle myoclonus was observed. Neuromuscular transmission 
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Recent research into the Guillain-Barré syndromes (GBS) has focused on anti-
ganglioside antibodies that correlate with specific clinical phenotypes. Our increasing 
understanding of the role of antibodies in mediating GBS has naturally focused our 
attention on complement involvement in the pathological procession. We have studied 
the axonal and glial components of the murine motor nerve terminal as a model site of 
antibody and complement mediated injury. Such studies are providing us with clear 
information on the molecular components underlying our clinicopathological model 
for GBS and have led us to the testing emerging complement therapeutics that are 
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Recent developments in our understanding of the Guillain-Barré syndromes (GBS) 
and variants including Miller Fisher syndrome (MFS) have divided them into distinct 
phenotypes with defining clinical, serological, electrophysiological and pathological 
features (Hughes and Cornblath, 2005). The major current research direction strongly 
suggests that antibody and complement mediated mechanisms are important in 
pathogenesis (Willison and Yuki, 2002; Yuki, 2001). It is clear that many different 
glycolipids act as autoantibody targets in peripheral nerve where their epitopes are 
spatially distributed in sites that reflect the clinical distribution of disease. Where 
antibody (of appropriate class and subclass) is found, complement follows, and there 
is also now extensive evidence that complement activation through the classical 
pathway is an important factor in driving pathology in animal models of GBS, 
supported by human pathological studies (Hafer-Macko et al., 1996a; Lu et al., 2000; 
Putzu et al., 2000; Wanschitz et al., 2003). This emphasis on humoral mechanisms sits 
in contrast to extensive past research based on predominantly T cell-mediated models 
of GBS, namely experimental allergic neuritis, in which clinical correlates have not 
been widely found to date, and in which complement would be expected to play a 
lesser role (Kieseier and Hartung, 2003). In this review and primary data report, we 
will focus on an area we have extensively researched in recent years, namely the 
emerging relationship between complement mediated distal motor nerve and motor 
nerve terminal injury, anti-GD1a, -GM1 and -GQ1b ganglioside antibodies, and motor 
axonal forms of GBS and MFS.  
 
GD3synthase knockout mouse:     
lacks b-series gangliosides




Figure 3.1. Schematic overview of the synthesis and composition of the ganglioside family  
Indicated are the synthesis steps that are catalyzed by GM2synthase and GD3synthase and the 








Our interest in the motor nerve terminal first arose through the knowledge that the 
pattern of weakness seen in MFS is similar to that seen in human botulism, a known 
disorder of presynaptic transmitter release at the neuromuscular junction (NMJ) 
(Lange et al., 2006). MFS comprises the clinical triad of ataxia, areflexia and 
ophthalmoplegia (Fisher, 1956). Interest in MFS was revived when Chiba and 
colleagues identified anti-GQ1b antibodies in the acute phase serum of MFS cases 
(Chiba et al., 1992). From this seminal observation, the measurement of anti-GQ1b 
antibodies in suspected cases of MFS is now widely used in clinical practice, with 
>90% sensitivity and specificity, akin to routine measurement of acetylcholine (ACh) 


















Figure 3.2.  
A schematic diagram of potential therapeutic targets and strategies based on inhibition or removal of 
anti-ganglioside antibodies, inhibition of steps in complement activation through blocking antibodies or 
enhancement of complement regulation. Complement components in oval boxes: on the left, classical 




Role of complement in murine models of GBS 
 
 
Gangliosides are sialylated glycosphingolipids, concentrated in the outer leaflet of 
plasma membranes. They are highly enriched in the nervous system, including 
synaptic membranes and biosynthetically regulated by specific glycosyltransferases. 
A scheme is shown in Figure 3.1 (Sandhoff and Kolter, 2003). Since gangliosides are 
recognised as the presynaptic ectoacceptors for botulinum toxin binding, we 
anticipated that anti-ganglioside antibody-associated syndromes might also affect this 
site. Armed with this information, we established a collaboration with John Newsom-
Davis and his colleagues in Oxford where we first demonstrated that the nerve 
terminal was indeed targeted by MFS-associated antibodies (Roberts et al., 1994). 
This landmark study inspired extensive subsequent work exploring the 
immunopathophysiology resulting from anti-ganglioside antibody and complement 
binding at the NMJ, as outlined in Figure 3.2. Many shared principles exist between 
anti-ganglioside antibody-associated syndromes and other antibody-mediated 
autoimmune diseases affecting the NMJ, including myasthenia gravis, Lambert-Eaton 
myasthenic syndrome and Isaac’s syndrome (Vincent et al., 2006); in this 
commemorative paper we thus acknowledge the huge contribution of John Newsom-
Davis and his group to our understanding of this field. 
 
 
Anti-ganglioside antibody and complement effects on 
neuromuscular transmission 
 
Following on from the early studies with the Newsom-Davis group (Benatar et al., 
1997; Roberts et al., 1994; Roberts et al., 1995; Willison et al., 1996), we 
subsequently studied the effects of MFS sera and related anti-ganglioside human and 
murine monoclonal antibodies (mAbs) on NMJ electrophysiology in more detail in 
Leiden (Plomp et al., 1999). We first tested the effects of incubation of mouse hemi-
diaphragm preparations with anti-GQ1b-positive MFS sera. The sera induced a 
dramatic increase in the frequency (up to 300-fold at some NMJs) of spontaneously 
released ACh quanta, measured as miniature endplate potentials (MEPPs), without 
significantly altering their amplitudes. This was followed by block of evoked ACh 
release resulting in paralysis of the preparation, similar to the effects of the paralytic 
neurotoxin α-latrotoxin (αLTx) (Rohou et al., 2007). Incubation with total MFS IgG 
alone was without effect but subsequent treatment with freshly prepared normal 
human serum (NHS) readily induced high frequency MEPPs followed by 
transmission block, suggesting the involvement of complement in the phenomenon. 
Further subclass purification of IgG showed that αLTx-like activity co-eluted with 
anti-GQ1b activity in the same complement fixing IgG subclasses (IgG3 or IgG1), 
suggesting that these antibodies were the responsible factors. We demonstrated 
identical complement-dependent electrophysiological effects of anti-GQ1b-positive 
MFS/GBS sera in experiments using anti-GQ1b IgM mAbs that were derived from 
mice immunized with lipo-oligosaccharides which contained GD3/GT1a-like 
structures and originated from MFS/GBS-associated C. jejuni strains (Goodyear et al., 
1999). In order to address whether the primary target of anti-GQ1b antibodies 
mediating the αLTx-like effect through complement activation were gangliosides or 
an unrelated (sialylated) antigen, for instance the αLTx receptor latrophilin, we 
exploited glycosyltransferase knockout mice that lack complex gangliosides (in 
collaboration with Furukawa). Through these studies we proved that the presynaptic 







antibodies and that the level of expression of gangliosides was a critical factor in 
influencing the extent of pathophysiology (Bullens et al., 2002). We have since 
demonstrated similar findings with anti-GD1a antibodies that occur in motor axonal 





Figure 3.3.  
A. Dependence of neurofilament (NF) loss on MAC deposition, assessed in total C6 deficiency (C6 
deficient (C6def) mouse with C6def human serum). No MAC is formed (left axis) and there is no NF loss 
(right axis). Reconstitution of C6def serum with purified C6 (pC6) leads to MAC deposits and NF loss. 
C3c is formed under both conditions (left axis). Student's two-tailed t-test: * = significantly different 
from NHS treated samples; # = significantly different from C6def serum treated samples. (BTx = α-
bungarotoxin). B and C. Electrophysiological analysis of NMJs under C6def conditions: Hemi-
diaphragms of C6def mice (n=2) were incubated serially in Ringer's medium, CGM3, C6def serum and 
C6def serum with added pC6. B. Spontaneous quantal ACh release at NMJs was measured as MEPPs 
with an intracellular microelectrode. MEPP frequency increased dramatically only when pC6 was 
added to the serum. Average MEPP frequency (n=2 muscles, 7-18 NMJs sampled per incubation). C. 
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Immunopathological effects at the nerve terminal 
 
In parallel with the electrophysiological studies described above, we assessed the 
immunohistological and morphological sequelae of anti-ganglioside antibody 
exposure to neuromuscular preparations in vitro, and to passively immunized mice. In 
topical immunostaining studies we had found that anti-GQ1b antibodies bound the 
NMJ (O'Hanlon et al., 2001; Willison and O'Hanlon, 1999) and thus also expected 
them to be deposited in passive immunization and exposure studies in vivo and ex vivo 
(Halstead et al., 2004). In contrast to the NMJ, we found little evidence of antibody 
penetration and binding to intramuscular nerve-bundles including nodes of Ranvier, 
despite reactive antigens being present in topical immunostaining studies. It is thus 
likely that antibody access to nerve fibres and nodes of Ranvier beyond the NMJ is 
limited by the blood nerve barrier, as we have previously observed for sheathed 
sciatic nerve preparations (Paparounas et al., 1999) and this finding reinforces our 
preference for understanding pathophysiological pathways using the NMJ as a model, 
rather than more proximal nerve sites.  
Using confocal and immuno-electron microscopy (EM), we were able to distinguish 
the presynaptic neuronal elements, the perisynaptic Schwann cell (pSC) and the post-
synaptic structures which comprise the NMJ, and the detailed localization of anti-
ganglioside antibody and complement deposits at the NMJ using these methods has 
been examined. Depending upon the gangliosides examined and the strain of mouse 
used for the studies, extensive immunoglobulin deposits can be detected on 
presynaptic axonal membranes or pSC membranes, or both. At the fluorescence 
microscopy level, the former can be identified by proximity to α-bungarotoxin 
staining (marking ACh receptors and therewith the postsynaptic membrane), and the 
latter by observing that the labelling pattern extends around the nuclei of pSCs and 
co-locates with the Schwann cell specific marker, S100 in double staining studies. For 
anti-GQ1b antibodies, this has also been resolved by immuno-gold EM (Halstead et 
al., 2004). 
At NMJs in mouse hemi-diaphragm preparation exposed to anti-GQ1b antibody in 
presence of NHS, complement products are deposited in a very similar distribution to 
anti-GQ1b immunoglobulins. Complement fragment C1q, C4, C3c, C5 and the pore-
forming membrane attack complex (MAC, also termed C5b-9) can all be readily 
detected. In an extensive series of ex vivo and in vivo experiments using C6 
complement component deficient sera and mice, we have demonstrated that the αLTx-
like effects do not occur in the absence of MAC. Key features of these published data 
are shown in Figure 3.3. Whilst this does not preclude important pro-inflammatory 
roles for earlier complement components including C3a and C5a, it indicates that the 
major acute injury in this model is mediated by MAC. Extensive MAC-dependent 
cytoskeletal and mitochondrial changes occur concomitantly with the αLTx-like 
effect. The axonal cytoskeleton is severely affected, as assessed by loss of 
neurofilament (NF) and beta-tubulin immunoreactivity and abnormal EM appearance, 
when compared to controls. At the EM level, the intra-terminal mitochondrial also 
show severe structural damage. Using this information, we have formulated a model 
of injury in which the dominant event is uncontrolled Ca2+ influx through MAC pores 
into the nerve terminal, resulting in uncontrolled ACh exocytosis, calpain activation 
with NF degradation and mitochondrial injury (O'Hanlon et al., 2003). This model is 









Figure 3.4. A schematic diagram of the events occurring at nerve terminals in experimental nerve-
muscle preparations exposed to anti-ganglioside antibodies in the presence of complement. Exocytosis 
is normally initiated by highly regulated Ca2+ entry through voltage-gated Ca2+ channels (VGCC) that 
activates the adjacent exocytotic protein complex and initiates synaptic vesicle fusion with the pre-
synaptic membrane. When MAC pores (on the right) are deposited in the pre-synaptic membrane, 
unregulated Ca2+ entry triggers massive, uncontrolled exocytosis and Ca2+/calpain mediated intra-
terminal injury, including cytoskeletal degradation, assessed by measuring neurofilamant (NF) levels, 
and mitochondrial injury. The pore forming toxin, α-latrotoxin (on the left), is believed to act in part 
through a similar mechanism, allowing unregulated Ca2+ influx with similar electrophysiological and 
morphological sequelae to those resulting from MAC pores. 
 
 
The experimental data described above is derived from mouse modelling and what 
remains unclear is the extent to which the distal motor axon is a site of injury relevant 
to human disease. The availability of (motor point) muscle biopsy tissue from human 
cases at the appropriate time point in the clinical course is practically very limited, 
either in MFS or in GBS, and even if it were available the interpretation is likely to be 
confounded by the co-occurence of Wallerian degeneration arising from more 
proximal axonal injury. Direct electrophysiological assessment of human distal motor 
axonal function is relatively crude and imaging this site is not feasible. These factors 
make is difficult to assess the validity of these mouse data as a direct model of the 
human disease. However, indirect evidence indicates that the distal motor axon is an 
affected site in axonal forms of GBS (Ho et al., 1997; Kuwabara et al., 2003), along 
with other sites including nerve roots and trunks. Furthermore, several case studies 
have supplied clinical electrophysiological indications for NMJ defects in MFS 
(Lange et al., 2006; Lo et al., 2006; Sartucci et al., 2005; Uncini and Lugaresi, 1999; 
Wirguin et al., 2002). Irrespective of the human clinical relevance of the distal motor 
axon, the principles governing the effects of antibody binding with complement 
fixation at ganglioside-rich membrane sites are likely to be applicable to axonal and 




Role of complement in murine models of GBS 
 
 
The influence of endogenous complement regulators on 
motor nerve terminal injury 
 
One perplexing issues surrounding our model of anti-GQ1b and MAC mediated injury 
is its dependence upon an exogenous, heterologous source of complement to induce 
the neuropathic lesions in mouse tissues; in our case we achieve this with NHS. 
Previously, we have attempted to generate a model by intraperitoneal injection of anti-
ganglioside mAb, relying on mouse serum as a source of complement; whilst we 
could demonstrate clear antibody deposits overlying presynaptic nerve terminals 
accompanied by subtle electrophysiological abnormalities, no behavioural defects 
were observed (Willison et al., 1996). In subsequent studies we have sought mouse 
complement deposits and found them to be very sparse. We considered factors that 
might influence this failure of anti-ganglioside antibodies to activate mouse 
complement on the presynaptic membrane. To this end, we have conducted a range of 
studies in parallel with a positive control study in the form of a complement fixing 
anti-acetylcholine receptor (AChR) rat mAb (McAb3, kindly provided by Vanda 
Lennon, Mayo Clinic), that is known to induce complement-dependent experimental 
myasthenia gravis on passive immunization in mice in the absence of a heterologous 
complement source. As this antibody binds on the postsynaptic membrane, only ~50 
nM distant from the anti-ganglioside mAb binding region on the presynaptic 
membrane, it would appear to be a good control in terms of the diffusion dynamics of 
antibody and complement components from the circulation.  
In this comparative study we first confirmed that all the mouse mAbs we were using 
in passive immunization studies were able to fix mouse complement in an equivalent 
manner to the rat anti-AChR mAb, McAb3 (primary data, Figure 3.5). There are 
variations both the complement fixing abilities of different antibodies and in 
complement activity in laboratory mice strains that confound these issues (Rice, 
1950). For example, the low haemolytic capacity of mouse serum may be in part due 
to the inability of the C4b subunit of the classical pathway C5 convertase to bind C5 
(Ebanks and Isenman, 1996). Nevertheless, these data show that the mouse anti-
glycolipid mAbs used in our studies are as able to effectively fix mouse complement 
as a known myasthenia gravis-inducing pathogenic antibody reactive to AChR, using 
C57bl/6 serum in solid-phase ELISA studies, conducted according to Zwirner with 
minor modifications (Zwirner et al., 1998). From this starting point it seems very 
likely that unknown inhibitory factors must present in the presynaptic membrane that 
differ from those in the postsynaptic membrane. Candidate molecules include the 
murine complement regulators complement receptor-1 related gene/protein Y (Crry), 
CD59a, decay accelerating factor 1 (DAF1, CD55) and Factor H that are widely 
distributed and limit the formation of activated complement products (Figure 3.2). We 
can clearly observe CD59a by immunofluoresence microscopy in the presynaptic 
axonal and pSC membranes using mouse anti-CD59 mAb 7A6 (Donev et al., 2008). 
This is illustrated in Figure 3.6 (primary data), using transgenic mice provided in 
collaboration with the Thompson laboratory that also express the endogenously 
fluorescent proteins cyan fluorescent protein (CFP) and green fluorescent protein 
(GFP) respectively in the cytoplasm of these NMJ components (Feng et al., 2000; Zuo 
et al., 2004). We have also previously shown that CD59a deficiency plays an 
aggravating role in our model of injury, although in these studies the complement 
source was provided by NHS, a heterologous source of complement whose degree of 







expression of membrane-associated DAF1 and Crry has been more difficult to detect 
at this site by immunohistology.  
Using CD59a and DAF1 deficient mice in the McAb3 passive immunization model of 
myasthenia gravis, exacerbation of pathology has clearly been shown in comparison 
to wildtype, the presumption therefore being that both CD59a and DAF1 are present 
in the postsynaptic membrane (Lin et al., 2002; Morgan et al., 2006). In collaboration 
with the Medof laboratory, our passive immunization experiments conducted to date 
in CD59a/DAF1 double knockout mice with anti-ganglioside antibody (in the absence 
of NHS as a source of complement) have not clearly demonstrated any major clinical 
or morphological differences when compared with wildtype controls. This is in clear 
contrast to the situation with the myasthenia gravis model, both from the published 
data and from experiments we have also conducted in Glasgow in parallel by way of 
control. We are currently assessing these double knockout mice for subtle 
electrophysiological abnormalities (Zitman and Halstead, unpublished observations). 
Although we do observe an increase in C3c deposits in these double knockout mice, 
one of the limitations in detailing subtle quantitative changes in MAC levels in these 
studies has been the absence of suitable mouse MAC probes producing the very low 
backgrounds needed for our quantitative analytical methods, in comparison with the 
widely available reagents for human MAC. We therefore cannot conclude that no 










Figure 3.5. Complement 
activation ELISA 
Activation of complement in 
human and mouse serum was 
compared between 3 antibodies 
of different specificities, 
species and subclasses. MAbs 
CGM3 (mouse IgM), MOG35 
(mouse IgG2b) and McAb3 (rat 
IgG) were captured on micro-
titre plates and serial dilutions 
of human (A) or mouse serum 
(B) was applied. The 
complement activation capacity 
of the antibodies was assessed 
by detecting the presence of 
activated C3 with an anti-C3c 
antibody (Dako). Mouse mAbs 
CGM3 and MOG35 had 
comparable levels of human 
C3, while rat mAb McAb3 
fixed human C3 to a slighter 
lesser degree. All 3 mAbs 
activated mouse C3 to similar 
levels. Method based on 
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Many other complement regulators exist, and cross-regulation across species is 
complex and controversial (Morgan et al., 2005). Our previous studies using NHS in 
passively immunized mice have demonstrated activation of the complement cascade 
via the classical pathway (Halstead et al., 2004); however classical pathway deposited 
C3b can also serve as a nidus for the alternative pathway positive feedback loop, 
thereby resulting in the further amplification of the cascade (Fearon and Austen, 
1980). A key regulator of the alternative pathway is the soluble glycoprotein Factor H 
(fH), which has both decay accelerating activity against the alternative pathway C3 
convertase (Pangburn and Muller-Eberhard, 1978; Weiler et al., 1976) and cofactor 
activity for Factor I mediated C3b cleavage (Pangburn et al., 1977). Sialic acid 
enriched membrane (in our case the presynaptic membrane) has also been shown to 
prevent alternative pathway activation, by increasing the affinity of fH for C3b 
(Fearon, 1978; Kazatchkine et al., 1979). Indeed, we see heavy deposits of fH at 
NMJs as detected with polyclonal sheep anti-fH antibody (Abcam; primary data, 
Figure 3.7), but only in the presence of activated complement in our anti-ganglioside 
antibody and NHS passive immunization model. The amount of fH deposited in other 





Figure 3.6. Illustrative immunofluorescence image of whole-mount triangularis sternae nerve-
muscle preparation demonstrating the presence of CD59a at the NMJ 
Transgenic mice which express cytoplasmic green fluorescent protein in their Schwann cells (SC; 
upper right panel) and cyan fluorescent protein in their axons (Axon; lower left panel) were stained 
with α-bungarotoxin to delineate their postsynaptic nicotinic acetylcholine receptors (nAChR; upper 
left panel) and anti-mouse CD59 (upper middle panel). CD59 is present on both the motor axon and 
perisynaptic Schwann cells (asterisk).  







We therefore hypothesize that the failure of endogenous mouse complement to 
generate a pathological lesion in our anti-ganglioside antibody passive immunization 
model results from the relative inability of the classical pathway C5 convertase to 
cleave C5 and progress to MAC formation in the presynaptic membrane. In other 
sites, for example the postsynaptic membrane that is targeted in myasthenia gravis, 
this might be overcome by amplification of the alternative pathway loop which is 
activated through the deposition of classical pathway C3b. On the presynaptic 
membrane, where anti-ganglioside antibodies bind their sialic-acid containing 
ganglioside targets in glycolipid-enriched microdomains (functional rafts), it is 
possible that the alternative pathway loop might be especially highly regulated by fH 
because of the rich sialic acid environment at this site. fH could thereby more tightly 
regulate the progression of the cascade to MAC in this site compared with other sites 
where autoantibodies bind protein targets such as AChR, i.e. the postsynaptic 
membrane. This hypothetical model remains consistent with our unpublished 
observation of a rise in C3c levels in the DAF1/CD59a double knockout as the 
relative deficiency in the classical pathway C5 convertase (component C4b), along 
with the fH regulation discussed above, follows after the step at which DAF1 exerts 
its C3 convertase regulation. The implication of this is that the deficiency of CD59a, 
which regulates at the C5b-8 level, does not overcome the inhibitory events earlier in 
the pathway as there are no or very low levels of activation products for it to regulate. 
Further studies are needed to address these complex issues surrounding the activation 
and regulation of complement in different sites and species in models of antibody 
mediated autoimmune disease. 
 
 
Therapeutic strategies for the attenuation of complement 
activation 
 
As a result of the apparent inability of anti-glycolipid antibodies to fix mouse 
complement in the presynaptic membrane, our studies have been pursued with NHS 
as a source of heterologous complement. The mechanism(s) by which activation of 
human complement is able to proceed, where mouse complement fails is unknown, 
but presumably relates to a relative inefficiency of heterologous regulation. In our 
situation this species-specific effect has the fortuitous benefit of allowing us to test 
any complement therapeutics in a model system in which the complement component 
proceeding to MAC has essentially been “humanized”, and thus has added relevance 
to preclinical testing of agents that might be suitable for human clinical trials. 
Although anti-ganglioside antibodies may exert some of their paralytic effects directly 
(independent of complement) as shown in an extensive series of studies from the 
Toyka group (Buchwald et al., 2001), tissue bound antibody of the appropriate class 
as found in GBS (human IgG1 and IgG3) inevitably fixes complement to exacerbate 
injury unless complement regulation is highly active. Thus, one key approach that 
might be expected to suppress disease activity in anti-ganglioside antibody-mediated 
neuropathy is the suppression of complement activation. Since it is very clear that 
complement activation with MAC formation drives neural membrane injury in anti-
ganglioside antibody treated mouse tissue and in rabbit models of acute motor axonal 
neuropathy (Susuki et al., 2007a), it would appear likely that blocking MAC 
formation locally should prevent MAC-dependent tissue injury, even if anti-
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investigated this using the complement inhibitor APT070 that contains the C3/C5 
convertase inhibiting region of complement receptor 1 and a membrane-localizing 
peptide that allows it to inhibit complement accumulation. APT070 pretreatment 
completely abrogated MAC formation and acute tissue injury of anti-ganglioside 




Figure 3.7.  Illustrative immunofluorescence images of mouse triangularis sternae nerve-muscle 
organ bath preparations in vitro, demonstrating complement deposition at the NMJ  
Live mouse tissue was incubated with the anti-ganglioside IgM mAb, CGM3, followed by 40% normal 
human serum (NHS) as a source of complement, according to Halstead (Halstead et al., 2005b). A. 
Postsynaptic nicotinic acetylcholine receptors (nAChR) delineate the NMJ (top). Factor H (fH, middle) 
is extensively deposited present on the terminal motor axon and perisynaptic Schwann cells (asterisk). 
B. In this model, the complement cascade in human serum is activated, culminating in human 
membrane attack complex (MAC; middle) deposits over presynaptic neuronal and Schwann cell 
membranes.  







We have also assessed the efficacy of the humanized anti-C5 mAb eculizumab, which 
neutralizes C5 and thereby blocks the formation of human C5a and C5b-9, in 
preventing the anti-ganglioside antibody and complement-mediated motor nerve 
terminal injury (Halstead et al., 2008a). In these studies, eculizumab completely 
prevented electrophysiological and structural lesions at anti-GQ1b antibody pre-
incubated NMJs in vitro when using NHS as a complement source. In our in vivo 
mouse model of MFS generated through intraperitoneal injection of anti-GQ1b 
antibody and NHS, mice developed respiratory paralysis due to transmission block at 
diaphragm NMJs, resulting from anti-GQ1b antibody binding and complement 
activation. Intravenous injection of eculizumab effectively prevented respiratory 
paralysis and associated functional and morphological hallmarks of terminal motor 
neuropathy. Very recently we have also assessed whether the complement C5 
inhibiting recombinant protein, rEV576, derived from tick saliva (Hepburn et al., 
2007), is able to prevent neural injury in the mouse model for MFS (Halstead et al., 
2008b). Again, mouse hemi-diaphragm preparations were treated with anti-GQ1b 
antibody and NHS as a source of complement with added rEV576 or control protein. 
In control tissue C3c and MAC were deposited at NMJs, along with terminal motor 
axonal NF degradation, pSC injury and electrophysiological and functional 
impairment. In tissue treated with rEV576, all these indicators of motor neuronal 
damage were absent, except for the presence of C3c, indicating effective inhibition of 
C5. These results demonstrate that rEV576 is a further agent that effectively prevents 





It is well established that MAC is present in human GBS nerve biopsy and autopsy 
material and that this is likely to be an important step in generating pathology and 
functional loss. It is also very clear that complement activation with MAC formation 
drives neural membrane injury in our models of anti-ganglioside antibody treated 
mouse tissue. Since MAC is a convergence pathway in many antibody and 
complement-mediated diseases it would seem an excellent target for human 
therapeutic trials. Whilst our studies focus on ganglioside targets in the presynaptic 
membrane, other presynaptic targets and the postsynaptic membrane that is targeted 
by antibody in myasthenia gravis are also important candidates for therapeutic 
complement inhibition. The use of complement inhibition trials in clinical practice is 
thus eagerly awaited across several disease areas of antibody-mediated clinical 
neuroimmunology at the NMJ, to which the pioneering contribution of John Newsom-
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Anti-GQ1b ganglioside antibodies are the serological hallmark of the Miller Fisher 
syndrome (MFS) variant of the paralytic neuropathy, Guillain-Barré syndrome, and 
believed to be the principal pathogenic mediators of the disease. In support of this, we 
previously showed in an in vitro mouse model of MFS that anti-GQ1b antibodies 
were able to bind and disrupt presynaptic motor nerve terminals at the neuromuscular 
junction (NMJ) as one of their target sites, thereby causing muscle paralysis. This 
injury only occurred through activation of complement, culminating in the formation 
and deposition of membrane attack complex (MAC, C5b-9) in nerve membranes. 
Since this step is crucial to the neuropathic process and an important convergence 
point for antibody and complement mediated membrane injury in general, it forms an 
attractive pharmacotherapeutic target. Here, we assessed the efficacy of the 
humanized monoclonal antibody eculizumab, which blocks the formation of human 
C5a and C5b-9, in preventing the immune-mediated motor neuropathy exemplified in 
this model. Eculizumab completely prevented electrophysiological and structural 
lesions at anti-GQ1b antibody pre-incubated NMJs in vitro when using normal human 
serum as a complement source. In a novel in vivo mouse model of MFS generated 
through intraperitoneal injection of anti-GQ1b antibody and normal human serum, 
mice developed respiratory paralysis due to transmission block at diaphragm NMJs, 
resulting from anti-GQ1b antibody binding and complement activation. Intravenous 
injection of eculizumab effectively prevented respiratory paralysis and associated 
functional and morphological hallmarks of terminal motor neuropathy. We show that 
eculizumab protects against complement-mediated damage in murine MFS, providing 
the rationale for undertaking clinical trials in MFS and other antibody-mediated 
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Miller Fisher syndrome (MFS) is characterized by the triad of ataxia, areflexia and 
ophthalmoplegia (Fisher, 1956) and is a clinical variant of the post-infectious 
paralytic neuropathy, Guillain-Barré syndrome (GBS) (Hughes and Cornblath, 2005). 
MFS is associated with anti-GQ1b ganglioside antibodies that are considered to be the 
predominant pathogenic factor and may arise through molecular mimicry during a 
preceding infection with Campylobacter jejuni or other microbes bearing GQ1b 
mimics in their lipooligosaccharide (Goodyear et al., 1999; Willison and O'Hanlon, 
1999; Yuki, 2001; Bowes et al., 2002). Gangliosides are a family of sialylated 
glycosphingolipids that are enriched in neuronal cell membranes (Ledeen, 1985). 
Opthalmoplegia in MFS is thought to be related to the relatively high GQ1b 
ganglioside level in oculomotor nerves, forming a preferential antigenic target for 
anti-GQ1b antibodies (Chiba et al., 1993). Furthermore, anti-GQ1b antibody binding 
to the presynaptic motor nerve terminal compartment of the neuromuscular junction 
(NMJ), causing synaptic transmission block, has been proposed by us and others from 
animal studies (Roberts et al., 1994; Buchwald et al., 1995; Plomp et al., 1999). This 
idea was based on data that 1) botulism, an established NMJ disorder, is an important 
differential diagnosis for MFS, 2) cholinergic synapses are highly enriched in 
gangliosides (Schwarz and Futerman, 1996) and 3) NMJs are easily accessible by 
antibodies because there is no blood-nerve barrier. A number of case studies have 
since supplied clinical electrophysiological indications for NMJ dysfunction in MFS 
(Uncini and Lugaresi, 1999; Wirguin et al., 2002; Sartucci et al., 2005; Lange et al., 
2006; Lo et al., 2006).  
We have developed an in vitro experimental mouse model for MFS in which NMJs of 
the diaphragm-phrenic nerve preparation are exposed to mouse or human 
(monoclonal) anti-GQ1b antibodies or anti-GQ1b positive patient sera. The model has 
been extensively characterized in electrophysiological, morphological and functional 
studies (Goodyear et al., 1999; Plomp et al., 1999; Bullens et al., 2000; O'Hanlon et 
al., 2001; Jacobs et al., 2002; Halstead et al., 2004). These studies demonstrate that 
both human and mouse anti-GQ1b polyclonal antisera and monoclonal antibodies 
bind to the presynaptic motor nerve ending and activate the complement cascade, 
culminating in the formation of membrane attack complex (MAC, C5b-9). This pore-
forming complex damages the presynaptic membrane, causing uncontrolled 
neurotransmitter release, ultrastructural destruction of the nerve terminal, and finally, 
blockade of neuromuscular transmission with resultant paralysis.  
Tissue-bound antibody of the appropriate class fixes complement and experimental 
neuropathological effects in our MFS model are strictly dependent on complement 
activation (Plomp et al., 1999; Bullens et al., 2000; Halstead et al., 2004). 
Furthermore, there is evidence of complement involvement in variants of GBS 
(Sanders et al., 1986; Koski et al., 1987; Hartung et al., 1987; Hafer-Macko et al., 
1996a). In view of the above, the complement system is an attractive target for 
pharmacotherapeutic intervention in MFS, and has led us to examine inhibitors of 
complement activation as potential therapies for the disease in humans, and by 
inference, also for pathophysiologically similar forms of GBS and other autoimmune 
neuropathies, including chronic inflammatory demyelinating polyneuropathy and 
multifocal motor neuropathy (Halstead et al., 2005a). Eculizumab (Soliris, Alexion 
Pharmaceuticals) is a humanized monoclonal antibody (mAb) that specifically binds 







the formation of the proinflammatory and cell lytic molecules C5a and C5b (Thomas 
et al., 1996). Targeted blockade of complement at C5 preserves the earlier 
immunoprotective effects of complement activation (e.g. C3b opsonisation and 
phagocytosis). In addition to protecting against antibody mediated effects, 
complement inhibitors also have the potential to protect against secondary events such 
as those occurring in Wallerian degeneration (Ramaglia et al., 2007). Eculizumab has 
recently been approved to treat paroxysmal nocturnal haemoglobinuria, a genetic 
disorder with complement-mediated haemolysis as the primary clinical manifestation 
(Hillmen et al., 2006). 
Here, we investigated the possible benefit of eculizumab in immune-mediated 
neuropathy by assessing its effects in the existing in vitro model for MFS and in a 
newly generated in vivo mouse model with paralytic symptoms. Despite extensive in 
vitro data, characterization of an anti-GQ1b antibody mediated clinical phenotype in 
active or passive immunisation models in the living mouse has not been achieved to 
date. Here we have used plethysmography to quantify respiratory function in living 
mice passively immunized with anti-GQ1b antibody and human complement through 
intraperitoneal injection and demonstrate the rapid development of a severe 
respiratory phenotype. Eculizumab completely prevented the presynaptic 
electrophysiological dysfunction and structural damage at in vitro NMJs that had been 
pre-incubated with anti-GQ1b mAb and efficiently prevented in vivo respiratory 






Male Balb/c mice (3-6 weeks old, 10-25 g) were obtained from Harlan (UK or NL). In 
some muscle contraction experiments (see below) male and female GM2synthase 
null-mutant mice (Bullens et al., 2002) were used at 12-22 weeks of age (19-37 g). All 
animal experiments were carried out in accordance to UK Home Office guidelines 
(UK PPL60/3096), Dutch law and Glasgow and Leiden University guidelines. 
 
Monoclonal antibodies and normal human serum  
The IgM anti-GQ1b ganglioside mAb, CGM3 was derived from mice inoculated with 
a GT1a-bearing C. jejuni lipooligosaccharide (Goodyear et al., 1999). CGM3 reacts 
with gangliosides GQ1b, GD3 and GT1a that all share the terminal disialylgalactose 
structure. Previous in vitro studies have shown that CGM3 has similar ganglioside 
specificity and induces identical complement-dependent pathogenic effects as human 
MFS sera (Goodyear et al., 1999; Plomp et al., 1999; Bullens et al., 2000; Jacobs et 
al., 2002; Jacobs et al., 2003). The advantage of using a mAb for these studies is that, 
unlike human sera, it is a quantitatively unlimited and homogeneous resource that can 
be fully quantified and characterized and prepared as a stock solution for long-term 
use during the course of the experiments. CGM3 concentration was measured using 
quantitative ELISA (Bethyl Laboratories). Normal human serum (NHS) was taken 
from a single donor stock that had been freshly frozen and stored in multiple aliquots 
at -70 °C to preserve complement activity. Prior to experimental use, CGM3 and NHS 
were dialyzed for 24 h at 4 °C against Ringer’s solution (116mM NaCl, 4.5mM KCl, 
1mM MgCl2, 2mM CaCl2, 1mM NaH2PO4, 23mM NaHCO3, 11mM glucose, pH 7.4), 
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and a non-specific isotype-matched control mAb ALXN3300 were obtained from 
Alexion Pharmaceuticals and stored at 4 ºC. Eculizumab binds plasma C5 only and 
thereby prevents its cleavage into C5a and C5b in the liquid-phase, but does not bind 
to membrane bound C5b as part of the MAC complex. The anti-C5 antibody is 
therefore not deposited in the tissue. Eculizumab is also monospecific for human C5, 
and does not bind to C5 from other species, including the mouse. Thus in this model, 
eculizumab is only capable of neutralizing the heterologous C5 in the human serum 
added as a final step in the in vitro exposure and passive immunization paradigms. 
 
In vitro MFS model  
The in vitro model for MFS using CGM3 and NHS has been described before 
(Goodyear et al., 1999; O'Hanlon et al., 2001). In short, mouse hemi-diaphragms with 
phrenic nerve attached (or triangularis sterni muscle in some cases for illustrative 
NMJ immunohistology) were dissected and mounted in Ringer's medium at room 
temperature (20-22 °C). Untreated small control sections were removed from each 
muscle preparation prior to any incubation and snap frozen on dry ice for subsequent 
baseline immunohistological analysis. Muscles were incubated with CGM3 (50 
µg/ml) for 2-2.5 h at 32 ºC, then for 30 min at 4 ºC and then equilibrated for 10 min at 
room temperature, rinsed in Ringer's medium and subsequently exposed to 33 or 40% 
NHS in Ringer's medium for 1 h at room temperature. Eculizumab (100 µg/ml) or the 
control mAb (100 μg/ml) was mixed with NHS 10 min prior to the incubation of the 
muscle preparation. In vitro electrophysiological measurements at the NMJ (see 
below) and scoring of muscle fibre twitching, a hallmark of uncontrolled transmitter 
release at NMJs in this model (O'Hanlon et al., 2001; Jacobs et al., 2002), were 
performed before and after CGM3 incubation, and during the 1 h NHS incubation. 
Muscle strips were frozen on dry ice and stored at -20 °C, both before and after 
incubation with NHS. NMJs and terminal motor axons were assessed for levels of 
IgM, C3c, MAC, neurofilament (NF) and for perisynaptic Schwann cell (pSC) 
viability (see below). 
 
In vivo MFS model 
Balb/c mice (3-4 weeks old, 10-15 g) were injected intraperitoneally with 1.5 mg 
CGM3, followed 16 h later by an intraperitoneal injection of 0.5 ml 100% NHS. Mice 
were observed for a further 4-6 h and analyzed with whole-body plethysmography 
(see below) and grip strength testing as described before (Kaja et al., 2007a). The 
mice were then killed by CO2 asphyxiation and hemi-diaphragm muscle tissue was 
dissected and analyzed in electrophysiological and muscle contraction experiments 
(see below) or further processed for immunohistological analyses (see below). The 
effect of eculizumab on the in vivo symptoms and the subsequently analyzed 
electrophysiological, functional and histological lesions was tested in this model by 
injecting 200 μg eculizumab or control mAb in the tail vein, shortly before 
intraperitoneal NHS injection. Initial dose-range finding experiments (data not shown) 
indicated that eculizumab at doses of >50 µg/mouse protected against neuropathy. 
 
Plethysmography 
Non-invasive whole-body plethysmography (EMMS) was employed to demonstrate 
changes in breathing parameters in in vivo experiments. Baseline data was collected 
prior to onset of experiment. Mice were injected with CGM3 followed by NHS with 







for 6 h. Flow derived parameters of breath frequency and tidal volume were collected 






Figure 3.8. Immunohistological demonstration of the protective effect of eculizumab against MAC 
deposition and terminal motor axonopathy at NMJs in the in vitro MFS model. Mouse hemi-diaphragm 
preparations were pre-incubated with anti-GQ1b ganglioside mAb CGM3 (50 µg/ml) and subsequently 
treated with 40% normal human serum (NHS) with either added eculizumab (anti-human C5 
neutralizing mAb; 100 µg/ml) or non-specific isotype-matched control mAb (100 µg/ml), and 
compared with untreated tissue. A. Tissues treated with NHS/eculizumab showed intense C3c staining 
at NMJs, similar to that of NHS/control mAb-treated tissues (p=0.12). B. Membrane attack complex 
(MAC) staining was not observed (intensity comparable to baseline, p=0.92), indicating complete 
inhibition of terminal complement. C. Axonal integrity was preserved, as assessed by presence of 
neurofilament (NF) signal, comparable to baseline in untreated controls (p=0.80). D-F. Illustrative 
immunofluorescent images of NMJs in whole-mount muscle demonstrating the protective effect of 
eculizumab against MAC deposition (D), perisynaptic Schwann cell damage (stained with ethidium 
homodimer-1; EthD1; E) and terminal motor axonal damage (F), as compared to NHS/control mAb 
treatment. Postsynaptic nicotinic acetylcholine receptor (nAChR) staining was used to delineate the 
NMJ. Intermediate complement protein C3c (D) remains abundantly deposited at NMJs. 
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In vitro electrophysiological analysis of NMJs and visual scoring of muscle 
contractility 
Left and right hemi-diaphragms with their phrenic nerve attached were dissected and 
pinned out in a silicone rubber-lined dish in 1.5 ml Ringer's medium at room 
temperature. Intracellular recordings of miniature endplate potentials (MEPPs, the 
postsynaptic events arising from spontaneous release of single acetylcholine quanta 
from the presynaptic motor nerve terminal) were made at NMJs at 20-22 °C. Muscle 
fibres were impaled near the NMJ with a 10-20 MΩ glass micro-electrode filled with 
3 M KCl, connected to a GeneClamp 500B amplifier (Axon Instruments/Molecular 
Devices) for amplifying and filtering (10 kHz low-pass) of the signal. Signals were 
digitized, stored and analyzed (off-line) using a Digidata 1322A interface, Clampex 
9.2 and Clampfit 9.2 programs (all from Axon Instruments/ Molecular Devices), Mini 
Analysis 6.0 (Synaptosoft) and routines programmed in Matlab (The MathWorks 
Inc.). 
The occurrence of spontaneous asynchronous fibre twitches that are induced by a high 
MEPP frequency resulting from CGM3/complement-mediated presynaptic damage 
(Plomp et al., 1999) was scored visually every 5 min (O'Hanlon et al., 2001). The 
tissue scored 0 for no activity, 1 for the twitching of <10 fibres, 2 for a small amount 
of twitching across the tissue, 3 for a moderate amount and 4 for an extensive amount. 
The average score during each measuring period was calculated. The final result of 
CGM3/complement-mediated presynaptic damage is a silencing of synaptic 
transmission at the NMJ. The number of “silent” NMJs (i.e. without detectable 
MEPPs and occurrence of phrenic nerve-stimulation evoked muscle action potentials) 
was expressed as percentage of the total number of NMJs sampled (8-41) in a muscle 
under each experimental condition. 
 
Muscle contraction experiments 
The protective efficacy of eculizumab on in vitro CGM3/NHS-induced loss of nerve 
stimulation-evoked contraction force of the hemi-diaphragm preparation was tested. 
We used diaphragm from GM2synthase null-mutant mice because earlier studies 
showed a somewhat higher sensitivity of muscle of this strain to CGM3/NHS-induced 
loss of contraction (Bullens et al., 2002). Left and right phrenic nerve-hemi-
diaphragm preparations that had been pre-incubated with 200 μg/ml CGM3 for 3 h at 
32 °C were mounted in a silicone-rubber lined dish containing 2.25 ml Ringer's 
medium at room temperature (20-22 °C), continuously bubbled with 95% O2 / 5% 
CO2. The ribcage side of the muscle was thoroughly fixed to the bottom of the dish by 
multiple small pins and the central tendon was connected via a metal hook and a 
string to a force transducer that was connected to an amplifier and digitizing 
equipment, as described earlier (Kaja et al., 2007a). Supramaximal stimuli (usually 
~10 V) of 100 μs duration were delivered every 5 min for 3 s at 40 Hz from a Master-
8 programmable stimulator (AMPI). Basic tension was adjusted with a vernier control 
to obtain maximal stimulated tetanic contraction force (usually about 10 g). Stability 
of the elicited contraction was monitored for 30-50 min. Subsequently, the medium 
was replaced by NHS (33%) to which eculizumab (3, 6, 9, 12, 25, 50 or 100 μg/ml) 
had been added and admixed for ~10 min prior to addition and the effect was 
monitored for 100-200 min, under continuous gentle bubbling with 95% O2 / 5% CO2. 
In the control experiments without added eculizumab, 100 μg/ml of the control mAb 
was added to the NHS. The amplitude of contractions was cursor-measured off-line in 
the Clampfit 9.0 program (Axon Instruments/Molecular devices), at 2 s after the start 







Tetanic and twitch contraction forces were also measured upon in vitro nerve 
stimulation of left hemi-diaphragm muscles that were dissected from mice that had 





Figure 3.9. Eculizumab protects against electrophysiological and functional defects induced at NMJs 
in the in vitro MFS model. Mouse hemi-diaphragm preparations were pre-incubated with anti-GQ1b 
ganglioside mAb CGM3 (50 μg/ml) and subsequently treated with 40% normal human serum (NHS) 
with either added 100 μg/ml eculizumab (anti-human C5 neutralizing mAb) or non-specific isotype-
matched control mAb. A. Spontaneous uniquantal acetylcholine release, measured as MEPP frequency, 
at the NMJ. Eculizumab prevented the induction of a high MEPP frequency by NHS at CGM3-
incubated NMJs (p<0.001, n=5 muscles). B. Representative 1 s duration traces obtained during 
incubation with NHS, either with added eculizumab (upper trace) or control mAb (lower trace). C. 
Asynchronous twitching of muscle fibres induced by NHS was largely prevented by eculizumab 
(p<0.01, n= 5 muscles). D. Eculizumab completely prevented the occurrence of “silent” NMJs (i.e. 
without detectable synaptic electrophysiological signals). E-G. Hemi-diaphragm muscle-nerve 
preparations were pre-incubated with 200 μg/ml CGM3 and the protective effect of several 
concentrations eculizumab (0-100 μg/ml, n=2-5 muscles per concentration) added to the NHS was 
observed in muscle contraction force recording experiments. E. Examples of the contraction profiles 
observed at 0, 30, 60 and 90 min after the start of the NHS incubation with either no eculizumab added 
or 6 or 100 μg/ml added. Each contraction was elicited by supramaximal electric stimulation of the 
phrenic nerve for 3 s at 40 Hz. F. Development of the contraction loss during NHS incubation with the 
various concentrations eculizumab added. G. Concentration-effect relationship of eculizumab and the 
protection against loss of contraction after 90 min after the start of the NHS incubation. A Boltzmann 
sigmoidal curve is fitted through the data points, yielding an EC50 of 7.1 μg/ml.  








Unfixed hemi-diaphragm sections were mounted in Lipshaw’s M-1 mounting 
medium, and longitudinal cryostat sections (8-20 µm) were cut onto 3-
aminopropyltriethoxysilane coated slides, air-dried, then stored at –20 °C. To localize 
NMJs, TRITC and bodipy-labelled α-bungarotoxin (αBTx, diluted 1/750 to 1.3 μg/ml; 
Molecular Probes) were used. The intermediate complement component C3c was 
detected by incubation with FITC-labelled rabbit anti-C3c (1/300; Dako) for 1 h at 4 
ºC. MAC was detected using mouse anti-human C5b-9 (1/50; Dako) followed by 
FITC conjugated goat anti-mouse IgG (1/300), both for 1 h at 4 ºC. 
For NF staining, sections of unfixed tissue were pre-incubated for 1 h at 4 ºC with 
TRITC-conjugated αBTx, rinsed, immersed in ethanol at –20 ºC for 20 min, then 
incubated overnight at room temperature with the rabbit polyclonal serum 1211 
(1/750; reactive with phosphorylated NF; Affiniti Research Products Ltd.) followed 
by FITC conjugated goat anti-rabbit IgG (1/300; Southern Biotechnology Associates) 
for 3 h at 4 ºC. All detection antibodies were diluted in phosphate-buffered saline 
(PBS). 
pSC viability was assessed using ethidium homodimer-1 (EthD-1), a membrane 
impermeant dye that labels with red fluorescence the nucleic acids of membrane-
permeabilized cells (Molecular Probes). In brief, nerve-muscle preparations were 
exposed to Ringer’s containing 2 μM EthD-1. The tissue was incubated in the dark at 
room temperature for 1 h, rinsed in Ringer’s solution and frozen for 
immunohistology. NMJs were identified in 15 μm cryostat sections by staining with 
bodipy conjugated αBTx (1.3 μg/ml), and the percentage of NMJ with EthD-1 
positive nuclei at NMJs was calculated. 
For illustrations, whole mount triangularis sterni muscles were incubated with CGM3 
(50 µg/ml) and fluorochrome-conjugated αBTx (TRITC/FITC/Cy5) (2 μg/ml; 1:500), 
followed by NHS plus eculizumab or control mAb. Preparations were incubated with 
fluorescently conjugated αBTx and various combination of the following: mouse anti-
C5b-9 (1:40; Dako), anti-C3c-FITC (1:200; Dako), or EthD-1 (2 µM) in Ringer's 
medium for 1 h at room temperature, rinsed in Ringer's medium, followed by fixation 
for 20 min in 4% formaldehyde in PBS. Unreactive aldehyde groups were quenched, 
by incubating with 0.1 M glycine for 10 min. The antibodies were then reapplied in 
PBS and agitated overnight at room temperature. For staining of intracellular antigens, 
muscle was fixed in 4% formaldehyde for 20 min followed by 10 min in 0.1M glycine 
and then incubated in a permeabilizing solution of 0.5% Triton-X100 in PBS for 30 
min at RT, and either rabbit anti-S100 (1:150; Dako) or rabbit anti-NF (1:150; 
Chemicon) diluted in permeabilizing solution applied overnight at room temperature.  
Tissue was rinsed in PBS and where necessary incubated in the following 
fluorescently conjugated antibodies diluted 1:300; anti-rabbit IgG-FITC, anti- mouse 
IgG-FITC or -TRITC and agitated for 7h at room temperature in the dark. Tissue was 
rinsed in PBS and mounted in Citifluor mounting medium (Citifluor Products).  
 
Image acquisition, quantitation and statistical analysis 
Digital images were captured using both Zeiss Pascal confocal laser scanning 
microscope and Zeiss Axio Imager Z1 with ApoTome. Image-analysis measurements 
were made using Scion Image (Scion Corporation Frederick) image analysis software. 
For quantitative analysis of IgM, C3c, MAC and NF, three staining runs of each 
marker were performed on tissue from at least three individual hemi-diaphragms, and 
quantified as previously described (O'Hanlon et al., 2001). All studies were observer 







comparisons were made using Mann-Whitney Test employing a 1% level of 
significance. For comparison of EthD-1 positive pSC at the NMJ, chi-squared test was 





Figure 3.10. Respiratory paralysis in the in vivo MFS model is prevented by eculizumab due to 
inhibition of presynaptic block of neuromuscular transmission in the diaphragm. Mice (n=6) were 
intraperitoneally injected with 1.5 mg anti-GQ1b ganglioside mAb CGM3 and, 16 h later, with 0.5 ml 
100% normal human serum (NHS) as complement source. A dose of 200 μg eculizumab or control 
mAb was injected in the tail vein shortly before the NHS injection. A. Grip strength analysis at 2h post-
NHS injection. Eculizumab prevented the loss of pulling force observed in the control mAb group 
(p<0.01). B. Average tidal volume and C. breathing rate measured with whole-body plethysmography 
before NHS injection and during the 2nd, 4th and 6th hour post-NHS injection. The development of 
breathing difficulty was prevented by eculizumab. D. Example 1 s traces of plethysmography flow rate 
obtained in eculizumab- and control mAb-treated mice. E. Twitch force and F. tetanic force elicited in 
the dissected diaphragm muscle by single and 40 Hz electrical nerve stimulation, respectively. 
Eculizumab completely prevented the severe paralysis observed in muscles from control mAb-treated 
mice (p<0.01). G. Eculizumab almost completely prevented the occurrence of “silent” NMJs (i.e. 
without detectable synaptic electrophysiological signals) in these mice (p<0.001). H. Thirty 
superimposed representative traces of 1 s duration obtained in NMJs of muscle from eculizumab-
treated (upper traces) or control mAb-treated (lower traces) mice.   
Error bars in the bar graph panels of this figure represent SEM. 









Figure 3.11. Morphological analysis of NMJs of diaphragm tissue from in vivo MFS mice. Mice were 
passively immunized with 1.5 mg anti-GQ1b ganglioside mAb, CGM3, followed 16 h later with 
concomitant injections of 0.5 ml 100% NHS (intraperitoneal) and eculizumab or control mAb 
(intravenous; 200 µg). A-B. C3c and membrane attack complex (MAC) deposition is reduced at 
neuromuscular junctions (NMJs) of eculizumab-treated mice compared with controls (p< 0.01). C. 
Neurofilament (NF) signal was significantly greater at NMJs of muscles from eculizumab-treated mice, 
compared with control (p<0.01). D-E. Illustrative immunofluorescent images of NMJs in whole-mount 
muscle. Postsynaptic nicotinic acetylcholine receptors (nAChR) staining was used to delineate NMJs. 
D. C3c and MAC deposition. E. NF integrity and MAC deposition. F. Electron micrograph of 
eculizumab-protected nerve terminals with tightly packed synaptic vesicle and electron dense 
mitochondria with parallel cristae. At NMJs from control mAb-treated mice, nerve terminals are 
electron lucent with sparse synaptic vesicles and swollen mitochondria. #p<0.01, different from control 









Eculizumab prevents complement-mediated structural and functional lesions in 
the in vitro MFS model  
In the in vitro MFS model, treatment of diaphragm nerve-muscle preparations with 
CGM3 anti-GQ1b mAb and NHS, in the presence of an irrelevant isotype matched 
mAb (100 μg/ml), that served as a negative control for eculizumab, induced 
complement activation at NMJs. This was morphologically evidenced by C3c and 
MAC deposition (Figure 3.8A, B, D, E and F), as well as damaged pSCs and motor 
nerve terminals shown by EthD-1 staining and loss of neurofilament (NF) staining, 
respectively (Fig. 3.8C, E and F). These features were identical to those reported 
before (Goodyear et al., 1999; O'Hanlon et al., 2001; Halstead et al., 2004). The 
addition of 100 μg/ml eculizumab to the NHS as complement source completely 
prevented MAC deposition (Fig. 3.8B, D, E and F; p<0.001) and terminal axonal NF 
loss (Fig. 3.8C and F; p<0.001), while the deposition of the earlier complement 
component C3c was not affected (Figure 3.8A and D; p= 0.12). Furthermore, damage 
to pSCs was abolished as only 2% of the 1439 NMJs investigated had one or more 
EthD-1 positive nuclei, compared with 33% of 1529 NMJs investigated in control 
mAb-treated tissue (Figure 3.8E; p<0.001). 
These immunohistological observations paralleled the electrophysiological and 
functional observations. At CGM3 pre-incubated NMJs, NHS (40%) in the presence 
of the control mAb induced a large increase in the frequency of MEPPs, the 
postsynaptic events arising from spontaneous release of single acetylcholine quanta 
from the presynaptic motor nerve terminal, as previously observed (Goodyear et al., 
1999). This effect was almost completely prevented by 100 μg/ml eculizumab. The 
MEPP frequency was about 0.7 s-1 before and after 50 μg/ml CGM3 incubation and 
rose to 34.0 ± 4.6 s-1 in the presence of NHS with 100 μg/ml control mAb added. In 
contrast the MEPP frequency was only 3.1 ± 1.3 s-1 in the presence of NHS with 100 
μg/ml eculizumab added (Figure 3.9A and B; n=5 muscles; p<0.001).  
Eculizumab did not alter the muscle fibre resting membrane potential or MEPP 
amplitude, rise- and decay times (data not shown). As described before (Goodyear et 
al., 1999; Plomp et al., 1999), asynchronous twitching of individual muscle fibre 
occurs during NHS incubation (median visual score 4; n=5 muscles). Eculizumab 
prevented such high grade of twitching. Only a median score of 1 was observed 
(Figure 3.9C; n=5 muscles, p<0.01, Mann-Whitney test), which equals the low basal 
levels observed in the observation periods before and after CGM3 incubation.  
The final result of anti-CGM3/complement-mediated presynaptic damage is block of 
synaptic transmission at the NMJ due to the inability to release acetylcholine 
(Goodyear et al., 1999). Eculizumab completely prevented this effect. No “silent” 
NMJs (i.e. absence of MEPPs and nerve-stimulation evoked muscle action potentials) 
were encountered, whereas in the control mAb condition 19 ± 2.6 % of the total 
number of NMJs sampled were observed to be silenced (Figure 3.9D; n=5 muscles). 
Furthermore, we quantified the protective effect of eculizumab on muscle paralysis in 
the in vitro MFS model. Eculizumab inhibited loss of nerve stimulation-induced 
contraction force of hemi-diaphragm preparations in a concentration dependent 
manner following 200 μg/ml CGM3 and 33% NHS treatment (Figure 3.9E and F). In 
the control experiments without eculizumab, NHS induced almost complete loss of 
contraction force within 90 min. Addition of 3 or 6 μg/ml eculizumab to the NHS 
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at 39 and 60 min, respectively, compared to 27 min in the control condition; Figure 
3.9F). Higher eculizumab concentrations of 9 and 12 μg/ml were almost completely 
protective (>90% of the initial contraction left after 90 min) while 25, 50 and 100 
μg/ml completely prevented any CGM3/NHS-induced loss of contraction. A 
Boltzmann sigmoidal curve fitted through the obtained concentration-effect data 
points yielded an EC50 of 7.1 μg/ml for eculizumab under these conditions (Figure 
3.9G). These immunohistological and functional analyses show that eculizumab 
efficiently prevents complement-mediated pathophysiological effects in the in vitro 
MFS model. 
 
Eculizumab protects against neuropathy and respiratory paralysis in an in vivo 
MFS model 
In order to determine the in vivo efficacy of eculizumab, we generated an in vivo MFS 
mouse model through intraperitoneal injection of CGM3 anti-GQ1b antibody and 
NHS as complement source. At 16 h after the CGM3 injection, a dose of 200 μg 
eculizumab or control mAb was administered systemically, via the tail vein, followed 
by intraperitoneal injection of 0.5 ml NHS. The protocol of different injection routes 
of eculizumab and NHS was applied to avoid the immediate inhibition of C5 in the 
NHS by eculizumab within the confinement of the peritoneal cavity. Mice treated 
with CGM3, NHS and control mAb (n=10) developed a general weak appearance, in 
some cases a low-back posture, invaginated abdominal flanks and breathing 
difficulties (panting) within 2 h following the NHS injection (see supplementary 
material). Intravenous eculizumab injection completely prevented the development of 
these symptoms (n=11). We quantified weakness with grip strength measurement in 
CGM3 pretreated mice, before and 2h after injection of control mAb or eculizumab 
and NHS (Figure 3.10A). Control group mice (n=5) pulled 56.0 ± 5.7 g just before the 
control mAb and NHS injection, while the eculizumab group mice (n=5) pulled 54.3 ± 
8.4 g (p=0.87) at this stage. The pulling force 2 h after control mAb/NHS injection 
was 22% lower (43.7 ± 4.5 g; p<0.005). Eculizumab prevented such an effect (8% 
reduction; p=0.07). Respiratory disturbance was assessed with whole-body 
plethysmography continuously after mAb/NHS injection for a period of 6 h (Figure 
3.10B and C; n=5 mice per group). The tidal volume before CGM3 injection was 
similar in both groups (0.21 ± 0.01 and 0.22 ± 0.03 ml in the control mAb and 
eculizumab group, respectively). A reduction of ~50% (p<0.001) was observed in the 
control mAb group at 4 and 6 h after NHS injection. Such a decrease was largely 
prevented by eculizumab (only 17% reduction at these time points, Figure 3.10B). 
Similarly, respiration rate was depressed in the control mAb group by ~30% (p<0.01) 
at 4 and 6 h post-NHS injection. In the eculizumab group, this reduction was only 7% 
(Figure 3.10C). Both treatment groups showed an equal initial reduction of about 40% 
of the respiration rate when measured 2 h post mAb/NHS, compared to the rate before 
CGM3 injection, which apparently was due to the intraperitoneal injection regimen. 
Example traces of the respiration flow rate obtained 4 h post-NHS are shown in 
Figure 3.10D.  
We dissected hemi-diaphragm phrenic nerve preparations from in vivo CGM3/NHS 
treated mice at 4 h following NHS injection and performed electrophysiological 
measurements at NMJs, muscle contraction experiments, and detailed 
immunohistological analyses. Visual inspection indicated that only a very small part 
of the muscles from control mAb-treated mice contracted upon supramaximal 
electrical stimulation of the phrenic nerve, as compared to a complete contraction of 







tissues harvested from passive immunizations, this effect was quantified (Figure 
3.10E and F). Twitch and tetanic (40 Hz) tension was 0.07 ± 0.06 and 0.92 ± 0.61 g, 
respectively, in the control mAb group (n=4), while that in the eculizumab group 
(n=4) was 1.36 ± 0.29 and 9.26 ± 0.65 g, respectively, equalling the values of muscles 
from non-NHS treated age-matched mice (data not shown). With electrophysiological 
analysis we tested whether paralysis was caused by NMJ dysfunction. In dissected 
muscles from the control mAb group 66 ± 7% of the sampled NMJs had been 
“silenced”, i.e. there were no detectable MEPPs and no muscle action potentials upon 
nerve stimulations. In the eculizumab group only 3 ± 2% had been “silenced” (Figure 
3.10G and H; p<0.001). Immunohistological analysis showed that CGM3 was 
deposited equally at NMJs of the two treatment groups (data not shown). C3c deposits 
were identified at NMJs of both groups, albeit with a somewhat less intensity in the 
eculizumab group (Figure 3.11A and D; p<0.001). MAC was clearly deposited at 
NMJs of muscles from control mAb-treated mice but virtually absent in the 
eculizumab-treated group (Figure 3.11B, D and E). Eculizumab prevented loss of 
terminal integrity at NMJs of CGM3- and NHS-treated mice, as evidenced by the NF 
signal intensity and pattern overlying the endplate region, i.e. terminal axonal 
branching clearly remaining intact (Figure 3.11C and E). In addition, electron 
microscopy showed the presence of a well-preserved presynaptic ultrastructure at the 
NMJ of eculizumab-treated mice in comparison with that of control mAb-treated mice 
which showed characteristic terminal swelling, synaptic vesicle depletion and swollen 
mitochondria (Figure 3.11G) (O'Hanlon et al., 2001). These electro-physiological, 
functional and immunohistological data show that complement-mediated terminal 
motor neuropathy occurs in our in vivo MFS model and that diaphragm paralysis 
contributes to the observed respiratory deficits. Most importantly, in vivo eculizumab 





Our previous in vitro studies demonstrated a key role for MAC, the pore-forming 
complement complex, consisting of C5b, C6, C7, C8 and C9 (Morgan, 1989), in 
mediating anti-ganglioside antibody-induced terminal motor neuropathy and pSC 
injury. We have observed a direct correlation between the extent of complement 
deposition, the degree of terminal axon injury, and the functional deficits at NMJs, 
suggesting a direct pathogenic action of complement in this model. In studies using 
C6-deficient NHS as a complement source (Halstead et al., 2004) or other means of 
preventing MAC formation (Halstead et al., 2005a), the development of 
morphological and electrophysiological lesions at NMJs is substantially attenuated, 
identifying MAC as the key factor. Similarly, in a rabbit model of anti-GM1 antibody-
mediated acute motor axonal neuropathy, MAC formation is a prominent feature of 
the pathological phenotype suggesting a causal relationship between MAC formation 
and tissue injury (Susuki et al., 2007a). Whilst the contribution of MAC in mediating 
axonal injury in human inflammatory neuropathies cannot be readily assessed, it is 
evident from autopsy studies of GBS cases that MAC deposition at glial and axonal 
membranes is an important immunopathological factor (Hafer-Macko et al., 1996a; 
Putzu et al., 2000). Specific blockade of MAC may therefore be a way of preventing 
the pathological effects of the terminal complement while preserving the 
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central role for complement activation with MAC formation in our MFS mouse 
model, it should be recognized that anti-ganglioside antibodies might exert 
complement independent effects on nerve function (Ortiz et al., 2001; Santafé et al., 
2005; Buchwald et al., 2007; Lehmann et al., 2007). While such effects may be of 
relevance in certain pathophysiological circumstances, they are not evident in this 
model. Furthermore, antibodies found in GBS and related disorders are of the 
complement-fixing type (IgG1/3 and IgM; Willison and Veitch, 1994) and will 
inevitably activate complement.  
Eculizumab is a humanized mAb directed against the complement protein C5 
(Thomas et al., 1996). By binding to C5, eculizumab prevents the cleavage by C5-
convertase into C5a and C5b, which is a crucial step in the terminal complement 
activation leading to MAC formation.  Earlier components of the complement cascade 
are unaffected by C5 inactivation by eculizumab, such as the anaphylatoxin C3a 
which exerts potent proinflammatory effects, for example by mediating cellular 
chemotaxis. Eculizumab has recently undergone successful clinical trials in 
paroxysmal nocturnal haemoglobinuria, a disorder caused by complement-mediated 
lysis of red blood cells due to the genetic deficiency of complement inhibitory 
proteins (Hillmen et al., 2006; Hill et al., 2007). In the current study, eculizumab 
treatment was effective at ameliorating the clinical, electrophysiological and 
morphological symptoms of terminal motor neuropathy in experimental mouse MFS 
models, using anti-GQ1b mAb and NHS as complement source. Immunohistological 
analyses demonstrated virtually complete blockade of MAC formation at NMJs of 
eculizumab-treated mice and muscle-nerve preparations while C3c deposition 
remained almost unchanged.  
In this study we have generated a new in vivo mouse model for MFS, displaying a 
respiratory paralysis phenotype that can be quantified with whole-body 
plethysmography that may prove useful in experimental drug studies. In this model it 
is likely that the almost complete paralysis of the diaphragm muscle is underlying the 
respiratory difficulties. The only slightly reduced grip strength of the MFS mice 
suggests that the respiratory paralysis is not accompanied by major limb muscle 
weakness. Normal contraction and NMJ function of dissected limb muscles support 
this idea (unpublished data, J.J. Plomp). This regional difference in paralysis is due to 
limited systemic distribution of the injected human complement from the peritoneal 
cavity rather than limited CGM3 distribution, as NMJs of dissected limb muscles have 
intense deposits of CGM3 and readily develop functional and morphological lesions 
when exposed to NHS (unpublished data, J.J. Plomp and S.K. Halstead). 
One major difference between our mouse models and human MFS/GBS is the rapid 
time course at which the neuropathological symptoms develop, i.e. within tens of 
minutes in the in vitro model and within 2 h in the in vivo model, as compared with 
the days to weeks of onset of neuropathic symptoms in human patients. This could be 
due to the difference in the rate of anti-ganglioside antibody level elevation between 
the models and patients, i.e. a stepwise elevation by the incubation or injection 
occurring over seconds to minutes in the mouse models versus a slower, gradual 
increase in antibody production by B-cells in the patient occurring over days to 
weeks. The rapid onset of tissue injury in our in vitro and in vivo models required that 
eculizumab was added prior to the addition of NHS or injected concomitantly with 
NHS in order to protect against acute MAC mediated damage. This experimental 
protocol does not parallel the clinical context for MFS/GBS in which initiation of 
treatment would always follow (partial) symptom onset. Although eculizumab may 







treatment would prevent further MAC deposition from taking place, hopefully 
limiting disease symptoms and thereby positively affecting the prognosis for long-
term recovery (van Koningsveld et al., 2007). 
Another, more fundamental, difference between our mouse MFS models and the 
human condition is the necessity to use human, i.e. heterologous, complement to 
induce the neuropathic lesions in mouse tissues. Previously, we attempted to generate 
an all-mouse model by intraperitoneal injection of anti-ganglioside antibody only 
(Goodyear et al., 1999). While we demonstrated antibody deposits overlying 
presynaptic nerve terminals, only sparse complement deposits were found in some 
mice and no functional defects were observed, even in mice lacking the complement 
regulators CD59a and DAF1 (unpublished data). However, mouse complement 
deposition at NMJs has been observed in such mice deficient in CD59a and/or DAF1 
in a model of myasthenia gravis, an anti-acetylcholine receptor antibody-mediated 
neuromuscular disorder (Lin et al., 2002; Morgan et al., 2006; Kaminski et al., 2006). 
The reason for the apparent inability of complement fixing anti-ganglioside IgM or 
IgG mouse mAbs to lead to MAC deposition in our MFS model is unclear.  It is most 
likely related to variations in complement activity and regulators in laboratory mice 
strains, as compared with humans. The complement activities of many different 
species have been compared in detail (Rice, 1950). In particular, a low haemolytic 
capacity of mouse serum seems due to the absence of classical pathway C5 convertase 
activity of mouse C4 (Ebanks and Isenman, 1996). For this reason, our studies have 
been pursued with NHS as a source of heterologous complement. Since eculizumab is 
specific for human C5 and unable to inhibit mouse C5 (Thomas et al., 1996), the data 
described here, despite being conducted in the mouse, relate very closely to human 
complement activation and inhibition. These results provide a basis for undertaking 
clinical trials with eculizumab in MFS and other neuropathies in which antibody-
mediated complement activation is thought to be pathophysiologically relevant. 
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Guillain-Barré syndrome and its clinical variants, including the anti-GQ1b 
ganglioside-mediated Miller Fisher syndrome, comprise the world’s leading cause of 
acute neuromuscular paralysis. Presently no specific drug therapies exist. The 
complement cascade, which is activated in these patients, forms an attractive drug 
target. In this study we tested whether the complement C5-inhibiting recombinant 
protein, rEV576, was able to prevent neural injury in a previously developed in vitro 
mouse model for MFS. Mouse hemi-diaphragm preparations were treated with anti-
GQ1b antibody and normal human serum as a source of complement with added 
rEV576 or control protein. Immunohistology in control tissue showed deposition of 
C3c and membrane attack complex at neuromuscular junctions (NMJs), along with 
terminal motor axonal neurofilament degradation as well as ethidium homodimer-2 
staining showing perisynaptic Schwann cell (pSC) injury. Electrophysiological and 
functional analyses showed block of synaptic transmission at the NMJ after an initial 
period of a dramatically high level of asynchronous acetylcholine release. In tissue 
treated with rEV576, all these indicators of motor neuronal damage were absent, 
except for the presence of C3c, indicating effective inhibition of C5. These results 
demonstrate that rEV576 effectively prevents development of neuronal and pSC 
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The development and use of complement inhibitors have increased considerably in 
recent years, driven by growing understanding of the role of complement in the 
pathogenesis of various diseases. These include Guillain-Barré syndrome (GBS) and 
its clinical variants including Miller Fisher syndrome (MFS), neuropathies that are 
frequently associated with serum antibodies against gangliosides. Gangliosides are 
sialylated glycosphingolipids that are abundant in the outer leaflet of the neuronal 
membrane. Activated complement components have been reported in GBS patient 
cerebrospinal fluid and serum samples (Hartung et al., 1987; Sanders et al., 1986; 
Koski et al., 1987) and deposited on peripheral nerve (Hafer-Macko et al., 1996a; 
Putzu et al., 2000), thereby highlighting the complement cascade as a key pathway in 
GBS pathogenesis.  
We have previously described an in vitro mouse model for MFS in which phrenic 
nerve-hemi-diaphragm preparations are incubated with anti-GQ1b ganglioside 
antibody or serum and normal human serum (NHS) as a source of complement 
(Halstead et al., 2004; O'Hanlon et al., 2001; Plomp et al., 1999). Immuno-
histological, functional and electrophysiological analyses showed that presynaptic 
binding of anti-GQ1b antibody at the neuromuscular junction (NMJ) activates 
complement, culminating in the formation of the lytic membrane attack complex 
(MAC; C5b-9), and that the ensuing damage leads to block of neurotransmission, 
causing paralysis of the nerve-muscle preparation. Other experimental studies on 
models of MFS and GBS conducted in vivo have also reported dependence of the 
pathological procession upon complement activation (Goodfellow et al., 2005; Susuki 
et al., 2007a). 
rEV576 is a recombinant form of a soft tick (Ornithodoros moubata) saliva protein 
which protects the tick from attack by the host’s complement system (Nunn et al., 
2005). It is a small (17 kDa) and stable protein with a circulating half-life of 30 h in 
the mouse. rEV576 binds to human and mouse complement component C5, and 
thereby effectively inhibits cleavage into the anaphylatoxin C5a and the factor C5b, 
the first component necessary for the formation of MAC. Blockade of the complement 
cascade at the level of MAC generation is advantageous as it prevents the destructive 
effects of MAC while retaining the immunoprotective role of upstream complement 
components (e.g. C3b opsonization and phagocytosis). 
Here we examined whether rEV576 is able to attenuate neural injury in the mouse in 







Male Balb/c mice were obtained from Harlan and used at 4-6 weeks of age. All 
animal experiments were carried out in accordance to UK Home Office guidelines 
(UK PPL60/3096), Dutch law and Glasgow and Leiden University guidelines. 
 
Antibodies, sera and protein 
The immunoglobulin (Ig) M anti-ganglioside monoclonal antibody CGM3 reacts with 







structure (Goodyear et al., 1999). CGM3 concentration was measured using 
quantitative ELISA (Bethyl Laboratories). NHS was taken from a single donor stock 
that had been freshly frozen and stored in aliquots at -70 oC to preserve complement 
activity. Both CGM3 and NHS were dialyzed against Ringer's solution (116 mM 
NaCl, 4.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 1 mM NaH2PO4, 23 mM NaHCO3, 
11 mM glucose, pH 7.4) for 24 h at 4 oC.  Anti-C5 recombinant protein, rEV576, 
control protein, bovine serum albumin (BSA), were stored at -20 ºC until required. 
 
In vitro nerve-muscle preparations for immunohistology 
Hemi-diaphragms were dissected and prepared for in vitro studies in Ringer's solution 
at room temperature (RT; 20-22 oC), pre-gassed with 95% O2 / 5% CO2 as previously 
reported (Plomp et al., 1999). Untreated control sections of diaphragm were removed 
from each muscle preparation prior to any incubations and snap-frozen on dry ice for 
subsequent baseline immunohistological analysis of neurofilament (NF) and activated 
complement proteins levels. Muscles were incubated with CGM3 (50 µg/ml) for 2 h 
32 ºC, then 30 min at 4 ºC, then equilibrated for 10 min at RT. Muscle preparations 
were then rinsed in Ringer’s, and exposed to 40% NHS, as a source of complement, 
plus rEV576 (100 µg/ml) or control protein BSA (100 µg/ml) for 1 h at RT. NHS and 
rEV576/BSA were mixed 10 min prior to its addition to the muscle preparation. 
Tissue was assessed for levels of C3c, MAC, NF and pSC viability using ethidium 
homodimer-2 (EthD-2) as described below.  
 
Figure 3.12. Mouse hemi-diaphragm in vitro preparations incubated with anti-GQ1b mAb CGM3 
followed by NHS with added rEV576 or BSA, as control protein, at 100 µg/ml. The staining intensity 
of (A.) complement C3c was slightly reduced and of (B.) membrane attack complex (MAC) was 
substantially reduced over the neuromuscular junction in preparations treated with rEV576 compared 
with BSA (p<0.01, for both C3c and MAC). C. The neurofilament signal was preserved in tissue 









Unfixed hemi-diaphragm sections were mounted in Cryo-M-Bed medium (Bright 
instrument company limited), and longitudinal cryostat sections (8-20 µm) were cut 
onto 3-aminopropyltriethoxysilane-coated slides, air-dried and then stored at –20 oC. 
To localize the NMJ, nicotinic acetylcholine receptors (nAChR) were stained with 
Alexa 555-conjugated α-bungarotoxin (αBTx, diluted 1/750 to 1.3 µg/ml; Molecular 
Probes). Activation of the intermediate complement component C3, that leads to 
deposition of C3b (a complex that includes the C3c component prior to its liberation 
as a soluble factor, and herein termed C3c according to the antibody nomenclature) 
was detected by incubation with FITC labelled rabbit anti-C3c (1/300; Dako) for 1 h 
at 4 ºC. The terminal complement complex, MAC, was detected using mouse anti-
human C5b-9 (1/50; Dako) followed by FITC-conjugated goat anti-mouse IgG 
(1/300), both for 1 h at 4 ºC. 
For NF staining, sections of unfixed tissue were pre-incubated for 1 h at RT with 
Alexa 555-conjugated αBTx, rinsed, immersed in ethanol at -20 oC for 20 min and 
then incubated overnight at RT with the rabbit polyclonal serum 1211 (1/750; reactive 
with phosphorylated NF; Affiniti Research Products Ltd.) followed by FITC labelled 
goat anti-rabbit IgG (1/300; Southern Biotechnology Associates) for 3 h at 4 ºC. All 
detection antibodies were diluted in phosphate-buffered saline (PBS). 
Perisynaptic Schwann cell (pSC) viability was assessed using EthD-2, a membrane 
impermeant dye that labels with red fluorescence the nucleic acids of membrane-
permeabilized cells (Molecular Probes). Nerve-muscle preparations were exposed to 
Ringer’s containing 2 µM EthD-2. The tissue was incubated in the dark at RT for 1 h, 
rinsed in Ringer’s solution and frozen for immunohistology. NMJs were identified in 
15 µm cryostat sections by staining with Alexa 488-conjugated αBTx (1.3 µg/ml), and 
the percentage of NMJs with EthD-2-positive nuclei overlying the motor endplate was 
calculated. 
For illustrations, muscle preparations were stained as follows. Whole-mount 
triangularis sterni muscles were incubated with CGM3 (50 µg/ml) and Cy5-
conjugated αBTx (2 µg/ml; 1:500), followed by NHS plus rEV576 or BSA as control. 
Preparations were then incubated with αBTx–Cy5 (1:500) and various combination of 
the following primary detection antibodies, mouse anti-C5b-9 (1:40; Dako), anti-C3c-
FITC (1:200; Dako) or rabbit anti-NF (1:500; clone 1211; Affiniti Research Products 
Ltd), in Ringer’s for 1 h at RT and rinsed in Ringer’s, followed by fixation for 20 min 
in 4% formaldehyde in PBS. Unreactive aldehyde groups were quenched, by 
incubating with 0.1 M glycine for 10 min. The antibodies were then reapplied in PBS 
and gently mixed overnight at RT. Muscle were rinsed in PBS and where necessary 
incubated with agitation in the following fluorescently conjugated antibodies; anti-
rabbit IgG-FITC and anti-mouse IgG-tetramethyl Rhodamine iso-thiocyanate for 6 h 
at RT.  
 
Image acquisition, quantitation and statistical analysis 
Digital images were captured using both a Zeiss Pascal confocal laser scanning 
microscope and a Zeiss Axio Imager Z1 with ApoTome (Zeiss). Image analysis 
measurements were made using Image J (National Institutes of Health) image analysis 
software. For quantitative analysis of C3c, MAC and NF, staining runs of each marker 
were performed on non-consecutive sections of muscle from at least 5 individual 
hemi-diaphragms. Samples were quantified by determining fluorescence intensity 
(ranging from 0 (negative) to 255 (signal saturation)) of the various markers directly 







observer blinded. For immunohistological analysis of non-parametric data, statistical 
comparisons were made using Mann-Whitney test employing a 1% level of 
significance. For comparison of EthD-2-positive pSC at the NMJ, chi-square test was 




Figure 3.13. Illustrative immunofluorescent images of whole-mount muscles demonstrating neuronal 
and perisynaptic Schwann cell (pSC) protection at neuromuscular junctions (NMJs) by rEV576: In all 
panels, postsynaptic nicotinic acetylcholine receptors (nAChR) staining was used to delineate the NMJ. 
A. Intermediate complement cleavage product C3c deposits but no membrane attack complex (MAC) 
was seen overlying the NMJ in tissue treated with rEV576. B. pSC damage occurs in control-treated 
tissue, but is absent in tissue protected with the C5 cleavage inhibitor, rEV576. C. Axonal integrity is 
compromised in control tissue, as demonstrated by the absence of neurofilament (NF) staining 
overlying the NMJ. rEV576 protects against axonal damage.  
Scale bar: 20µm. 
 
 
In vitro electrophysiology 
Hemi-diaphragms were dissected with the phrenic nerve attached and pinned out on a 
silicone rubber-lined dish in Ringer's medium pre-gassed with 95% O2 / 5% CO2 at 
RT. Samples were incubated for 2.5 h with 50 µg/ml anti-GQ1b ganglioside CGM3 at 
32 °C. Subsequently the preparations were rinsed in Ringer's and then treated for 1 h 
at RT with 33% NHS with added rEV576 or control protein BSA at 100 µg/ml, pre-
mixed 10 min before application. Using a glass microelectrode (10-20 MΩ) filled 
with 3 M KCl, intracellular recordings of miniature endplate potentials (MEPPs), 
arising from presynaptic spontaneous uniquantal release of acetylcholine (ACh), were 
made at NMJs of preparations at RT just before the CGM3 incubation and again 
during the 1 h rEV576 or BSA incubation period. Recordings were amplified and 
filtered (10 kHz low-pass, 1 Hz high-pass) with a GeneClamp 500B amplifier and 
digitized and stored using a Digidata 1322A interface, Clampex 9.2 and Clampfit 9.2 
(all from Axon Instruments/Molecular Devices). Data was analyzed off-line with 






Complement inhibition abrogates mouse neural injury 
 
 
Visual scoring of muscle fibre twitchings and evoked muscle contraction 
During the electrophysiological assessment of the hemi-diaphragms incubated with 
NHS and rEV576/BSA, the muscles were visually scored (grades 0-4) for the 
occurrence of spontaneous asynchronous fibre twitching, as described before 
(O'Hanlon et al., 2001). These twitches are a hallmark of CGM3/complement-
mediated destruction of NMJs (Plomp et al., 1999). We also scored (grades 0-2) for 
the extent of tetanic muscle contraction upon 40 Hz nerve stimulation. In addition, 
spontaneous asynchronous twitching was visually scored (0-4) in an assay using small 
diaphragm strips, as described before (Jacobs et al., 2002). The incubation protocol 
was as described above for the complete hemi-diaphragms. Scores were summed over 
time. After the NHS and rEV576/BSA incubation period the strips were assessed 
electrophysiologically for the percentage of “silent” NMJs (i.e. without any detectable 
synaptic electrophysiological signal), which is the final result of the presynaptic 
damage caused by complement. 
Group comparisons were made using a Students t-test. A p value <0.05 was 






The C5 inhibitory effects of rEV576 were tested in an in vitro mouse model of MFS. 
Mouse hemi-diaphragm preparations were incubated with monoclonal anti-
ganglioside antibody CGM3, followed by NHS with added rEV576 or control protein 
BSA.  
C3c intensity at the NMJ (Figure 3.12A) was reduced by a small but statistically 
significant degree in hemi-diaphragm tissue treated with rEV576 (median level, 214; 
n=746) compared with control (median level, 233; n=727; p<0.01), despite similar 
intensities of IgM deposits (data not shown). In contrast to C3c levels and as 
predicted, MAC intensity (Figure 3.12B) was greatly reduced in tissue treated with 
rEV576 (median level, 5; n=678), compared to control tissue (median level, 88; 
n=704; p<0.01). Axonal integrity was assessed by NF staining over the NMJ (Figure 
3.12C), which was abolished in control tissue (n=678) but preserved in rEV576-
treated tissue (n=704). EthD-2 uptake was extensive, as expected, in tissue treated 
with CGM3 and NHS plus BSA control protein (54% of NMJs showed positive 
nuclei; n=2338), while only 1% of NMJs (total sampled n=1954) demonstrated 
damaged pSC in rEV576-protected tissue (chi square test, p<0.01). 
Illustrative immunofluorescent images of whole-mount muscles demonstrating 
neuronal and pSC protection at NMJs by rEV576 are shown in Figure 3.13.  In all 
upper panels, postsynaptic nAChRs were stained to delineate the NMJ, and this 
postsynaptic staining remains unaffected throughout, as shown in previous studies. In 
the presence or absence of rEV576, intermediate complement cleavage product C3c 
deposits were seen in tissues treated with anti-ganglioside antibody plus human 
complement (Figure 3.13A, B). However, no MAC was seen overlying the NMJ in 
tissue treated with rEV576 (Figure 3.13A, C). pSC damage as manifested by EthD-2 
uptake into pSC nuclei, occurred in control-treated tissue but was absent in tissue 
treated with rEV576, as shown in Figure 3.13B. Axonal integrity was compromised in 







absence of NF staining overlying the NMJ, whereas rEV576 protected against this 




Figure 3.14. Mouse hemi-diaphragm preparations were pre-incubated with 50 μg/ml anti-GQ1b 
ganglioside CGM3 for 2.5 h at 32 °C. Subsequently the preparations were treated for 1 h with 33% 
NHS with either rEV576 or control BSA protein added at 100 μg/ml.  A. Spontaneous uniquantal 
acetylcholine release at the NMJ measured as MEPP frequency is significantly increased in the control 
group, compared to untreated NMJs. This rise was prevented in the group treated with rEV576 (p<0.05; 
n=3 muscles).  B. Typical example traces of 1 s MEPP recordings (overlay of 5 traces). C. During the 
incubation of whole hemi-diaphragm in NHS with either rEV576 or control BSA, spontaneous 
twitching of the muscle fibres was scored visually. Muscle twitching was completely prevented by 
rEV576 (n=3). D. During the incubation period also evoked contraction (sustained muscle contraction 
resulting from stimulation of the phrenic nerve) was visually scored. After 1 h rEV576 still fully 
protected for impairment of evoked twitching (n=3). E. A muscle strip twitch assay was used for 
additional quantification of spontaneous twitching. Twitching was graded and represented as summed 
score over time (n=4-6). rEV576 almost completely inhibited the spontaneous fibre twitches caused by 
NHS. F. rEV576 protects almost completely against the development of “silent” NMJs (i.e. without 








In the in vitro electrophysiology study we found a MEPP frequency of 0.94 ± 0.08 s-1 
in the muscle-nerve preparations that were pretreated with CGM3 and then incubated 
with NHS and rEV576. This frequency was similar to that which we measured in the 
untreated group (pre-CGM3; 0.77 ± 0.10 s-1, p=0.24). But in the control group that 
was pretreated with CGM3 and then incubated with NHS and BSA we encountered a 
more than 40-fold higher MEPP frequency (44.12 ± 12.06 s-1, p<0.05). The results 
show that the CGM3/complement-mediated presynaptic damage which causes 
uncontrolled asynchronous release of acetylcholine from the presynaptic terminal is 
completely prevented by rEV576 (p<0.05; Figure 3.14A and example traces of MEPP 
recordings in Figure 3.14B).  
Visual scoring of spontaneous twitching and nerve stimulation-evoked contraction 
during electrophysiological measurements also showed the protective effect of 
rEV576. Spontaneous twitching was absent in rEV576-treated tissue, while in the 
control group, it was visible from 5 min after the start of the incubation with NHS and 
control BSA during the whole 1 h scoring period with an average maximum score of 3 
(n=3; Figure 3.14C). The control group also showed an impairment of evoked 
contraction on visually scoring, starting after 30 min of incubation. The muscles that 
were incubated with NHS and rEV576, however, maintained the maximal evoked 
muscle contraction scoring (grade 2) during the complete 1 h incubation period (n=3; 
Figure 3.14D). Similar results were obtained in the strip twitch assays. The summed 
twitch score at the end of the 1 h incubation was greatly different between the two 
groups (control 18.5 ± 0.5, n=4; rEV576 4.2 ± 1.9, n=6; p<0.01; Figure 3.14E). 
Afterwards we determined that almost all NMJs in the control group had been 
“silenced”, i.e. they were without any detectable electrophysiological signals, while 
rEV576 had protected muscle strips against this phenomenon (control 98 ± 2.3% and 





We have previously demonstrated, through the use of complement component C6 
knockout mice in conjunction with C6-deficient human serum (i.e. conditions under 
which MAC cannot be formed) that the development of terminal motor neuropathy in 
our in vitro mouse model of MFS mediated by anti-GQ1b antibody is dependent on 
the generation of MAC (Halstead et al., 2004). Therefore, successful inhibition of the 
complement cascade with therapeutic inhibitors prior to or directed at the level of 
MAC within the complement cascade would be predicted to ameliorate pathological 
damage. In order to progress this knowledge towards clinical use in autoimmune 
neuropathy, we have recently studied complement inhibitors that are in preclinical or 
clinical development (Halstead et al., 2005a; Halstead et al., 2008a).  Here we report 
the effects of a further inhibitor, the recombinant protein rEV576 that inhibits the 
conversion of human C5 into C5a and C5b and in this way prevents formation of 
MAC. Our data show that MAC formation is completely inhibited by rEV576 in our 
mouse MFS model (which involves the use of human complement), and consequently 
that there is complete protection of the motor nerve terminal against immune-
mediated neuropathy, as assessed by electrophysiological, functional and 
morphological analyses. In comparison, the differential effect on C3 activation and 







MAC is heavily deposited, most likely due to a positive feedback effect of MAC on 
complement activation.  
The data presented here are comparable in terms of therapeutic efficacy of rEV576 to 
a recent study showing a substantially protective effect in an antibody and 
complement-mediated model of myasthenia gravis in the rat (Hepburn et al., 2007). 
That study also reported the known biochemical data in detail on the half-life, 
complement-inhibiting mechanisms and immunogenic properties of rEV576.  
In our mouse model of MFS, complement is activated through the classical pathway 
and directed to the motor nerve terminal and pSC by membrane-bound anti-GQ1b 
antibody. Wallerian degeneration can result as a secondary effect after 
neuroimmunological axonal attack and this process has been shown to be complement 
dependent and delayed by complement inhibition (Ramaglia et al., 2007; Ramaglia et 
al., 2008). Thus, complement inhibition as a therapeutic strategy for treating 
peripheral nerve axonal disorders may have a dual benefit.  
The field of complement therapeutics is growing rapidly with a range of agents now 
available for pre-clinical and clinical testing that inhibit complement activation at 
various stages of the cascade (Ricklin and Lambris, 2007). One particular advantage 
of complement inhibition at the level of C5 that rEV576 fulfils is that the 
antimicrobial opsonization effects of upstream complement factors are not inhibited. 
Conversely, this could also be a disadvantage in terms of therapeutic effectiveness 
when considering the possible role of macrophage and polymorphic cell infiltration in 
the pathogenic cascade in patients. 
While this study demonstrates the therapeutic principle of axonal neuroprotection for 
rEV576 in a neuropathy model using an anti-GQ1b antibody directed at the motor 
nerve terminal, in accord with our previously published data, it is highly probable that 
any axonal membrane localized elsewhere and sensitized to complement attack by any 
other anti-ganglioside antibody would be similarly protected. Our previous work has 
shown complete concordance between mouse and human anti-GQ1b and other 
ganglioside IgG and IgM antibodies with respect to their MAC-dependent paralytic 
effects at the motor nerve terminal. These data should thus give further impetus 















Neuropathophysiological potential of anti-
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Some Guillain-Barré syndrome patients have serum antibodies against antigenic 
epitopes formed by a complex of two different gangliosides but direct evidence for 
pathogenicity is lacking. Here we show that anti-GM1/GD1 and anti-GM1/GQ1b 
complex-positive sera can induce functional damage at motor nerve terminals of 
mouse neuromuscular junctions ex vivo, similar to effects shown by us earlier of 
antibodies against single gangliosides. However, only about half of the 27 
investigated anti-ganglioside complex sera induced neuropathogenic effects, with high 
variability in potency, and requiring high antigenic density. These results suggest 
antigenic presence of ganglioside complexes in living neuronal membranes and show 
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With the current methods, anti-ganglioside antibodies are detected in 50-60% of 
patients with Guillain-Barré syndrome (GBS) (Kusunoki et al., 2008; Notturno et al., 
2009; Van Doorn et al., 2008). Gangliosides are a family of sialic acid-containing 
amphiphilic sphingolipids that are enriched in neuronal membranes. Anti-ganglioside 
antibodies are thought to be pathogenic, either by disturbing neuronal functions of 
gangliosides or by mediating complement activation, thereby damaging peripheral 
nerve axons and possibly also motor nerve terminals at the neuromuscular junction 
(NMJ) in some cases (Van Doorn et al., 2008; Plomp and Willison, 2009). Recently, it 
has been suggested that combinations of two different gangliosides can form a novel 
antigenic epitope and that some GBS patients have antibodies against such a complex 
(Kusunoki et al., 2008; Kaida et al., 2004a). Clinical correlation and fine-specificity 
studies estimate that 10-20% of GBS patients has anti-ganglioside complex antibodies 
(Notturno et al., 2009; Kaida et al., 2007; Kuijf et al., 2007). Interestingly, antibodies 
against GD1a/GD1b and GD1b/GT1b complexes seem associated with disease 
severity (kaida et al., 2007), although this not confirmed by others (Notturno et al., 
2009). In the GBS variant Miller Fisher syndrome (MFS), associated with anti-GQ1b 
ganglioside antibodies, the incidence of anti-complex antibodies seems higher: a study 
by Kaida and colleagues showed that 7 of 12 MFS sera contained antibodies against a 
complex of at least GQ1b or GT1a and another ganglioside (kaida et al., 2006). 
The observations that anti-ganglioside complex antibodies disappear upon clinical 
recovery (Kuijf et al., 2007) and their association with disease severity (Kaida et al., 
2007) support a neuropathophysiological role. However, this has not yet been directly 
shown. We here performed a first investigation of 17 GBS sera with anti-GM1/GD1a 
complex activity and 10 GBS variant sera with anti-GM1/GQ1b complex activity for 
their ability to induce complement-dependent deleterious effects at mouse diaphragm 
motor axon terminals. Earlier, we showed that antibodies against the single 
ganglioside species bind to and induce structural and functional lesions at this site, 
electrophysiologically hallmarked by a high frequency of miniature endplate 
potentials (MEPPs, the postsynaptic responses to uniquantal acetylcholine release), 
causing asynchronous muscle fibre twitches and, eventually, block of 
neurotransmission (Plomp and Willison, 2009). 
 
 
Material and methods 
 
Patient sera and mouse monoclonal antibodies 
Acute-phase sera were obtained from 27 GBS and GBS-variant patients from Japan (# 
5-15 and 18-27), The Netherlands (# 1-4) and Bangladesh (# 16-17) and stored at -80 
°C. Normal human serum (NHS) from a healthy donor was stored aliquoted at -80 °C. 
Mouse monoclonal antibodies (mAbs) against GQ1b (CGM3; 50 μg/ml), GD1a 
(MOG35; 100 μg/ml) and GM1 (DG2; 100 μg/ml) were used as positive controls 
(Goodfellow et al., 2005; Goodyear et al., 1999). Prior to experimental use, all sera 
and mAbs were dialyzed overnight at 4 °C against Ringer’s solution (116 mM NaCl, 
4.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 1 mM NaH2PO4, 23 mM NaHCO3, 11 mM 








Enzyme-linked immunosorbent assay  
Sera (1:100) were tested, as described (Kuijf et al., 2007), for IgM and IgG antibody 
activity against individual gangliosides and complexes, as indicated in the Results. 
Serum scoring an optical density (OD) of >0.2 was considered positive. For anti-
ganglioside-complexes, positivity was defined as having an OD of >0.2 higher than 
the highest OD for an individual ganglioside (Kaida et al., 2004; Kuijf et al., 2007). 
All samples were tested in duplicate.  
 
Bioassays at mouse hemi-diaphragm-phrenic nerve preparations 
Male and female wildtype and GD3synthase knockout (GD3s-KO) mice 11 were used 
at 1-4.5 months of age. Hemi-diaphragms with phrenic nerves were dissected and kept 
in Ringer's medium at room temperature (20-22 °C). Muscles were incubated with 
33% GBS heat-inactivated (30 min at 56 °C to destroy complement) serum in Ringer's 
medium or mouse mAbs for 3 h at 32 ºC, rinsed in Ringer's medium for 10 min and 
exposed to 33% NHS in Ringer's medium for 1 h at room temperature. Micro-
electrode recording of MEPPs (10-30 NMJs per session) and visual scoring of 
spontaneous asynchronous fibre twitching (0 for no twitching across the hemi-
diaphragm, 1 for twitching of <10 fibres, 2 for a small amount, 3 for a moderate 
amount and 4 for an extensive amount) were done as described (Zitman et al., 2008; 
O’Hanlon et al., 2001). Depending on the available volumes, sera were tested 1 to 4 
times and the mean values of the parameters were calculated. Animal experiments 
were carried out according to Dutch law and Leiden University guidelines.  
 
Complement immunohistochemistry 
C3 deposition at NMJs was quantified in a selection of the electrophysiologically 





Testing of sera for anti-ganglioside-complex specificity 
Sera were selected on the basis of their positivity for anti-ganglioside complexes 
(GM1/GQ1, GM1/GD1a or GD1a/GD1b), as had been determined at their original 
research centre. In addition, the Japanese sera had also been tested in Japan for 
activity against GT1a, GD3, GalNAc-GD1a, and GA1 and ganglioside complexes 
GM1/GalNAc-GD1a and GD1b/GT1b. In view of possible inter-laboratory variations 
(Willison et al., 1999), the complete series was re-tested in Rotterdam (Erasmus MC) 
in a single experimental ELISA run for IgG and IgM antibodies against gangliosides 
GM1, GQ1b, GD1a and GD1b and ganglioside complexes GM1/GQ1b, GM1/GD1a, 
GM1/GD1b, GD1a/GD1b. On the basis of these ELISA studies, we classified sera 
into two categories (Table 3.1): 1) sera that tested positive for GM1/GD1a ganglioside 
complex (17 sera: # 1-17) and 2) sera that tested positive for GM1/GQ1b ganglioside 
complex (10 sera: # 18-27). One serum (# 26) was found negative for anti-
GM1/GQ1b complex when re-tested but was still included in the second group 
because it had been found positive in Japan. Most sera of both categories showed 
additional activities against either the individual gangliosides of the complex for 
which they were positive, or against other individual gangliosides or other complexes 











A. Effect of anti-ganglioside complex sera on MEPP frequency at wildtype (left panel) and GD3s-KO 
(right panel) mouse diaphragms NMJs. Eight of the 17 tested anti-GM1/GD1a-complex sera induced 
MEPP frequency increases at GD3s-KO to a level of more than twice the pre-incubation control value. 
Only one serum (modestly) increased MEPP frequency at wildtype NMJs. Of the 10 investigated anti-
GM1/GQ1b complex sera, 5 induced (modest) MEPP frequency rise to levels of more than twice the 
control value, exclusively at wildtype NMJs. B. Effect of anti-ganglioside complex sera on muscle 
fibre twitches at wildtype (left panel) and GD3s-KO (right panel) mouse NMJs. Most anti-ganglioside-
complex sera that induced MEPP frequency elevation scored higher than 1 for muscle fibre twitching 









Examples of MEPPs recorded before incubation with heated anti-GM1/GD1a-complex serum # 7 
(upper panel in A) and during subsequent incubation with normal human serum as complement source 
(lower panel in A). Sweep length is 10 s. B. Example of C3c immunostaining (middle panel) at an NMJ 
(defined by fluorescently labelled α-bungarotoxin (αBTx) binding to acetylcholine receptors [AChR], 
left panel) from a muscle preparation that had been exposed to anti-GM1/GD1a complex serum # 14 




Pathophysiological effects at mouse neuromuscular synapses 
At NMJs of GD3s-KO mice (used because their membranes express upregulated 
density of GM1 and GD1a 15) 8 of the 17 anti-GM1/GD1a complex sera induced 
variable elevations of mean MEPP frequency (range 3.5-36.8 /s, the control pooled 
mean value before incubations was 1.2 /s; Figure 3.15 and Table 3.1) during the 
period of NHS incubation. From 8 of the 17 sera, sufficient material was present to 
also study their effects at wildtype NMJs: only one serum (# 1) showed moderate 
elevation of MEPP frequency (to 4.6 /s). In the anti-GM1/GQ1b series, elevated 
MEPPs were found for 5 of the 10 tested sera (range 3.3-7.2 /s) at wildtype NMJs. No 
effect was found at GD3s-KO NMJs (Figure 3.15).  
Elevated MEPP frequency generally was accompanied by muscle fibre twitching, as 
visually scored (range 0-4) every 5 min during the 1 h NHS incubation period (Figure 
3.16 and Table 3.1). Average twitching score was <0.5 in the control (pre-incubation) 
session. Similar scores were obtained with the GM1/GD1a series sera when tested in 
wildtype (range 0.0-0.3). In GD3s-KO muscles 7 of these sera scored >1.0 (Figure 
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sera scored >1.0 in wildtype muscles (range 1.2-2.3). At GD3s-KO muscles, 2 of the 
10 GM1/GQ1b sera scored >1.0 (1.7 and 1.9). The mean score of positive control 
mAbs was 2.2 or higher (Figure 3.16).  
 
Complement deposition at the neuromuscular synapse 
For the group of anti-GM1/GD1a sera, deposited amounts of complement component 
C3c at NMJs were found to be associated with levels of elevated MEPP frequency 
(p<0.01, Spearman’s rank correlation). In the anti-GM1/GQ1b series, NMJ C3c 
deposition was generally low and not consistently associated with MEPP frequency 





The special category of anti-ganglioside complex antibodies in GBS sera was 
discovered by Kaida and colleagues in ELISA studies (Kaida et al., 2004a). However, 
no direct evidence of a pathogenic action at living neuronal membranes has been 
provided yet. We here report the potency of sera containing either anti-GM1/GD1a or 
anti-GM1/GQ1b antibodies to produce pathophysiological effects at mouse NMJs. 
Our earlier studies at (ex vivo and in vivo) mouse NMJs demonstrated the damaging 
effects of patient sera, purified antibody or mouse mAbs with (ELISA-defined) 
activity against either single gangliosides GQ1b, GD1a, GM1 and GD1b (for review 
see Plomp an Willison, 2009). These presynaptic effects were complement-dependent 
and electrophysiologically hallmarked by a high frequency of MEPPs, sometimes 
triggering a muscle fibre contraction. Roughly half of the anti-ganglioside-complex 
sera tested in the current ex vivo experiments induced such effects, albeit at rather 
moderate level. This indicates that anti-ganglioside complex antibodies are in 
principal capable of binding to live neuronal membranes and, by activating 
complement, can induce pathophysiological effects. Thus, these antibodies are likely 
of pathogenic relevance, as already suggested from the clinical association with 
specific patterns of paralysis (in particular cranial nerve involvement) and, in some 
patient groups, the requirement of mechanical ventilation (Van Doorn et al., 2008; 
Kaida et al., 2007). Our findings at mouse NMJs suggest that paralysis in anti-
ganglioside complex antibody-positive patients may, besides axonal dysfunction, also 
involve some degree of NMJ synaptopathy. 
However, our results are not unambiguous. First, not all anti-ganglioside complex-
positive sera induced the deleterious effects at mouse NMJs. Second, the level of the 
effect caused by the active sera was only moderate as compared with that of the 
positive control mouse mAbs as well as with earlier tested patient sera with activity 
against single ganglioside species (Goodfellow et al., 2005; Greenshields et al., 2009; 
Plomp et al., 1999). These two inconsistencies may relate to variability in titre and 
affinity of the pathogenic antibodies amongst sera in combination with the likely 
existence of an antibody binding threshold for the induction of pathophysiological 
effects at NMJs. Third, the effects of anti-GM1/GD1a sera were only found at NMJs 
of GD3s-KO mice and not at those of wildtypes, indicating the requirement of high 
density of the targeted ganglioside complexes, possibly indicating that human patients 
have a special predisposing ganglioside configurations in their neuronal membranes. 







activities against single types of gangliosides and some sera even had additional 
activity against different complexes (Table 3.1). This complicates the interpretation of 
the result, in particular because the two monospecific anti-GM1/GD1a sera (# 16 and 
17) lacked pathophysiological effects. This might suggest that besides anti-
GM1/GD1a complex activity, another activity must be present in order to have 
enough antibody binding to exert effects. It is even not completely excluded that 
either antibodies against GM1a or GD1a were solely responsible for inducing effects, 
because all MEPP frequency-elevating anti-GM1/GD1a-positive sera were also 
positive for antibodies against at least one of these two individual gangliosides. On 
the other hand, there were also non-MEPP frequency elevating sera that contained 
activity against either GM1, GD1a, or both. Activity against single gangliosides was 
less of a problem in the GM1/GQ1b group where 2 of the 6 monospecific anti-
ganglioside complex sera induced effects at wildtype NMJs and not at GD3s-KO 
NMJs (which contain no GQ1b; Figure 3.15), making it highly likely that the anti-
ganglioside complex antibodies were responsible. However, in this series, the effects 
were rather modest in magnitude and complement deposition did not very well 
correlate with elevation of MEPP frequency, further complicating matters. 
In conclusion, it is clear that a proportion of the anti-ganglioside complex sera has 
neuropathophysiological effects at mouse NMJ, suggesting a pathogenic role in GBS 
patients, but there are also some difficulties in the interpretation of these results at this 
stage. Development of high-affinity mouse mAbs with monospecific activity against 
defined ganglioside complexes is needed to allow a more detailed and extensive study 


















Table 3.1. (next page) 
Anti-ganglioside (IgG or IgM) activity, effects on MEPP frequency (fMEPP), muscle fibre twitching 
and C3c deposition at neuromuscular junctions of sera with positivity for either anti-GM1/GD1a 
antibodies (sera # 1-17) or anti-GM1/GQ1b antibodies (sera # 18-27). 
Columns anti-ganglioside activity: - : negative. 
Columns fMEPP: - : < twice the control mean; + : > twice the control mean and <10 /s; ++ : between 
10 and 20 /s; +++ : >20 /s; empty: not done. Elevated MEPP frequencies are also highlighted. 
Columns twitching: - : <1.0; + : between 1.0 and 2.0; ++ : more than 2.0; empty: not done. 
C3c staining was done in one experimental run on 17 tissue samples. Indicated is the relative intensity 
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Anti-GM1 ganglioside autoantibodies are used as diagnostic markers for motor axonal 
peripheral neuropathies and are believed to be the primary mediators of such diseases. 
However, their ability to bind and exert pathogenic effects at neuronal membranes is 
highly inconsistent. Using human and mouse monoclonal anti-GM1 antibodies to 
probe the GM1-rich motor nerve terminal membrane in mice, we here show that the 
antigenic oligosaccharide of GM1 in the live plasma membrane is cryptic, hidden on 
surface domains that become buried for a proportion of anti-GM1 antibodies, due to a 
masking effect of neighbouring gangliosides. The cryptic GM1 binding domain was 
exposed by sialidase treatment that liberated sialic acid from masking gangliosides 
including GD1a or by disrupting the live membrane by freezing or fixation. This 
cryptic behaviour was also recapitulated in solid-phase immunoassays. These data 
show that certain anti-GM1 antibodies exert potent complement activation-mediated 
neuropathogenic effects, including morphological damage at living terminal motor 
axons, leading to a block of synaptic transmission. This occurred only when GM1 was 
topologically available for antibody binding, but not when GM1 was cryptic. This 
revised understanding of the complexities in ganglioside membrane topology provides 
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The sialic acid-containing glycosphingolipids known as gangliosides are concentrated 
in plasma membrane microdomains where they modulate the topological organization 
and function of membrane proteins (Sandhoff and Kolter, 2003; Simons and Ikonen, 
1997). Their oligosaccharide head groups protrude from the lipid bilayer into the 
extracellular environment to act as (co)receptors for a diverse range of glycan binding 
proteins including autoantibodies, sialic acid binding Ig-like lectins (siglecs), 
microbial toxins and viral components (Varki, 2007; Bullens et al., 2002; Willison, 
2005; Crocker et al., 2007; Lencer and Tsai, 2003; Tsai et al., 2003). 
In a subset of autoimmune peripheral nerve diseases, including Guillain-Barré 
syndrome (GBS) and multifocal motor neuropathy, autoantibody-ganglioside 
interactions are believed to be a critical pathogenic factor (Willison and Yuki, 2002; 
Yuki, 2001). Serum anti-GM1, -GD1b -GQ1b and -GD1a ganglioside antibodies are 
associated with nerve injury in both human clinical studies and animal models 
(Goodfellow et al., 2005; Kusunoki et al., 1996; Yuki et al., 2001; Plomp et al., 1999), 
with anti-GM1 antibodies being highly associated with motor neuropathy variants 
(Willison and Yuki, 2002). With respect to the antibody induction phase of the illness, 
it is clearly established that anti-GM1 antibodies can arise through molecular mimicry 
with structurally homologous Campylobacter jejuni lipooligosaccharides (LOS) 
(Bowes et al., 2002; Yuki et al., 1993; Yuki et al., 2004; Ang et al., 2002). In contrast, 
examination of the effector pathways through which anti-GM1 antibodies selectively 
bind to and induce injury in motor nerve membranes, while avoiding damage to other 
neural and non-neural plasma membranes containing abundant GM1, is confounded 
by inconsistent and often counterintuitive data (Willison and Yuki, 2002; Arasaki et 
al., 1993; Buchwald et al., 2007; Nores et al., 2007; Paparounas et al., 1999). In 
particular, the sensitivity or resistance of the membrane toward undergoing anti-GM1 
antibody-mediated injury cannot be fully explained by the presence and density of 
plasma membrane GM1. 
One reason for the uncertainties surrounding anti-GM1 effector pathways may be that 
protein-ganglioside interactions are typically identified by in vitro solid phase binding 
studies using immobilized gangliosides or structurally related natural and synthetic 
glycans. The translation of this in vitro binding data to physiologically and 
pathophysiologically relevant protein-glycan binding behaviour in intact membranes 
in vivo is where the complexities and inconsistencies arise. For example, an antibody 
that binds a specific glycan by immunoassay may apparently be unable to bind the 
same ganglioside when present in an intact membrane (Schwarz and Futerman, 1996). 
Furthermore, different anti-GM1-specific antibodies can have very different binding 
patterns in the CNS (Iwamoto et al., 1990; Laev and Mahadik, 1989). In addition to 
differences in antibody affinities, one explanation for such discrepancies might be 
that, within the complex environment of glycolipid-enriched microdomains, the 
interacting oligosaccharide headgroup is masked from the protein binding partner by 
surrounding molecules. Furthermore, fixation procedures might influence the 
antibody binding characteristics of gangliosides (Schwarz and Futerman, 1996). 
However, the detailed mechanisms underlying these determinants of antibody-
ganglioside binding are unknown. 
In the current study we addressed these issues by investigating a group of mouse and 
human anti-GM1 monoclonal antibodies (mAbs) for their potential neuropathogenic 







topological requirements for their binding to GM1 in neuronal membrane. Previously 
we showed that anti-GQ1b and anti-GD1a antibodies bind to the presynaptic motor 
nerve ending and activate complement, leading to membrane attack complex (MAC, 
C5b-9) formation, which causes intense neurotransmitter release and ultrastructural 
destruction, thereby blocking synaptic transmission at the neuromuscular junction 
(NMJ) (Goodfellow et al., 2005; Plomp et al., 1999; Goodyear et al., 1999; Halstead 
et al., 2004). We here show that mouse and human anti-GM1 mAbs also bring about 
these destructive neuropathic effects but that antigenic GM1 in the living neuronal 
membrane is cryptic for a proportion of the mAbs, thereby rendering them harmless, 
due to a masking effect of neighbouring gangliosides including GD1a. These findings 
indicate that anti-GM1 antibodies are pathogenically relevant in motor neuropathy 
and that masking and unmasking of GM1, such as may occur in membranes 
undergoing dynamic changes associated with normal axonal maintenance or during 
axonal regeneration, might have a profound influence on antibody pathogenicity 






Mice lacking complex gangliosides (GM2s-KO) were used to generate anti-
ganglioside antibodies in response to inoculation of ganglioside liposomes or 
ganglioside mimicking LOS (Bowes et al., 2002; Townson et al., 2007; Aspinall et 
al., 1994). Hybridoma cells were maintained to generate stocks of mAbs, which were 
affinity purified by protein G sepharose chromatography (Amersham BioSciences), 
desalted and stored at -70 oC. Their binding properties are shown in the Table 3.2. 
Human mAbs were cloned as previously described (Townson et al., 2008) and their 
binding properties are shown in the Table 3.2. 
 
Mice 
Male and female GD3s-KO (Okada et al., 2002), GM2s-KO (Takamiya et al., 1996) 
and wildtype (WT) mice were used at 4-8 weeks of age. All mice were killed by a 
rising concentration of CO2 in accordance with UK Home Office, Dutch law and 
Leiden University guidelines. 
 
Immunohistochemistry on frozen tissue sections 
Topical mAb binding studies. Diaphragm was snap-frozen and cryostat sectioned at 8 
μm onto APES (Sigma-Aldrich) coated slides. For staining, mAbs were applied at 20 
μg/ml and CTB-FITC (Sigma-Aldrich) at 1 μg/ml diluted in phosphate-buffered saline 
(PBS), along with BTx-TRITC (Molecular Probes, 1.3 μg/ml). mAbs/CTB were 
incubated for 3.5 h at 4 oC. For secondary detection of mAbs, slides were rinsed in 
PBS and anti-mouse IgG-FITC (Southern Biotech, 1.3 μg/ml in PBS) was applied for 
3 h at 4 oC. All slides were mounted in Citifluor (Citifluor) following a final rinse in 
PBS.  For CTB blocking of mAbs, sections were firstly incubated in unlabelled CTB 
(4 μg/ml in PBS, Sigma) or PBS as a control, for 1.5 h at 4 oC, rinsed thoroughly in 
PBS and mAbs applied as before. 
 
Ig, C3, MAC and neurofilament quantification. Diaphragm (previously exposed ex 
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and 20 μm onto APES coated slides (thicker sections were designated for 
neurofilament staining). All solutions were made up in PBS, and incubations done at 
4oC. BTx-TRITC was used at 1.3 μg/ml throughout. To detect mAb binding, FITC 
subtype specific anti-mouse IgG or anti-human IgM (Southern Biotech) was applied 
at 3.3 μg/ml for 3 h at 4 oC, along with BTx-TRITC. For detection of the activated 
complement component C3, slides were incubated in FITC-Goat anti-human C3 
(Dako, 33 μg/ml) and BTx-TRITC for 2 h at 4 oC. MAC staining was performed with 
mouse anti-human C5b-9 (Dako, 363 μg/ml), applied to slides for 3.5 h with BTx-
TRITC. After rinsing in PBS, MAC was detected with FITC goat anti-mouse IgG2a  
applied at 5 μg/ml for 3.5 h. Sections for neurofilament analysis were firstly stained 
for 1 h in BTx-TRITC, rinsed in PBS, and placed for 20 min in freezing ethanol (-20 
oC) prior to overnight application of 1211 (rabbit polyclonal, diluted 1:750, Affinity 
BioReagents). Slides were rinsed and incubated in FITC goat anti-rabbit IgG (3.3 
μg/ml) for 3.5 h. Slides were finally rinsed and mounted in Citifluor. 
 
Immunostaining of live tissue 
For triangularis sternae neuromuscular preparations, the ribcage was removed and 
pinned in a Sylgard (Sigma-Aldrich) lined dish with standard Ringer's medium (119 
mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, 23 mM 
NaHCO3, 11 mM glucose, pH 7.4 pre-gassed with 95% O2 / 5% CO2) and triangularis 
sternae was exposed. Preparations were incubated in mAbs (100 μg/ml in Ringer's) or 
CTB (2 μg/ml) and BTx-TRITC (2 μg/ml) for 2 h at 32 oC, followed by 30 min at 4 
oC. Tissue was thoroughly rinsed in Ringer's and fixed for 20 min at room 
temperature in 4% PFA (Sigma-Aldrich). Tissue was rinsed again in Ringer's and 
incubated for 10 min in 0.1 M glycine. For detection of mAbs, tissue was incubated 
overnight in subtype-specific FITC anti-mouse or anti-human IgM secondary 
antibodies (3.3 μg/ml in PBS). For neurofilament staining, 1211 (Affinity 
BioReagents) was applied overnight (rabbit polyclonal, diluted 1 in 200) in 1%Triton-
X100/PBS and following 3 rinses in PBS, was  detected with cy-5 anti-rabbit IgG (3.3 
μg/ml in PBS) at 4 oC for 8 h. Following a final rinse in PBS, all immunostained 
muscles were whole-mounted in Citifluor.  
 
Ex vivo pathogenesis: hemi-diaphragm 
Mouse hemi-diaphragms with attached phrenic nerves were dissected out and pinned 
under tension in Sylgard lined dishes with oxygenated Ringer’s medium. The dorsal 
portion of each was removed and immediately snap frozen for baseline 
immunohistological measurements. Hemi-diaphragms were incubated in either 
Ringer’s (as a control) or mAbs (100 μg/ml) for 2 h at 32 oC, followed by 30 min at 4 
oC and 10 min at room temperature. mAb solutions were removed and retained, then 
preparations rinsed in Ringer’s.  
Normal human serum (NHS) from a single donor stock was diluted to 40% in 
Ringer’s, and added as a source of complement. After 1 h at room temperature, NHS 
was rinsed off and the diaphragm tissue snap-frozen before being processed for 
analysis. 
 
Ex vivo electrophysiology at the NMJ 
Left and right hemi-diaphragms were dissected with their phrenic nerve attached and 
mounted in standard Ringer’s medium (as before) at room temperature. mAbs and 







Intracellular recordings of MEPPs at the NMJ were made from muscle fibres at room 
temperature (20-22 °C) using a glass micro-electrode (10-20 MΩ, filled with 3 M 
KCl) connected to a Geneclamp 500B (Axon Instruments/Molecular devices) for 
amplifying and filtering (1 Hz high-pass and 10 kHz low-pass) of the signal. The 
signal was digitized using a Digidata 1322A interface (Axon Instruments/Molecular 
Devices) using Mini Analysis 6.0.3 (Synaptosoft). 
Electrophysiological data is presented as group mean ± SEM of the mean muscle 
values calculated from the mean NMJ values. At least 10 NMJs were sampled per 
muscle per experimental condition. 
 
Microscopy  
For quantification of immunofluorescence over the NMJ, each experimental repeat (n 
of 3 animals/experiments for statistical analysis) was stained in a separate staining 
run, and at least 120 NMJs were imaged using constant acquisition settings for each 
marker. Dual colour images were acquired with a Zeiss LSM 5 Pascal microscope 
(Carl Zeiss). All samples were analysed observer-blinded.  Semi-quantification was 
based on the αBTx-TRITC signal to define the NMJ, and was done with Scion Image 
analysis software (Scion Corporation), either by analysing the percentage of 
immunofluorescence over the NMJ (as previously described, (O’Hanlon et al., 2001)) 
or analysing the intensity of fluorescence over the NMJ. For illustrative images of 
whole mount triangularis sternae, 3D reconstructions were generated from z-stacks 
using the software package Voxx-2 (http://www.nephrology.iupui.edu/imaging/voxx). 
 
Membrane treatments 
For ex-vivo neuromuscular preparations, 1-5 units/ml of Neuraminidase (Clostridium 
perfringens, Sigma) was applied to tissue for 1-1.5 h at 32 oC. The enzyme was rinsed 
off and tissues incubated in mAb and/or complement as already described.  For CTB 
pre-incubation of tissue prior to neuraminidase, unconjugated CTB (4 μg/ml) was 
applied to tissue for 1.5 h at 32 oC, and thoroughly rinsed off with Ringer’s prior to 
neuraminidase treatment. For GPI-anchored protein removal, PC12 cells were 
incubated at 37 oC for 1 h in 2 units/ml of PI-PLC (Sigma-Aldrich). Ex vivo 
neuromuscular preparations were treated for 1.5 h at 32 oC in 3.5 units of PI-PLC. For 
cholesterol depletion, 5 mM methyl-μ-cyclodextrin (Sigma-Aldrich) was incubated 
for 45 min at 37 oC. Cellular cholesterol was measured using Infinity Cholesterol 
reagent (Alpha Laboratories). 
 
GD1a/GM1 co-localization 
MOG35 (IgG2b) was primary labelled using a Zenon Mouse IgG Labelling Kit 
(Invitrogen) according to manufacturer’s instructions. Co-localization of DG2 and 
MOG35 was determined using the Metamorph (version 6.3.3; Molecular Devices 
Corp.) “correlation plot” application to compare the fluorescence in each pixel of the 
FITC and TRITC channels after subtracting background fluorescence. 
 
PC12 cell staining  
Cells were grown on poly-L-lysine (Sigma-Aldrich) coated coverslips, and mAbs 
applied (12.5 μg/ml in PBS) for 30 min at 4 oC. Following 3 rinses in PBS, mAbs 
were detected with FITC anti-mouse IgG (3.3 μg/ml) for 45 min at 4 oC.  Coverslips 
were rinsed again, fixed for 15 min in 4% PFA, and finally rinsed before mounting in 
Citiflour. For “Live/Dead staining” (Molecular Probes Inc.) a mixture of Calcein 
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for 30 min at 37 oC. Coverslips were rinsed in PBS, mounted in PBS and immediately 
imaged.  
 
Raft isolation, affinity purification and Western blotting 
Approximately 100 x 106 PC12 cells were suspended in either MOG35 or control 
mAb EG1 (anti-GD3, GT1a and GQ1b) at 15 μg/ml for 1 h at 4 oC. Cells were 
washed in chilled PBS, and kept on ice for subsequent steps. Cells were resuspended 
in 500 μl of 25 mM MES/150 mM NaCl, pH 6.5 (MBS), 0.5% Brij-96 (Sigma-
Aldrich) and protease inhibitors (Roche Applied Science). Following incubation at 4 
oC for 20 min, solubilised cells were homogenised with 10 strokes of a Dounce 
homogenizer. Of the lysate, 0.4 ml was mixed with 80% sucrose and overlaid 
successively with 2.2 ml of 30% sucrose and 1.4 ml of 5% sucrose. Following 
overnight centrifugation at 240,000 g, fraction 1 was collected by removing 390 μl 
from the top of the gradient and successive fractions through to fraction 12 were 
collected in this way. Protease inhibitors were added immediately upon fraction 
collection.  
Fractions 3-5 from MOG 35 incubated cells were pooled following retention of an 
equal aliquot from each (for Western blotting along with other fractions). This was 
also done for control mAb-incubated cells. Pooled samples were halved; half for 
affinity purification and half retained as starting material. For affinity purification, 
anti-mouse IgG-coated Dynabeads (Invitrogen) were incubated with the samples for 
30 min at 4 oC on a rotating mixer. Tubes were exposed to a magnet and the unbound 
material removed and retained. Beads were rinsed 4x in PBS, Novex loading buffer 
(Invitrogen) added to the rinsed beads and boiled to release the bound fractions for 
electrophoresis alongside unbound material and starting material. 
For electrophoresis, samples were reduced by addition of 25 mM dithiothreitol (DTT, 
Amersham) and run on Novex 16% Tricene gels (Invitrogen). Gels were blotted 
overnight in a transfer cell according to manufacturer’s instructions (BioRad) onto 
nitrocellulose membranes. Membranes were blocked in 5% non-fat milk in 
PBS/0.01% Tween-20 (PBST) and incubated in anti-ganglioside mAbs (20 μg/ml) or 
0.1 μg/ml horseradish-peroxidase conjugated CTB (HRP-CTB, Invitrogen). After 
rinsing, and if required, secondary antibody (HRP-conjugated anti-mouse IgG, Sigma) 
was added at 0.38 μg/ml in 1% non-fat milk/PBST. ECL (Amersham) was used to 
develop the membranes.  Fractions 1-12 were also subject to Western blotting to 
confirm success of the raft isolation using antibodies against flotillin (BD 
Biosciences), SNAP 25 (Chamberlain et al., 2001) and transferrin receptor 
(Invitrogen), all at 10 μg/ml. 
 
Immunoassays 
Gangliosides were purchased from Sigma Chemicals or Accurate Chemical and 
Scientific. ELISA was performed as previously described (Willison et al., 1999). In 
brief, Immunolon 2HB plates (Thermo) were coated with 100 µl of ganglioside (2 
µg/ml) diluted in methanol. To create ganglioside complexes, a 50:50 (v/v) mixture of 
the two component gangliosides in methanol was sonicated for 3 min. A volume of 
100 µl of this solution, (containing 100 ng of each ganglioside) was then applied to 
the appropriate wells. Control wells were coated with methanol alone. The average 
OD reading from control wells was subtracted from all other wells to correct for 
background. The mAbs DG1 and DG2, used at their GM1 half maximal binding 
concentrations of 0.5 µg/ml and 0.4µg/ml respectively, and the appropriate secondary 










diluted in 1% BSA (bovine serum albumin). The assay was conducted at 4 ºC. For the 
PVDF glycoarray, gangliosides and ganglioside complexes (100 µg/ml) were 
prepared as described for ELISA. PVDF (polyvinylidene difluoride) membrane on 
glass slides was spotted (100 nl per spot) with each target ganglioside or ganglioside 
complex in duplicate at predefined locations on each membrane using an automated 
TLC sampler (Camag) as previously described (Kanter et al., 2006). Membranes were 
blocked with 2% BSA, and then probed with the same primary (1 µg/ml) and 
secondary antibodies (diluted 1/30000) as for ELISA. Chemiluminescent detection 
was performed using ECL plus (Amersham). Digitised film images were analysed and 
quantified by the array analysis component of ImageQuant TL software (Amersham). 
 
Campylobacter  jejuni 
Bacteria were cultured on Skirrow agar medium (E & O Laboratories) and maintained 
under microaerophilic conditions. For inactivation, bacteria were suspended in PBS 
and placed in a UV crosslinker for 30 min or suspended in 4% PFA for 25 min. 
 
FACS analysis 
For FACS analysis, anti-ganglioside mAbs were used at 10 μg/ml, CTB-FITC at 1 
μg/ml and Thy-1 (CD90, AbCam) at 7.8 μg/ml in PBS. Secondary antibodies (anti-
mouse IgG-FITC) were used at 3.3 μg/ml, and cells were rinsed by pelleting in PBS. 
FACS analysis was performed using a FACScan flow cytometer (Becton Dickinson). 
 
 
mAb Isotype Immunogen                Half maximal binding
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A Half-maximal binding values represent the reciprocal of the antibody concentration (in mg/ml) giving half maximal binding as 
determined by ELISA. B BiaCore analysis of antibody Fab fragments was used to determine the binding affinity (KD) of the 
antibodies to the shown ligands (Townson et al., 2007). C HS19 and 0:19 are the C. jejuni strains from which the LOS species 
were isolated and used to immunize GM2s-KO mice (Bowes et al., 2002). D Cloned from human patients with acute and chronic 
motor neuropathy (Paterson et al., 1995). 
 




The Mann-Whitney test was used for statistical analyses of non-parametric 
immunohistological data, otherwise, a one way analysis of variance was used to 
determine statistical significance, both employing a 5% level of significance.  Data 
are represented as box and whisker plots, with the horizontal line representing the 
median. One quarter of the data lying above the median, and one quarter of the data 
lying below the median are represented by the large box, and the vertical lines on 
either side show the remaining quarters of the data lying above and below the 
interquartile ranges. Outliers have not been shown for clarity, but were included in the 
statistical analysis. To assess whether binding to GM1 complexes was statistically 
different to GM1 alone on ELISA and PVDF array, General Linear Model ANOVA 
was used. Dunnett’s method was employed to maintain a family error rate of <0.05 
for multiple comparisons to the control level. Differences between DG1 and DG2 
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binding to each complex were assessed by the two sample t-test. Bonferroni’s 
correction was applied in view of the multiple comparisons being made, again to 
maintain a family error rate of <0.05. The normality of each data set was verified by 





Anti-GM1 binding characteristics of mouse and human mAbs  
The origin and properties of the anti-GM1 mouse mAbs DG1, DG2, anti-GD1b mAb 
MOG1, anti-GD1a mAb MOG35, and human anti-GM1 mAbs SM1 and DO1 
(derived from motor neuropathy patients) are shown in Table 3.2. By ELISA, both 
DG1 and DG2 react with GM1 with very similar half maximal binding values (0.5 
and 0.4 μg/ml respectively) as previously reported (Townson et al., 2007). Screening 
by ELISA against a panel of gangliosides (GM1, GM2, GM3, GD1a, GD1b, GT1a, 
GT1b, GQ1b, GD2, GD3, GA1) has demonstrated that DG1 only binds GM1, 
suggesting a binding epitope unique to GM1 that includes the internal sialic acid, 
whereas DG2 binds GM1, GA1, and more weakly to GD1b, suggesting the epitope 
principally comprises the non-reducing galactose-β 1-3 N-acetylgalactosamine 
[Gal(β1-3)GalNAc] moiety common to the 3 glycolipids. Supplemental figure 1 
shows details of relevant gangliosides and epitopes. Antibody sequencing has 
previously determined the variable region gene usage of DG1 and DG2 and 
established that they contain different immunoglobulin heavy and light chain gene 
rearrangements and thus have distinct clonal origins (Townson et al., 2007). Human 
mAb SM1 binds principally to GM1, and mAb DO1 binds to the Gal(β1-3)GalNAc 
moiety common to GM1, GA1 and GD1b.  
 
Both DG1 and DG2 bind to motor nerve terminals in frozen nerve-muscle tissue  
Prior to evaluating the ability of DG1 and DG2 to mediate any pathogenic effects on 
nerve, we first assessed the binding potency of DG1 and DG2 to NMJs in 
immunohistological analyses of unfixed frozen muscle-nerve preparation of 
diaphragm from WT, GD3synthase deficient (GD3s-KO) and GalNAc-transferase 
deficient (GM2s-KO) mice. The ganglioside composition of the glycosyltransferase 
deficient mice is shown in supplemental figure 1. These mice are used as they are 
powerful tools for analysing the relevance of specific ganglioside targets, with GM1 
being absent in GM2s-KO mice and overrepresented, along with GD1a and other a-
series gangliosides, in GD3s-KO mice as previously reported (Okada et al., 2002). 
Frozen muscle sections were immunostained with DG1 or DG2 or, as positive control, 
with cholera toxin B-subunit (CTB), a highly specific GM1 ligand (Merrit et al., 
1994). Fluorescence intensity and coverage of the NMJ area (defined by the area 
stained with fluorescent α-bungarotoxin [αBTx], labelling acetylcholine receptors at 
the NMJ) was quantitated. Under these conditions, all 3 ligands bound over nerve 
terminals in WT and GD3s-KO tissue (Figure 3.17). The intensity of DG1 and DG2 
immunostaining at NMJs was similar in GD3s-KO tissue (~100 arbitrary units, AU), 
but the level was somewhat lower for DG1 than DG2 in WT tissue. As expected, in 










Figure 3.17. Topical immunostaining of frozen diaphragm sections from WT, GD3s-KO (GD3s-/-) and GM2s-KO 
(GalNAcT-/-) mice. Fluorescence was quantified as either the area of the NMJ (stained with αBTx-TRITC) that is 
covered with by anti-GM1 ligand (i.e. FITC fluorescence), or as the intensity of the FITC signal overlying the 
NMJ. All ligands bound most abundantly at the GD3s-KO NMJ compared to the WT NMJ. * p<0.05, WT versus 
GD3s-KO. All images were acquired at x 40 magnification. Scale bars: 60μm. A. & B. CTB fluorescence is strong 
at the WT and GD3s-KO, but absent at the GM2s-KO NMJ. C. Examples of CTB binding at NMJs of each strain, 
taken under constant microscope settings to represent the quantifications shown in A and B. D. & E. Anti-GM1 
mAb DG1 stains both the WT and GD3s-KO, and is absent in the GM2s-KO NMJs. F. DG1 topical staining.  G. & 
H. DG2 binding profile is evident at WT and GD3s-KO, but absent at the GM2s-KO NMJs.  I. DG2 binding at the 










Figure 3.18. Pathophysiological effects of anti-GM1 antibodies in living nerve-muscle preparations ex vivo  
A. Reconstructed confocal images of triangularis sterni NMJs from GD3s-KO (GD3s-/-) mice, following ex vivo 
incubation in CTB, DG2 and DG1. For CTB and DG2, axonal staining is present along with staining of the 
parajunctional fibroblast. DG1 binding is undetectable.  
B. Electrophysiology in ex vivo hemi-diaphragm of WT and GD3s-KO mice. mAbs were applied, followed by a 
source of complement, and under such conditions only DG2 caused an increase in MEPP frequency of each strain. 
Con, control.  
C. DG1 effect in ex vivo hemi-diaphragm (of WT and GD3s-KO). Following ex vivo muscle nerve incubations in 
mAb (or Ringer’s medium alone [R] as control), tissue was snap-frozen and sectioned for quantitative analysis. 
Graphs show IgG, C3c and MAC deposition (quantified as the signal intensity over the NMJ). Neurofilament (NF) 
loss is quantified as area coverage over the NMJ. DG1 binding is undetectable in the WT NMJ, and only weakly 
present in the GD3s-KO NMJ under maximal detection settings. MAC and C3c deposition do not translate into NF 
loss.  
D. The experiment was performed as described for C., but with the mAb DG2. DG2 is detectable in WT and 
GD3s-KO NMJs and activates complement to cause a NF loss compared with Ringer's medium alone-incubated 
control tissue. For both C and D note that the Y axes have been adjusted for clarity. * p<0.05 compared with the 
Ringer's control. 







DG2 and DG1 have different capacities to bind to live mouse motor nerve 
terminals and to exert complement-mediated neuropathogenic effects  
We next examined motor nerve terminal binding and possible pathophysiological 
effects of DG1 and DG2 at living NMJs in dissected triangularis sternae and 
diaphragm nerve-muscle preparations maintained as live preparations in oxygenated 
Ringer’s medium. In positive control experiments conducted to demonstrate the 
presence and level of GM1 at nerve terminals, CTB bound strongly to both GD3s-KO 
(Figure 3.18A, left panel) and WT  (not shown) nerve terminals, with strong staining 
of the pre-synaptic axon of the NMJ.  Since GM1 is widely distributed throughout the 
body, albeit at low levels, staining is also seen elsewhere, including connective tissue 
and blood vessels; thus CTB staining over other GM1 bearing structures is also seen 
in the upper region of Figure 3.18A (left panel). DG2 (Figure 3.18A, middle panel) 
showed a similar staining pattern to CTB, with particularly pronounced staining in 
this image of the para-junctional fibroblast, an extralaminar cell that caps the NMJ 
and also bears the GM1 ligand (Court et al., 2008).  GM2s-KO nerve terminals and 
other structures were not stained under these conditions, as expected (data not shown). 
DG2 strongly bound to GD3s-KO NMJs (~150 arbitrary units) and to a lesser extent 
(20-50 arbitrary units) to WT NMJs (Figure 3.20D). Unexpectedly, and in marked 
contrast to DG2 and to the situation observed in frozen sections as described above, 
DG1 binding was undetectable at all living WT NMJs and bound only very weakly at 
GM1-rich GD3s-KO NMJs (undetectable at >50% of NMJ and only at <10 arbitrary 
units at the most strongly positive NMJs, Figure 3.18A, C). As expected, neither of 
the two mAbs bound at GM2s-KO NMJs (supplemental figure 2A). Thus, whereas 
both DG1 and DG2 are able to bind well to GM1 at NMJs in frozen muscle-nerve 
preparation sections, only DG2 is capable of binding GM1 at live NMJs in 
physiological preparations, indicating that the topographical conformation of GM1 
and/or adjacent molecules in the neuronal membrane is substantially different under 
these two conditions. 
In order to study the ability of bound anti-GM1 antibody at live NMJs to activate 
complement and induce neuropathological effects, we exposed DG1- and DG2-pre-
treated live nerve-muscle diaphragm to normal human serum (NHS; as a complement 
source) and electrophysiologically monitored the occurrence of miniature endplate 
potentials (MEPPs, the spontaneous uniquantal acetylcholine release at NMJs) with 
intracellular microelectrode measurement. In the presence of human serum, DG2-pre-
treated NMJs showed a dramatic rise in MEPP frequency in WT and GD3s-KO 
preparations (Figure 3.18B and supplemental figure 2B), which caused asynchronous 
twitching of muscle fibres which eventually subsided and was followed by complete 
synaptic “silence”. This resulted in paralysis by block of transmission at the NMJ as 
judged from the inability of the diaphragm muscle to contract following phrenic nerve 
stimulation. As expected, in view of the finding that DG1 lacks binding activity to 
live WT NMJs, no such NHS-induced electrophysiological effects were observed at 
DG1-pretreated preparations (Figure 3.18B and supplemental figure 2C). 
We screened for immunohistological evidence of antibody-mediated complement 
activation by assessing C3c and MAC deposition at NMJs (Figure 3.18C, D and 
supplemental figure 2). Both components were clearly deposited at GD3s-KO and 
WT nerve terminals in conjunction with DG2 binding, although with less intensity in 
WT. At DG1 pre-treated nerve terminals from GD3s-KO mice in which very low 
levels of DG1 antibody were deposited, only very low levels of C3c (median <5 
arbitrary units) and MAC (median <5 arbitrary units) were present. WT NMJs pre-
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deposition. We next examined the structural integrity of the motor nerve terminal after 
MAC formation at the presynaptic membrane by quantifying neurofilament staining. 
DG2 pre-treated NMJs from WT and GD3s-KO mice that showed MAC deposition 
also displayed neurofilament loss (Figure 3.20D), whereas the very low level of DG1-
dependent complement activation at GD3s-KO NMJs was insufficient to induce such 
loss (Figure 3.18C).  
Taken together, these results in living nerve-muscle preparations show that of the two 
anti-GM1 mAbs DG1 and DG2, only DG2 binds to motor nerve terminals and 
induces complement-mediated neuropathophysiological and structural effects at motor 
nerve terminals. Apparently, DG1 is inhibited from binding GM1, despite its 
abundant presence, by unknown factors in the local environment of the living 
neuronal membrane. The observed neuropathic effects of DG2 are identical to the 
complement-mediated effects we have seen previously for anti-GQ1b and anti-GD1a 
antibodies at NMJs (Goodfellow et al., 2005; Plomp et al., 1999; Goodyear et al., 





Figure 3.19. Reactivity of anti-GM1 mAbs DG1 and DG2 to ganglioside complexes containing GM1 in solid-
phase 
The ganglioside complex at each location is established by combining the row and column labels. Thus, 
coordinates 1,4 and 4,1 represent GM1/GD1a complex. Wells labelled x are negative controls (methanol only). A. 
ELISA. DG1 (left) and DG2 (right) both bind GM1 alone, with no difference in average OD. The binding of both 
antibodies to complexes of GM1 and GM2 or GD1a is reduced as compared with GM1 alone. No difference was 
observed with other combinations investigated (GM1:GM3, GM1:GD1b and GM1:GD3). DG1 binding to 
complexes GM1/GM2 and GM1/GD1a was less than that of DG2. Mean results ± SEM from 3 experiments are 
shown. B. PVDF glycoarrays. DG1 was the primary antibody on the left membrane, DG2 on the right. Mean 
results ± SEM for 3 experiments are shown. No significant difference in GM1 binding was observed for the two 
antibodies. DG1 binding to GM1 complexes was significantly reduced compared to GM1 alone (p>0.05, 
significance level for these comparisons are not indicated in graph). DG2 binding GM1 complexes was marginally 
different compared with GM1 alone, but significant for GM1/GM2 and GM1/GD1a. The inhibitory effect of 
complexes on antibody binding is greater for DG1 than for DG2. The average absolute reduction in signal intensity 
for GM1/GD1a complex, compared to GM1 alone, is 75.1% for DG1 and 18.2% for DG2 (p<0.05). Error bars 








Figure 3.20. Effect of neuraminidase treatment on anti-GM1 antibody binding and pathogenic activity  
A. Reconstructed confocal images of DG1 binding at ex vivo GD3s-KO triangularis sterni NMJs. Left: DG1 
binding in living tissue is undetectable at the NMJ (stained with αBTx-TRITC).  Right: DG1 binding (FITC) 
following neuraminidase treatment of tissue. DG1 binding overlies the NMJ, and is co-localized with the axonal 
NF staining (Cy5), suggesting DG1 is binding to the presynaptic aspect (the axon terminal).  B. Ex vivo GD3s-KO 
hemi-diaphragm preparations, as described in Figure 3.180. Neuraminidase (N’ase) treatment of tissue prior to 
incubation with DG1 enabled DG1 to bind the NMJ (as shown by IgG deposition), fix complement, and cause a 
neurofilament (NF) loss. * p<0.05 compared with control tissue incubated in Ringer’s (minus neuraminidase) 
followed by DG1. C. Electrophysiology. DG1 and NHS as a source of complement caused a massive increase in 
MEPP frequency in the ex vivo GD3s-KO NMJ only when applied to neuraminidase-pretreated tissue. Scale bars: 
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The nerve terminal ligand for DG1 and DG2, and the immunopathological target 
for DG2 in live membranes is GM1 
The absence of nerve terminal staining in GM2s-KO tissue with CTB, DG1 or DG2 
(Figure 3.17) demonstrates that any potential ganglioside cross-reactivity of these 
GM1 ligands should only occur with the complex ganglioside series that are missing 
in GM2s-KO mice (supplemental figure 1). However, in order to assess for certain 
whether DG1 and DG2 might be binding to any of these ganglioside antigens other 
than GM1 at the nerve terminal in either frozen or live tissue, we conducted blocking 
experiments using the GM1-specific, high affinity ligand, CTB (supplemental figure 
3A). In frozen tissue experiments, CTB pretreatment completely inhibited binding of 
DG1 and DG2 to GD3s-KO NMJs. Furthermore, CTB also inhibited DG2 binding in 
WT NMJs, excluding possible cross reactivity with Gal(β1-3)GalNAc bearing 
epitopes. We next demonstrated that DG2 (which binds GM1, GA1 and GD1b in 
ELISA) does not bind GD1b in the living neuronal membrane as follows. We first 
showed the presence of GD1b at NMJs by incubating tissues with an anti-GD1b 
monospecific antibody, MOG1 (Boffey et al., 2005), and observing intense 
immunohistochemical staining at motor nerve terminals of WT mice (but neither 
GM2s-KO nor GD3s-KO mice that both lack GD1b). MOG1 also induced associated 
complement deposition and structural injury, as determined by neurofilament loss 
(supplemental figure 3B). We then showed that MOG1 binding was unaffected by 
CTB blockade (supplemental figure 3C). These data therefore exclude the possibility 
that DG2 is binding GD1b in the living tissue. They thus demonstrate that the Gal(β1-
3)GalNAc epitope on GD1b is cryptically orientated for DG2 binding in vivo, whereas 
the MOG1-reactive GD1b epitope is available for MOG1 binding in vivo. Since GA1 
(asialo-GM1) is absent from the mammalian nervous system (Seyfried et al., 1996), 
this potential cross-reactive antigen is not relevant in this context and potential 
binding to Gal(β1-3)GalNAc-bearing glycoproteins is excluded by the absence of 
staining in GM2s-KO mice. Furthermore, and consistent with the complete blocking 
seen in frozen tissue sections, CTB pre-incubation of ex vivo muscle tissue from WT 
mice inhibits the complement mediated actions of DG2, evidenced by abolition of 
C3c and MAC depositions over the NMJ (supplemental figure 3D). Collectively, 
these data indicate that DG2 is only binding GM1 in nerve terminal membranes in 
vivo. It should also be noted that the binding of DG2 to GD1b in ELISA is very weak, 
(half maximal binding, 2 x 102, see Table 3.2), further indicating that it is unlikely to 
bind avidly to GD1b in membranes. 
 
Inhibitory interactions between GM1 and adjacent gangliosides form under 
solid-phase conditions 
We speculated that the inability of DG1 to bind GM1 in the living plasma membrane 
was due to a masking effect arising from cis interactions with adjacent gangliosides 
and that these were disrupted following the death of tissue and subsequent processing 
to frozen sections. Since GD3s-KO mice are only able to synthesise a-series 
gangliosides, the most abundantly expressed species being GM1 and GD1a, we 
concluded that the masking effect in this mouse strain was most likely due to a 
GM1/GD1a cis interaction, notwithstanding the possibility that other gangliosides 
(e.g. GM2, GM3) could mediate similar blocking function in membranes with other 
ganglioside compositions. To investigate the potential inhibitory interaction between 
GM1 and GD1a for DG1 binding, we first attempted to recapitulate the in vivo 
interaction in solid phase binding assays using ELISA and then using newly 







GM1:GD1a-coated at a 1:1 ratio by weight, DG1 was significantly inhibited and DG2 
partially inhibited from binding GM1 in the presence of GD1a (Figure 3.19A). Both 
monoclonal antibodies were used at their GM1 half maximal binding concentrations 
of 0.5 µg/ml and 0.4 µg/ml respectively. Furthermore, DG1 was significantly more 
impaired that DG2 from binding the GM1/GD1a complex. This inhibitory effect was 
not unique to GD1a, also occurring to significant extent with GM1:GM2 and a mild 
extent (not significant) with GM1/GD1b. In marked contrast, complexes of 
GM1/GM3 and GM1/GD3 did not produce any inhibitory effects on DG1 or DG2 
binding, excluding the possibility that non-specific displacement of GM1 by a second, 
non-reactive ganglioside is accounting for the lower signal seen for the inhibitory 
GM1/ganglioside complexes.  
When isolated GM1 was displayed on PVDF membranes as dot blots, there was no 
significant difference in the binding of DG1 and DG2 (Figure 3.19B). When GM1 
was complexed with a range of other gangliosides, DG1 was almost completely 
inhibited from binding GM1. In contrast, DG2 binding to GM1 was minimally 
affected, although the difference in binding did reach significance for GM1/GM2 and 
GM1/GD1a complexes (Figure 3.19B). Throughout these PVDF studies, the reduction 
in complex binding for DG1 was substantially and significantly greater than for DG2. 
Under the PVDF array and ELISA assay conditions used in this study, DG2 is not 
demonstrated to bind to GD1b because of the very low half-maximal binding value 
for the DG2/GD1b interaction. 
 
Inhibitory interactions between GM1 and GD1a are not present in C. jejuni LOS 
To investigate whether or not this inhibitory interaction between GM1 and GD1a was 
a ganglioside-specific phenomenon or might also occur in other situations when GM1 
and GD1a oligosaccharides were juxtaposed, we exploited the neuropathy-associated 
Campylobacter species that bear GM1 and GD1a mimics on their LOS (it should be 
noted that DG1 was cloned following immunization with LOS). A Penner O:19 
Campylobacter jejuni isolate bearing  both GM1 and GD1a mimics (50:50 ratio) in 
the core oligosaccharide was assessed for binding to DG1 (anti-GM1) and MOG35 
(anti-GD1a) mAbs and CTB by FACS, in comparison with a non-ganglioside 
mimicking O:3 C. jejuni strain. DG1 was able to bind well to both live and killed 
(ultraviolet light or paraformaldehyde) O:19 isolate, indicating that an inhibitory 
complex between the GM1 and GD1a mimicking moieties of LOS is not present 
(supplemental figure 4). MOG35 and CTB also bound well to the O:19 isolate, 
confirming the presence of both the GM1 and GD1a mimics, and no ligands bound 
the control O:3 isolate (data shown for CTB only). 
 
Access of DG1 to GM1 in the living membrane is prevented by a masking effect 
of GD1a 
Based on the above data, we considered that the inability of DG1 to bind GM1 on the 
living neuronal membrane was due to closely adjacent gangliosides, including GD1a, 
which might cis-interact with GM1 to create a masking effect. Using live nerve-
muscle tissue preparations from GD3s-KO mice (which highly overexpress GM1 and 
GD1a), we cleaved the terminal sialic acid from GD1a with neuraminidase treatment 
thereby converting GD1a to GM1, and subsequently assessed the live tissue for DG1 
binding (Figure 3.20). This pretreatment massively promoted DG1 binding at the 
NMJ (Figure 3.20A, B), which subsequently activated complement, as shown by C3c 
and MAC deposition (Figure 3.22B). It thereby induced the previously described 
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frequency, muscle fibre twitching, and paralysis, described above for DG2. This 
unmasking effect for DG1 was also evident in neuraminidase-treated tissue from WT 
C57Bl/6 and Balb/c mice (supplemental figure 5A).  
In control experiments, we verified that neuraminidase treatment was able to digest 
most of the GD1a present at motor nerve terminals as assessed by a substantial 
reduction in the binding of the anti-GD1a mAb, MOG35 after treatment, in 
comparison with strong binding before treatment (supplemental figure 5B). DG1 
binding following neuraminidase treatment was also completely blocked by pre-
incubation with CTB, indicating that binding of DG1 was GM1-specific 
(supplemental figure 5C). Since neuraminidase treatment creates de novo GM1 from 
GD1a, it is very likely that this de novo GM1 would also be capable of acting as a 
ligand for DG1. Such binding confounds (without contradicting) the conclusion that 
masked “native” GM1 is released from its cis inhibition with GD1a by neuraminidase 
treatment to become available for DG1 binding. In order to investigate the extent to 
which the DG1 binding was directed to de novo GM1 generated from GD1a (rather 
than the pre-existing, native GM1), we first blocked native GM1 in the tissue 
preparation with CTB and then treated the tissue with neuraminidase, followed by 
probing with DG1 (supplemental figure 5D). Under these conditions DG1 binding to 
CTB-pretreated tissue was greatly reduced compared with binding to CTB-untreated 
tissue, indicating that a proportion of DG1 binding was to native GM1, unmasked 
from GD1a by neuraminidase treatment. After neuraminidase incubation, DG2 bound 
equally to both CTB pre-treated and untreated tissue, indicating that abundant de novo 
GM1 produced from GD1a was available for DG2 binding. The relatively weak 
binding of DG1 in comparison to DG2 (supplemental figure 5D) to de novo GM1 (i.e. 
CTB-blocked, neuraminidase-treated tissue; supplemental figure 5D), suggests that 
not all the de novo GM1 is available for DG1 binding. One explanation for this would 
be that de novo GM1 might itself form inhibitory cis interactions with remaining a-
series gangliosides (e.g. GM2, GM3) in the plasma membrane of GD3s-KO mice, 
although this was not addressed experimentally beyond the solid-phase PVDF 
membrane data shown in Figure 3.19. 
 
GM1 and GD1a co-localize to form an inhibitory environment for DG1 antibody 
binding in living PC12 cells and in lipid rafts 
To investigate the molecular environment that might account for the masking effects 
of GD1a we used rat neuroendocrine PC12 cells which, in their undifferentiated state, 
express gangliosides including GM1 and GD1a (Townson et al., 2008). DG1 was 
entirely unable to bind GM1 in living PC12 cells, in contrast to strong binding with 
CTB, DG2 and the anti-GD1a mAb MOG35 (Figure 3.21), as predicted from the live 
nerve terminal findings. Neuraminidase treatment resulted in intense DG1 binding to 
PC12 cells with complete concomitant loss of MOG35 binding (Figure 3.21B) under 
conditions in which cell viability was maintained, as monitored by ethidium 
homodimer-1 staining (data not shown). In co-localization studies of GM1 and GD1a, 
performed by comparing the binding of the mAbs DG2 and MOG35, the pixel by 
pixel correlation coefficient was 0.96, indicating very close proximity at the light 
microscopy level (Figure 3.21C). These findings in PC12 cells indicate a similar 
PC12 membrane interaction between GM1 and GD1a similar to that occurring in the 
mouse motor nerve terminal membrane and thereby suggest that this cis-inhibitory 
behaviour may be common other plasma membranes. 
Since gangliosides are enriched in lipid rafts (Simons and Ikonen, 1997), we 







and GD1a that were inhibitory for DG1 binding. First we disrupted rafts in live PC12 
cells with the cholesterol-sequestering agent methyl-β-cyclodextrin to establish 
whether GM1 became available for DG1 binding. This was not observed; indeed a 
general attenuation of ligand binding was seen (supplemental figure 6A). We next 
considered that raft-localized (GPI-anchored) proteins might exert a masking effect on 
GM1 for DG1 binding and investigated this by cleaving them with 
phosphatidylinositol-specific PLC (PI-PLC). PI-PLC treatment enhanced DG2 and 
MOG35 binding, suggesting that GPI anchored proteins can exert a general and non-
specific masking effect on both GM1 and GD1a, but had no significant effect on DG1 
binding which remained negligible or absent (supplemental figure 6B). We also 
conducted the PI-PLC study at live NMJs and observed the same trend as seen in 
PC12 cells (supplemental figure 6C).  
In order to support a molecular interaction hypothesis between GM1 and GD1a, it 
would be necessary to show that they co-localize in the same raft environment. To 
investigate this, we incubated PC12 cells with the anti-GD1a mAb MOG35 and an 
irrelevant isotype control, EG1 (which reacts with GQ1b, GT1a and GD3 but does not 
bind to PC12 cells; data not shown) and examined GD1a affinity-purified raft 
fractions by Western blot for GM1 content (Figure 3.21D). This demonstrated that at 
least a proportion of GM1 was present in the GD1a-enriched raft compartment. In 
control studies, EG1-affinity purification of raft fractions did not isolate any raft 
material (as assessed by raft protein markers) or yield any GM1 or GD1a signal. The 
raft fraction containing GD1a and GM1 also contained the raft marker flotillin, 
whereas SNAP25 was undetectable, indicating that a heterogeneous population of 
rafts exist with respect to protein and ganglioside composition in PC12 cells. This 
















Figure 3.21. Localization of GM1 and GD1a to raft fractions in PC12 cells (next page). 
A. PC12 cell immunostaining (original magnification, x40). DG1 binding to PC12 cells (shown in phase contrast) 
is not detectable despite the presence of GM1, as shown by CTB staining of cells. Scale bars: 15 μm. B.  Effect of 
neuraminidase on DG1 and MOG35 binding to PC12 cells. Double staining reveals that control cells are positively 
stained with MOG35 (TRITC), with no binding of DG1 (FITC).  Following neuraminidase (N’dase) treatment, 
MOG35 staining is diminished alongside a concomitant increase in DG1 binding. Scale bars: 15 μm (images 
acquired at x40 magnification). C. GM1 and GD1a pixel-by-pixel co-localization. FITC and TRITC (anti-GM1 
and anti-GD1a respectively) images (x 63 magnification) from double-stained PC12 cells, with co-localization 
appearing as yellow overlap. Scale bar represents 15 μm. Plane by plane co-localization (linear scatter plot) shows 
strong co-localization. D. Western blot of raft immunoprecipitation based on MOG35 binding, allowing isolation 
of GD1a-positive rafts by anti-mouse IgG-coated beads. In irrelevant antibody-incubated cells, no rafts were 
isolated by anti-mouse IgG-coated beads. Bound sample was concentrated (x10) to amplify any potentially weak 
signal. In MOG35-incubated cells, a population of rafts was isolated by the beads. Isolated fractions contained the 
raft-associated protein flotillin, but not SNAP25, which was taken as evidence that the raft extraction procedure 
did not lead to coalescence of the heterogenous raft population. Bound fractions also contained both the light chain 
(LC) and heavy chain (HC) of the anti-GD1a antibody, and the isolated rafts were positive for both GM1 and 
















Figure 3.22. Binding and neuropathophysiological effects of human anti-GM1 mAbs SM1 and DO1  
A. Ex vivo hemi-diaphragm preparations from GD3s-KO mice, as described for Figure 3.18. SM1 only binds 
NMJs following neuraminidase treatment and then causes a complement-mediated neurofilament (NF) loss. B. The 
experiment was performed as described for A., but with DO1. C. Absence of SM1 staining at GD3s-KO 
triangularis sterni NMJs (left), and presence of staining when the tissue was pre-incubated in neuraminidase 
(N’dase; right).  D. Electrophysiological analysis of the effects of SM1 and DO1 at GD3s-KO hemi-diaphragm 
NMJs, as described in Figure 3.20 for mouse mAb DG1. Following neuraminidase treatment, both SM1 and DO1 
bind at NMJs and cause a complement-dependent increase in MEPP frequency.  
Scale bars: 20 μm. Error bars represent SEM for 3 experiments performed in triplicate.  
 
 
Human neuropathy-associated anti-GM1 mAbs also exert complement-mediated 
neuropathophysiological effects at the mouse motor nerve terminal, provided 
GM1 is unmasked 
In order to bring clinical relevance to the findings observed with mouse mAbs, we 
screened human anti-GM1 antibodies cloned from motor neuropathy cases for similar 
behaviour. Human anti-GM1 IgM antibodies SM1 and DO1 (Paterson et al., 1995) 
were examined for their binding and complement-mediated neuropathophysiological 
effects at the mouse NMJ and we assessed a possible inhibitory effect of interaction 
between GM1 and GD1a (Figure 3.22). Neither mAb bound to GD3s-KO motor nerve 
terminals, and consequently they did not induce complement deposition (C3c and 
MAC) or neurofilament loss, as assessed with immunohistochemistry, and did not 
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neuropathogenicity. However, following neuraminidase pre-treatment of the nerve-
muscle preparations, deposits of IgM were massively present. Consequently, the 
complement cascade was activated, as shown by C3 and MAC deposits, with resultant 
neurofilament loss and electrophysiological injury as manifested by an increased 





This study has two principle findings. First, we demonstrate that under specific 
conditions, both human and mouse anti-GM1 antibodies have potent complement 
activation-mediated neuropathogenic effects at mouse terminal motor axons, 
including electrophysiological and morphological injury, leading to block of synaptic 
transmission at the NMJ, thereby resulting in paralysis of the nerve-muscle 
preparation. Second, we discovered that GM1 ganglioside in living neuronal 
membranes is masked from binding certain classes of anti-GM1 autoantibody by an 
interaction with GD1a (and presumably other gangliosides) that is able to shield a 
critical domain of the oligosaccharide head group involved in antibody binding. 
Consequently, this masking prevented the neuropathophysiological effects of these 
anti-GM1 antibodies from occurring. These findings have major implications for our 
understanding of the pathogenic potential of anti-ganglioside antibodies in 
neuropathy, their use and relevance as autoimmune disease diagnostics, and as 
ganglioside detection reagents. The epitope masking effect of this interaction is not a 
feature concerning all anti-GM1 antibodies, but is dependent upon subtle features of 
the antibody-antigen interaction that confer these characteristics, and needs to be 
assessed for each antibody on a case by case basis. Importantly, our results 
demonstrate that the ability of mouse and human anti-GM1 antibodies to bind isolated 
GM1 in solid phase assays or in frozen tissue sections cannot be used to predict their 
pathogenic behaviour in vivo. Our findings are likely to account for the markedly 
discrepant effects of anti-GM1 antibodies observed in many previously published 
models. 
Anti-GM1 antibodies are mainly associated with the acute motor axonal variants of 
GBS and chronic multifocal motor neuropathies (Willison and Yuki, 2002) and our 
immunohistochemical and electrophysiological findings at motor nerve terminals may 
provide a neuropathophysiological explanation for a component of the paralytic 
symptoms in such patients. In support of this as a clinically relevant site, motor nerve 
terminal degeneration has been shown at NMJs in a motor point muscle biopsy of an 
acute motor axonal neuropathy variant GBS patient with anti-GM1 antibodies, while 
sural nerve biopsy was normal (Ho et al., 1997). The terminal portion of motor axons 
may be relatively vulnerable for autoimmune attack because it is not protected by a 
blood-nerve barrier, in contrast to more proximal parts of the axon. GM1 is also 
present at nodes of Ranvier throughout the length of the nerve. Our results certainly 
do not exclude anti-GM1 binding and complement-mediated neuropathogenic effects 
at the more proximal parts of the axon, as has been observed in a rabbit neuropathy 
model (Susuki et al., 2003). 
The complement-mediated pathogenic effects of anti-GM1 mAbs at the NMJ shown 
here are identical to those observed by us in earlier (ex vivo and in vivo) mouse studies 







al., 1999; Halstead et al., 2004; O’Hanlon et al., 2001). Furthermore, anti-GD1a 
antibodies produce these effects, provided the density of GD1a is high, as in neuronal 
membranes of GD3s-KO mice (Goodfellow et al., 2005). Thus, this 
neuropathophysiological effect at murine NMJs is a common feature of certain classes 
of anti-GM1, -GD1b, -GQ1b and -GD1a antibodies. The heterogeneous distribution of 
clinical effects observed in patients with these anti-ganglioside antibody specificities 
does not correlate with the common paralytic effect of these antibodies at mouse 
NMJs. It is thus likely that regional differences in ganglioside expression, co-
expression and density in different neural and glial membranes from different 
anatomical regions in different species are critical determining factors.  
The differences in binding and pathogenic properties of individual anti-glycolipid 
antibodies may in part be attributable to differences in their affinity or avidity, in 
addition to their precise specificity. If the affinity of an antibody is high enough to 
compete effectively for a critical oligosccharide domain that may otherwise be 
masked by complex formation with a cis-interacting glycolipid, then the 
pathophysiological consequence of any complex formation might be annulled. 
Whether this range of affinities can be achieved for anti-glycolipid antibodies is 
unknown. However, in the case of the widely used high-affinity GM1 ligand CTB, the 
affinity for GM1 is reported as being in the 10-10 to 10-12  M range (Kuziemko et al., 
1996), which is 104- to 106-fold higher than the mAb DG1, used in the current study. 
Structural studies have demonstrated that CTB binds GM1 through a 2-fingered pinch 
interaction involving the nonreducing terminal galactose epitope of GM1 and the 
internal sialic acid, the latter being masked in our complex formation model 
(Kuziemko et al., 1996). DG1 also requires the presence of this internal sialic acid for 
binding to GM1. The implication is therefore that the very high affinity of CTB for 
GM1 is sufficient to disrupt an inhibitory complex that disguises the sialic acid from 
its binding domain on the toxin. In contrast, the affinity of DG1 for GM1 is 
substantially lower than CTB which most likely accounts for DG1’s inability to 
compete effectively for the cryptic sialic acid. Thus affinity may be a relevant factor 
in disrupting glycolipid-glycolipid complex interactions to allow ligand binding in 
certain situations.  The affinities of DG2 and DG1 for GM1 and GA1 were within 
fivefold of each other and the half maximal binding values for GM1 were very 
similar, yet they were completely polarized in terms of their pathogenic potential. It is 
therefore improbable that a simple explanation of affinity or avidity differences, 
regardless of dependence upon any complex formation, is the critical factor 
influencing binding in the current setting, but more likely that the pathogenic 
differences are due to differences in the fine specificity of the 2 antibodies, 
specifically their dependence upon the internal sialic acid for binding. Other 
experimental evidence discussed below also strongly supports this view. 
Our study underscores the complexities surrounding the topographical organization of 
glycolipids in living membranes and how these relate to topography in other types of 
detection systems such as are used in laboratory immunoassays. Considerable effort is 
currently focused on achieving optimal platforms for assessing protein-glycan 
interactions and the issues surrounding complex formation need to be considered in 
this context (Paulson et al., 2006). The cryptic behaviour of glycolipid headgroups in 
the plasma membrane, as assessed by accessibility to antibodies is a long recognized 
phenomenon (Hakomori et al., 1968; Lloyd et al., 1992), but its structural basis has 
never been demonstrated experimentally. This behaviour may in part be dependent 
upon ganglioside organisation in lipid rafts. In this study, raft disruption with a 
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indicating that the interaction of GM1 and GD1a is not cholesterol-dependent, as we 
also observed by solid phase immunoassay. Rather, it appears to be an intrinsic 
property of the interacting ganglioside species, possibly localized in a 
glycosphingolipid signalling sub-domain (Iwabuchi et al., 1998). The ganglioside 
clustering property may be due to the glycosphingolipid hydroxyl groups acting as 
hydrogen bond donors, allowing side-by-side interactions within a microdomain 
(Hakomori, 2002). However, gangliosides require substantial surface area to host their 
oligosaccharide chain and its associated hydration water, inferring that complex 
headgroups such as GM1 and GD1a will have large space requirements in the 
membrane (Sonnino et al., 2007), the consequence of which is unknown in terms of 
influencing their cis-interaction.  
Our observations in the GD3s-KO mouse implicate GD1a as the ganglioside that 
masks GM1 because in this artificial context these are the two predominant 
gangliosides. Our data on WT mice and in solid-phase assays also strongly suggest 
that other gangliosides (but not necessarily all gangliosides) may be capable of 
mediating this masking effect. In the GD3s-KO mouse, the GM1 concentration is 
substantially higher than in wild-type mice, thereby adding support to the view that 
the failure of DG1 to bind sialidase-naive WT or GD3s-KO tissue cannot be simply 
ascribed to limited availability of GM1 ligand.  
The heterogeneity of ganglioside and protein content in lipid rafts means there will be 
a wide range of raft-associated molecules which could potentially interact with GM1 
or inhibit binding of anti-GM1 antibodies through steric hindrance. Our observation 
that cleavage of GPI anchored proteins resulted in increased DG2 and CTB binding 
suggests that these proteins have a general masking effect for GM1, although this was 
not the particular masking effect that prevented the binding of DG1, because that 
remained at the same low level. 
Anti-GM1 mAbs cloned from neuropathy patients were also masked from binding 
GM1 and therefore unable to bind nerve terminals in ex vivo nerve-muscle 
preparations in these studies. This indicates that the observations with the mouse 
monoclonal anti-GM1 antibody DG1 is likely to be clinically relevant in man. Further 
studies are needed to explore the diversity of anti-GM1 antibodies seen in different 
patient populations to determine the extent of diversity in the context of ganglioside-
interaction mediated inhibition. In recent experiments, we have identified anti-GM1 
positive neuropathy patient sera that are capable of inducing the 
neuropathophysiological effects at NMJs as observed here, but only after 
neuraminidase treatment (J.J. Plomp et al., unpublished results). This further shows 
that clinically relevant anti-GM1 antisera exists that only bind to unmasked GM1. 
Such human antibodies may only become clinically important in conditions where the 
topological organization of gangliosides is destabilized, as for instance during nerve 
regeneration and the mechanisms by which they may or may not induce 
immunopathology in normal nerve are currently unknown. In regenerating nerve 
fibres (following experimental transaction injury), it has been shown that growth 
cones have enhanced activity of a membrane sialidase that acts to reduce complex 
gangliosides into GM1 that may thereby render GM1 available for complex attenuated 
antibody binding. Targeted delivery of sialidase to experimental nerve lesions in the 
rat enhances axon outgrowth, and this may in part be a result of the increased level of 
GM1 in the regenerating axon (Yang et al., 2006).  In addition, the sialidase-mediated 
decrease of GD1a interrupts the neuronal adhesion of myelin-associated glycoprotein, 
which normally inhibits regeneration (Vyas et al., 2002), causing disinhibited axonal 







unmasking of cryptic GM1 could allow previously harmless DG1-like antibodies to 
bind to GM1 rich growth cones and therefore become pathogenic through their ability 
to impair regeneration. There is experimental evidence, at least for anti-GD1a 
antibodies, that anti-ganglioside antibodies may influence neuronal regeneration 
(Lehmann et al., 2007). The existence of anti-GM1 antibodies like DG1 that 
specifically bind regenerating neural tissue and cause complement-mediated injury 
would have significant clinical consequences in that it could be the start of recurrent 
cycles of axonal injury and regeneration. Therefore, rapid and persistent clearance of 
such antibodies should be an important therapeutic goal. 
It is possible that GM1 masking occurs by interaction with gangliosides other than 
GD1a. Indeed, in our control experiments the Gal(β1-3)GalNAc moiety of GD1b was 
apparently shielded from binding DG2, whereas MOG1 - which presumably binds at 
least in part the internal disialosyl structure of GD1b as it is GD1b monospecific - was 
able to bind GD1b. Studies showing neuropathic effects restricted to sensory ataxia 
due to mono-specific anti-GD1b antibodies in a rabbit model are consistent with this 
finding (Kusunoki et al., 1999), as are recent studies using human ataxic GBS sera 
(Kaida et al., 2008a). We did not explore further the nature of this antibody-binding 
inhibitory interaction of GD1b with other gangliosides.  
With regard to the induction of anti-GM1 antibodies by C. jejuni infection in GBS, 
our findings illuminate the protective role of antibody in microbial defence, as 
balanced against the development of autoimmune injury. Thus, DG1 is able to bind 
the GM1 mimic in LOS on live C. jejuni that bears also a GD1a mimic in a 50:50 
ratio, indicating that a masking interaction does not occur. This shows that DG1-like 
antibodies could be bactericidal without binding to neuronal GM1, and thus (at least 
initially) would not exert an autoimmune neuropathic effect. Furthermore, DG1-like-
producing B-cell clones do not recognize self-GM1 in living membranes. Therefore, 
breaking tolerance to GM1 might not be required in order to generate protective 
immunity against self-mimicking microbial molecules.  
We were able to reproduce a masking effect of GD1a and other gangliosides on GM1 
in immunoassays conducted either on polystyrene plates or PVDF membranes, 
recapitulating the discordant findings observed in living membranes between DG1 
and DG2. Interestingly, the inhibitory complexes between GM1 and GD1a form on 
both polystyrene and PVDF immobilization platforms and thus the molecular 
interactions between GM1 and other gangliosides must spontaneously form when they 
are admixed, in addition to being organized or disorganized in living or dead 
membranes, respectively. Furthermore, these solid phase immunoassays demonstrated 
that interaction is not unique to GM1 and GD1a but can also occur between GM1 and 
other gangliosides. In addition, they form important support for the conclusion drawn 
from our neuraminidase experiments in live tissues - that the enabling factor for DG1 
binding to the neuronal membrane under these conditions is an unmasking of pre-
existing GM1 by the removal of the external neuraminic acid of GD1a, as opposed to 
simply an increase in GM1 density by creation of de novo GM1 from GD1a. 
Based on these experimental findings, we conclude that the micro-heterogeneity of 
ganglioside binding by anti-GM1 antibodies substantially influences their 
neuropathogenic potential, and that the basis for these differences is likely due to 
subtle conformational arrangements within the membrane, leading to complexes of 
GM1 with other gangliosides that inhibit binding of some types of anti-GM1 
antibodies. These ganglioside interactions appear to be stably formed in living 
membranes, but are highly susceptible to disintegration (and thus epitope exposure) in 
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living and dead/disrupted membrane that underlie these properties are unknown and 
difficult to investigate at the molecular biophysical level. In solid-phase 
immunoassays, these gangliosides interactions are also able to form. Recent studies 
showed that complexes of two different gangliosides can form neo-epitopes that 
specifically bind certain neuropathy-associated antibodies which do not bind to the 
single ganglioside species (Willison, 2005; Kaida et al., 2004b; Kaida et al., 2006). 
Together with the data provided here this leads to the conclusion that ganglioside 
interaction may either enable or inhibit antibody binding to the neuronal membrane, 
or be neutral, depending of the type of circulating antibody. To describe these 3 
conditions, we propose the terms complex-enhanced, complex-attenuated, and 
complex-independent. In the light of these findings, we need to critically evaluate any 
individual antibody-ganglioside interaction detected by the wide range of techniques 
available in order to be able to interpret the neuropathogenic potency of such an 
interaction in the living neuronal membrane. 
 
 



























Gangliosides form a group of sphingolipids that is much enriched in neuronal 
membranes, especially at synapses including the presynaptic membrane of the 
neuromuscular synapse. Therefore, they have been hypothesized to play important 
roles in neuronal function and in particular in neurotransmission. In this thesis the 
physiological and pathophysiological roles of gangliosides have been studied. Firstly, 
it was examined directly whether they play an important role in the release of 
neurotransmitter from the motor nerve terminal by studying synaptic transmission at 
NMJs of several types of ganglioside-deficient mice. It was found that both at young 
and older age, neurotransmitter release was not drastically impaired when subsets of 
the ganglioside family were lacking in knockout mice. Using electrophysiological 
methods, only subtle changes could be detected. Secondly, synaptic effects of 
antibodies against the gangliosides were studied at NMJs in vitro; in particular of 
antibodies directed at GM1 and at specific ganglioside-complexes. It was shown that 
these antibodies were able to interfere with neurotransmitter release in such a manner 
that block of neuromuscular transmission resulted, causing muscle paralysis. These 
effects were completely complement-dependent. Thirdly, an in vivo paralytic mouse 
model for anti-GQ1b ganglioside-induced peripheral neuropathy was developed. 
Finally, newly developed complement inhibitors were tested in the in vitro and in vivo 
neuropathy models. They were found to successfully prevent the 
neuropathophysiological effect of anti-ganglioside antibodies. In the sections below 
each of these themes will be discussed.   
 
 
The role of gangliosides in NMJ neurotransmitter release 
 
Gangliosides are part of the large family of glyscosphingolipids, which also includes 
the lacto-, globo-, and neolactoseries of lipids. This diverse group of 
glycosphingolipids is essential in life: mice that cannot express any of them, through a 
disrupted cGlcT gene, which encodes for glucosylceramide synthase, or a disrupted 
Ugcg gene, encoding for lactosylceramide (see figure 1.9), already die in the 
embryonic phase (Allende and Proia, 2002; Jennemann et al., 2005). When expression 
of solely the gangliosides is impaired (downstream of lactosylceramide), mice are 
viable (Yamashita et al., 2005), which suggests that gangliosides are redundant for at 
least early developmental functions. It was found that gangliosides play a role in 
many physiological processes in the human body, some of which are specific 
neurological functions like maintenance of the nervous system and axonal 
regeneration (Yamashita et al., 2005; Ribeiro-Resende et al., 2007). Gangliosides are 
especially abundant in the presynaptic membrane and co-localize with the exocytotic 
machinery (Chamberlain et al., 2001; Lang et al., 2001), suggesting they play a role in 
transmitter release. This section focuses on the results from our studies on ganglioside 
functioning in neurotransmitter release as described in this thesis.  
 
Gangliosides and the NMJ 
Ando and colleagues (1998) reported that gangliosides can act as modulators of 
synaptic functions: exogenous addition of ganglioside GQ1b or GM1 enhanced ACh 
release upon stimulation in synaptosomes. It was also shown that the gangliosides are 
especially enriched in presynaptic membranes (Hansson et al., 1977; Ledeen et al., 
1993) and pathophysiological effects on neurotransmitter release (i.e. alterations in 
synaptic activity) induced by anti-ganglioside antibodies present at the NMJ, were 




shown in several functional studies (Santafé et al., 2008; Buchwald et al., 2007; 
Nakatani et al., 2007b; Nakatani et al., 2009;  Buchwald et al., 2002; Ortiz et al., 
2001; Roberts et al., 1994; Plomp et al., 1999; Goodyear et al., 1999). These 
observations suggest that gangliosides play a specific and possibly essential role in 
ACh release at the motor nerve terminal. In a previous study with mice lacking the 
complete set of complex gangliosides (GM2s-KO mice), the first attempt to elucidate 
electrophysiological effects from an altered ganglioside composition in the NMJ was 
performed (Bullens et al., 2002). It revealed only subtle changes in transmitter release 
properties, like a reduced transmitter release at 17 °C, but no (sub)clinical deficits 
could be found. Here, other types of knockout mice were used for examination of the 
role of gangliosides in the release of neurotransmitter in the NMJ, i.e. mice expressing 
only the O- and a-series (GD3s-KO mice), or solely GM3 (i.e. dKO mice that have 
impaired GD3synthase and GM2synthase genes; Figure 1.9). However, these studies 
did not reveal crucial importance of any single ganglioside for transmitter release in 
the various ganglioside profiles tested. Even when in vitro all sialic acids were 
removed (by treating dKO mouse diaphragms with the enzyme neuraminidase from 
Clostridium perfringens), no major changes in neurotransmitter release occurred. 
Thus, based on these results, gangliosides seem to have a modulating function in NMJ 
neurotransmitter release rather than a crucial influence. This is quite unexpected in 
view of the presence of such an elaborate system of gangliosides in the neuronal 
membrane, especially at synapses. This presence was clearly indicated in the 
experiments with anti-ganglioside antibody incubations (or injections in case of the in 
vivo model for MFS) by presynaptic binding of these antibodies, as directly shown 
with immunofluorescence microscopy, as well as indirectly by the neuropatho-
physiological effects observed in the electrophysiological studies. It might be, though, 
that the different gangliosides are well able to compensate each other’s functions, 
which makes it difficult to show an absolute requirement for gangliosides in 
transmitter release. But, while the experiments with disrupted GM3, the last 
remaining ganglioside at dKO NMJs, indeed showed some degree of such 
compensation, they also clearly demonstrated that gangliosides have no fundamental 
function in transmitter release. Therefore, it has to be concluded that, at least at the 
NMJ, gangliosides have a modest role in synaptic transmission.  
  
Subtle changes in high frequency neurotransmitter release due to alterations in 
ganglioside subset expression 
Although we did not encounter clinical impairment of NMJ transmitter release in the 
muscles of ganglioside knockout mice tested, we did find some subtle changes. In 
dKO NMJs at high frequency nerve stimulation an increase in the physiological 
rundown of ACh release was observed compared to the control mice. The extent of 
this phenomenon was modest, the steady state rundown-level being only 5-7% lower 
than in wildtype controls. This more pronounced rundown was most obvious at 
frequencies of 30-70 Hz and was not seen at 3 Hz. In dKO tissues lacking all 
gangliosides due to neuraminidase degradation of GM3, rundown became even more 
pronounced (~20% lower than was seen in wildtype controls). When studied in older 
mice, where possible maintenance functions of gangliosides might become more 
important, we also found extra rundown for GM2s-KO mice, but not for GD3s-KO 
mice (aged dKOs could not be tested due to early death of this strain). One factor in 
sustained transmitter release is the pool size of readily releasable synaptic vesicles. It 
seems unlikely, though, that this pool is influenced by gangliosides, since application 





indirect measure of pool size, for all genotypes tested. Since GD3s-KO NMJs did not 
show the pronounced transmitter release rundown effect, we hypothesized that the O- 
and a-series gangliosides might be involved in high frequency transmitter release. The 
evoked release of ACh is crucially dependent on Cav2.1 Ca
2+
-channels (Urbano et al., 
2008; Uchitel et al., 1992). Experimental results suggest that there is a relationship 
between gangliosides and these Ca
2+
-channels (Ortiz et al., 2001; Nakatani et al., 
2009) and it was also shown that addition of the a-series gangliosides increased 
evoked ACh release from synaptosomes (Tanaka et al., 1997). There might be a role 
in this activity for the sialic acid residues of the gangliosides that protrude into the 
extracellular space and can bind Ca
2+
 (Hayashi et al., 1984; Rahmann et al., 1990). 
The high affinity for Ca
2+
 may concentrate the ions in the vicinity of the Ca
2+
-
channels and facilitate the transport through the channels. These interactions might 
modulate Ca
2+
-dependent processes of synaptic transmission with an effect that is 
subtle, and only becomes apparent at intensive high frequency use of the synapse. 
 
Temperature stabilizing effects of gangliosides 
Gangliosides are hypothesized to have a role in thermal adaptation of neuronal 
membranes (Rahmann et al., 1998). It was shown in fish that the polarity (i.e. number 
of sialylated fractions) of the ganglioside composition is modified specifically in 
neuronal membranes after (long-term) thermal adaptation, whereas in liver and 
muscle, adaptations of other lipids were detected (e.g. cholesterol in muscle). This 
reasonably suggests that the Ca
2+
-binding property of the membrane is also 
thermosensitive, as pure sialic acid has the highest affinity for Ca
2+ 
(Rahmann et al., 
1998). Furthermore, GQ1b and GD1a were found to reduce ion channel-conductance 
in a thermosensitive manner as well, by affecting the fluidity of the membranes in the 
areas surrounding the channels (Kappel et al., 2000). Therefore, with the study of 
ganglioside functioning in transmitter release here, different bath temperatures were 
tested in order to explore the thermal influence on transmitter release in the presence 
of the different ganglioside subsets in the presynaptic membrane. It was already found 
in GM2s-KO mice that at 17 °C both evoked and spontaneous transmitter release 
were reduced, compared to wildtype controls at the same temperature (Bullens et al., 
2002). In this thesis we also encountered temperature-dependent alterations. In short: 
at 17 °C, NMJs in young GD3s-KO mice showed a significant increase in the amount 
of ACh that was released spontaneous or evoked, compared to wildtype. At 35 °C an 
increase was seen for evoked release only. This tendency of increased release of the 
amount of ACh was also observed in the aged GD3s-KO mice, though at all 
temperatures tested (17, 20, 25, 30, and 35 °C). Furthermore, there was a slight 
tendency of an increase in evoked ACh release (calculated as quantal content) with 
temperature in young dKO and GD3s-KO mice and at 35 °C the evoked release in 
GD3s-KO NMJs was even ~40% higher compared to wildtype NMJs. This feature 
was not observed in the aged mice that were measured. In aged GM2s-KO and GD3s-
KO NMJs, however, spontaneous ACh release (measured as MEPP frequency) was 
decreased compared to wildtype at 17 °C. These findings indeed indicate a 
temperature-dependent role for gangliosides in neurotransmitter release. But apart 
from the 40% increase in transmitter release at 35 °C in GD3s-KO NMJs, the effects 





In neuronal cells from GM2s-KO mice, lacking complex gangliosides, impaired Ca
2+
-
regulating properties were found (Wu et al., 2004). In this thesis, this role of 






-regulation was further explored. Mouse muscle-nerve 
preparations were exposed to low or high (non-physiological) Ca
2+
-concentrations in 
the bath-applied medium. Using these extreme conditions we tried to elucidate a 
possible Ca
2+
-dependent effect of gangliosides on neurotransmitter release at the 
NMJ. As expected, the evoked and spontaneous release of ACh was steeply 
dependent on the extracellular Ca
2+
-concentration. However, we did not observe 
differences in transmitter release parameters between the NMJs of the diverse 
ganglioside knockout mice, except for aged GD3s-KO mice NMJs. At 0.2 mM Ca
2+
-
concentration we found increased ACh release compared to wildtype and GM2s-KO 
NMJs. The Ca
2+
-buffering capacity of the progressively increased density of GM1 
ganglioside in the aged GD3s-KO mice might be responsible for this effect (Wu et al., 
2004; Wu et al., 2007; Okada et al., 2002; Handa et al., 2005). 
 
Alterations in transmitter release parameters in aged mice  
Neuronal ganglioside compositions vary throughout life and gangliosides appear to 
become increasingly important upon ageing (Svennerholm et al., 1989; Yamamoto et 
al., 2008). In this thesis two studies on neurotransmitter release parameters in 
ganglioside knockout mice are described, one of which performed in NMJs of mice at 
young age (6-13 weeks) and the other in NMJs of old mice (>9 months). When 
comparing the results of the two studies, we find age-related changes in 
neuromuscular transmission. First of all, we encountered lower amplitudes of both 
EPPs and MEPPs in the aged mice compared to young ones. This is not due to 
alterations in ganglioside composition, because it was also seen in young versus old 
wildtype controls. Most likely this is related to the fact that young mice have muscle 
fibres which are smaller in diameter and have a higher input resistance than the 
muscle fibres of old mice. MEPP amplitude is proportional to the muscle fibre 
resistance (Harris and Ribchester, 1979). The MEPP frequency however, did show an 
age- and ganglioside-related alteration. MEPP frequency in NMJs of aged GD3s-KO 
mice was 43% higher than in aged wildtype mice and on average 46% higher than in 
all the young mice, including the young GD3s-KO mouse. The GD3s-KO mice have 
the O- and a-series gangliosides upregulated in their membranes, one of which is 
GM1. GM1 has been shown to influence Ca
2+
-buffering and membrane flux and, 
being upregulated, this ganglioside may therefore account for the higher MEPP 
frequency (Wu et al., 2004; Wu et al., 2007). Also, gangliosides contain negatively 
charged sialic acid residues that contribute to the membrane surface charge. In the 
vicinity of Ca
2+
-channels, an increase in density of O- and a-series gangliosides in the 
presynaptic membrane may therefore directly influence the kinetics and function of 
these ion channels (Wang et al., 1999b; Ledeen and Wu, 2006a).  
Furthermore, at aged GD3s-KO NMJs we observed decreased rise times and 
halfwidths of both EPPs and MEPPs, not previously seen at NMJs of young GD3s-
KOs or any of the other ganglioside-deficient mice. A presynaptic explanation for 
these kinetic changes does not seem likely, as gangliosides were reported to lack 
effect on the synthesis of ACh (Tanaka et al., 1997). Rather, postsynaptic gangliosides 
might modulate the behaviour of ACh receptors on the muscle membrane. 
Gangliosides co-localize with these receptors (Pato et al., 2008; Marcheselli et al., 
1993) and in the membranes from Torpedo marmorata they were found to interact 
(Mantipragada et al., 2003). Alternatively, progressive postsynaptic a-series 
upregulation might have influenced the passive electrical characteristics of the muscle 
fibre membrane (i.e. capacitance and resistance). However, these parameters were not 





age in GD3s-KO mice (as may occur in muscle membranes alike in neuronal 
membranes), could lead to these kinetic alterations that were not visible in the young 
GD3s-KO mice or in any of the other genotypic mice. It is an interesting feature that 
deserves more study.   
 
 
Interpretation and extrapolation of mouse studies 
 
Differences in effects of ganglioside deficiencies in mice and humans 
For this thesis three types of ganglioside knockout mice were used: GM2s-KO mice, 
which lack all complex gangliosides, GD3s-KO mice, which only express the O- and 
a-series gangliosides, and the dKO mice that can only express ganglioside GM3. 
Whether the phenotypical features of these mice (as described in chapter 1) are due to 
the lack of particular gangliosides or to an overexpression of the remaining ones is not 
clear. Accumulation of ganglioside GD3, for example, can alter mitochondrial 
function and induce cell death in a caspase-dependent manner (De Maria et al., 1997), 
and also GM3 was found to be a modulator of in vivo neuronal cell death (Sohn et al., 
2006): overexpression of these gangliosides may account for (part of) the 
pathophysiological features that are seen in aged GM2s-KO mice. On the other hand, 
the pathophysiological phenotype of these mice may also be due to an impaired nerve 
maintenance function for which some of the complex gangliosides are required (Vyas 
et al., 2002; Yamashita et al., 2002; Cao et al., 2007; Yang et al., 1996). 
Simpson and colleagues (2004) identified a human autosomal recessive infantile-onset 
symptomatic epilepsy syndrome associated with developmental stagnation and 
blindness. Patients with this syndrome had a nonsense mutation in the SIAT9 gene, 
which results in the premature termination of the GM3synthase enzyme. Individuals 
indeed lacked GM3 and its biosynthetic derivatives, and had an increase in their 
plasma of lactocylceramide and its alternative derivatives. Primary cultures of skin 
fibroblasts of three patients homozygous for this mutation were established for 
research. The fibroblasts exhibited a large reduction (93%) in cellular ganglioside 
content, which was not compensated for by activation of an alternate pathway of 
ganglioside synthesis. In fibroblasts from GM3s-KO mice, however, compensation 
did occur: the O-gangliosides were found to be expressed in the fibroblasts, which do 
not normally express these gangliosides (Shevchuk et al., 2007; Liu et al., 2008). 
Unlike the patients described by Simpson and colleagues (2004), the GM3s-KO mice 
do not show seizure activity (Yamashita et al., 2003). However, mice that have a 
mutated SIAT8a gene (encoding GD3synthase) and a mutated Galgt1 gene (encoding 
for GM2synthase) do show susceptibility for lethal audiogenic seizures (depending on 
the strain) (Kawai et al., 2001), which is alike the epilepsy that is seen in humans with 
a deficit in the SIAT9 gene. It can be hypothesized that basically the function of the 
gangliosides is not different in mice from humans. However, a deficit in the 
ganglioside biosynthetic pathway apparently can be compensated for in mice and not 
in humans (as is seen in the cultured fibroblasts). This can account for (part of) the 
phenotypic differences. Until now no other human patients are described that lack 
subsets of gangliosides, therefore no further conclusions can be made on this issue. 
 
NMJ dysfunction in human GBS patients 
About half of the GBS patients and over 90% of the MFS patients were found to have 
anti-ganglioside antibodies in their acute phase serum. (Willison et al., 1993; Hafer-




Macko et al., 1996b; Lange et al., 2006; Van Doorn et al., 2008). Antibody titres are 
highest in the acute phase and decrease with clinical improvement, suggesting a 
pathogenic role. Several studies using single fibre electromyography or repetitive 
nerve stimulation in MFS patients suggest that the weakness of the ocular muscles is 
due to a presynaptic neuromuscular transmission defect, which was found to coincide 
with the elevated antibody titre of anti-QG1b in the patient’s serum (Lange et al., 
2006; Lo et al., 2004; Lo et al., 2006; Sartucci et al., 2005). This rightly fits with the 
pathological features in our mouse models, in which presynaptic binding of anti-
ganglioside antibodies at the mouse NMJ leads to impaired neuromuscular 
transmission and structural damage of the motor nerve terminal in a complement-
mediated fashion. To my knowledge there are no reports of motor endplate biopsies 
taken from MFS patients, in which complement deposition has been studied; in post 
mortem studies of GBS patients, however, the deposition of complement at the NMJ 
has been reported (Koski et al., 1987; Hafer-Macko et al., 1996a; Hafer-Macko et al., 
1996b) and it was also found that GBS patients have an elevated level of the 
complement components C3a and C5a in their cerebrospinal fluid (Hartung et al., 
1987). Therefore, the mechanism of action of the anti-ganglioside antibodies as seen 
in our in vitro and in vivo mouse models shows similarities to the human pathological 
situation in MFS and GBS. Yet, it should be noted that anti-ganglioside antibodies are 
not exclusively encountered at presynaptic nerve membranes, but were also found to 
bind gangliosides in the membranes of perisynaptic Schwann cells in mice (O’Hanlon 
et al., 2001) and in patients with the AMAN variant of GBS the target sites for 
antibodies were found to be the axolemma and the nodes of Ranvier (Hafer-Macko et 
al., 1996b). The more proximal nerve sites (including the nodes of Ranvier), however, 
showed little penetration and binding of antibodies in mice during a 6 h time window, 
most probably due to the protection of the blood nerve barrier (Paparounas et al., 
1999); this makes the NMJ, which lies outside the blood nerve barrier, a more suitable 
model site for studying the pathological mechanisms of GBS. 
 
The immune system 
When studying autoimmune neuropathies, also the immune system must be taken into 
account. Complement activity, as part of the innate immune system, differs between 
humans and other mammals, although there are many similar factors. It was reported 
that common laboratory mouse strains have much lower complement activity than 
humans (Rice, 1950; Ong and Mattes., 1989), and the anti-GQ1b IgM that we used in 
our in vivo mouse model for MFS was not able to activate the mouse complement, 
although this antibody was a very potent activator of the human complement. 
Important when using mouse models is the finding that also between mice strains the 
immune system functioning can differ. This was for example shown for antibody class 
switching of mature B cells that differed among three common strains of mice 
(Kaminsky and Stavnezer, 2007). Also, it was thought that BUB mice expressed 
complement that was far more active than was seen in other laboratory mice (although 
still not as active as in human) and three strains that were (recently) derived from the 
wild even had complement levels as high as rabbits and rats (Ong and Mattes, 1989; 
Ong et al., 1992). Adding to the complexity, more recently (Osmers et al., 2006) it 
was reported that complement activity in most mouse inbred strains is similar, but that 
the result depends on the type of assay that is used. For instance, BUB mouse serum 
shows increased performance in hemolytic assays compared to other strains, but no 
elevated activity in opsonization experiments using bacteria. Therefore it should be 





or the animal model that is used and that general conclusions about the relevance to 
human conditions are not easy to make.  
 
In vivo mouse model for MFS 
In this thesis we developed an in vivo mouse model for MFS that may be very useful 
in upcoming studies of newly developed complement inhibitors, neuroprotective 
agents or other experimental drugs aimed at limiting the nadir and/or facilitating 
recovery of the paralytic symptoms of GBS. In short, the model was generated as 
follows: the mouse received an intraperitoneal injection with a purified monoclonal 
anti-GQ1b ganglioside antibody. After an overnight incubation period, a second 
injection with normal human serum as a source of complement was given. After some 
hours (depending on the antibody dose) the mouse developed breathing problems and 
became lethargic. Breathing and behavioural parameters were recorded before and 
during the experiment. At the end of the experiment (~6 h after the source of 
complement was injected), the diaphragm with phrenic nerve attached was dissected 
and electrophysiological measurements were performed. While creating this model, 
several attempts were made to induce neuromuscular paralysis without adding normal 
human serum as heterologous complement source. However, we were not able to 
achieve this. Apparently the low activity of endogenous mouse complement prevented 
development of a deleterious effect, as explained above. Even the use of knockout 
mice that lacked particular complement regulation factors, facilitating complement 
activation on mouse self membranes, did not yield a paralytic model with a clear 
neuropathology. Therefore exogenous complement was inevitable in the current 
model. This raised questions about the relevance of the model, which also has some 
drawbacks since it involves an extra injection in the abdomen (for the complement 
addition) and the complement concentration in the abdomen at that point is rather high 
compared to other sites in the body, due to the localized injection of the complement. 
But it turned out that the addition of an exogenous source of human complement 
made the model very practical when testing compounds that specifically inhibit 
human complement factors such as the C5-inhibiting monoclonal antibody 
eculizumab. Therefore, the combined model of passive immunization with mouse 
monoclonal antibodies against the GQ1b ganglioside in combination with normal 
human serum as complement source forms a rather straightforward model for MFS 
that can be applied in future drug studies.  
 
Gangliosides and their native micro-environment 
Antibody binding 
The experimental work described in this thesis demonstrated an interesting 
discrepancy between the actions of anti-ganglioside antibodies in ELISA and in live 
neuronal tissue. The study on anti-GM1 antibodies showed that differences in affinity 
of patient sera or antibodies in ELISA tests were not well-predicting their effect at the 
mouse NMJ in live tissue. Apparently, complications due to ganglioside configuration 
in the living membrane exist. Gangliosides may interact with each other or with other 
membrane components of the lipid microdomains in which they are present 
(Hakomori, 2003). Like, for example, gangliosides and cholesterol co-localize in 
microdomains in the vicinity of the neurotransmitter release machinery (Simons and 
Ikonen, 1997). According to Cantu and colleagues (2009) gangliosides are likely to 
play their physical roles in a three-dimensional manner through curvature, 
metamorphism (i.e. displaying multiple space filling geometries), cooperativity and 
demixing (both in presence and absence of cholesterol). An interesting example of 




this is seen in a study by Terrell and colleagues (2008), who found that liposome 
membrane fluidity played a major role in cholera toxin B-subunit binding. GM1 is a 
natural ligand for the B-subunit, and after their binding, cholera toxin A subunit can 
enter the cell (being the biologically active protein). When liposomes were prepared 
with cholesterol added in, the binding ability decreased. Presumably, cholesterol 
would act to make the liposomes, which are quite rigid at room temperature, more 
fluidic. This increased fluidity of the membrane may affect the ability of GM1 to 
allow binding of cholera toxin. This example stresses the importance of the local 
membrane properties in determining the binding potency of ligands to gangliosides. 
Thus, it may well be that binding specificities of antibodies, as defined with ELISA 
assays, do not faithfully reflect the binding properties in vivo, because gangliosides in 
ELISA are not embedded in a biological membrane. Therefore, one need to be careful 
to draw a conclusion based on a single type of assay. On top of that, the accessibility 
of gangliosides may not only vary between assay-environment, but also between sites 
within the human body. While sensory and motor nerves express similar quantities of 
GD1a and GM1 (Gong et al., 2002), the AMAN-associated anti-GD1a/GM1 
antibodies only affect motor neurons. Lopez and colleagues (2008) studied the fine 
specificity of ganglioside orientation and exposure in the two nerve types and found a 
differential expression of a critical GD1a epitope for antibody binding. Also 
O’Hanlon and colleagues (1998) showed that immunoreactive epitopes for anti-GM1 
antibodies, are not confined to the motor system, but are ubiquitous within the human 
nervous system. They state that if anti-GM1 antibodies are central to the pathogenesis 
of AMAN, then “a simplistic present or absent approach to epitope distribution at 
clinically affected or unaffected sites is not sufficient to account for their effects”. In 
the experimental models used in this thesis, most studies were performed in mouse 
phrenic nerve-diaphragm preparations: following the above, it remains unclear 
whether findings can be directly applied to NMJs in other muscles. Ganglioside GQ1b 
appears to be prominently expressed in the motor nerve terminals of the mouse 
phrenic nerves, but this is not confirmed for human phrenic nerves. The breathing 
difficulties in the mouse model following anti-GQ1b antibody immunization may be 
exaggerated due to the intraperitoneal injection, maximally exposing the diaphragm. 
Breathing difficulties are not a general feature in MFS patients (Mori et al., 2001). 
However, another study (Kaida et al., 2004a) suggests that GBS patients with anti-
GQ1b antibodies more often require mechanical ventilation, although responsibility of 
a possible anti-GT1a antibody activity could not be excluded. Furthermore, in MFS 
patients with anti-GQ1b antibodies present in their serum no affected limb muscles 
were reported (Kuwabara et al., 2007); in the mouse model, however, we also found 
anti-GQ1b antibody binding at limb NMJs. So, pathological activity of anti-
ganglioside antibodies is likely determined by both the specificity of the ganglioside 
composition in the membrane and the interaction of these gangliosides with their 
surroundings.  
 
Acetylcholine release and recycling 
As mentioned above, gangliosides and cholesterol co-localize in membrane lipid rafts 
near the neurotransmitter release machinery. An important factor for ACh release at 
the NMJ might be found in the presence of cholesterol as a prominent component in 
the presynaptic membrane. Cholesterol has been proposed to function as a spatial 
organizer of synaptic vesicle recycling. Wasser and colleagues (2007) reported 
observations that suggest that synaptic cholesterol is a crucial component of the 





they state that proper maintenance of synaptic function requires tight regulation of 
cholesterol levels in the membrane. Removal of cholesterol is likely to increase 
membrane fluidity and this may promote vesicle fusion, as was seen at crayfish NMJs 
(Zamir and Charlton, 2006). It has been reported that cholesterol is regulated and 
metabolized in a manner that is entirely independent of the metabolism of complex 
gangliosides. However, in dKO mice small elevations of cholesterol levels were found 
(Li et al., 2008). Since cholesterol and gangliosides are present in the same lipid rafts, 
it might be possible that deletion of particular gangliosides interferes with cholesterol 
functioning at the presynaptic terminal. Therefore, if ganglioside deletion has an 
indirect effect on synaptic vesicle (re)cycling at the NMJ, long-duration stimulation 
protocols (lasting for minutes, rather than seconds, as studied in this thesis) might 
reveal such a putative role. 
 
Exogenous addition of gangliosides 
Another interesting point of study may be the effect of exogenous addition of specific 
gangliosides to the NMJ. The combination of murine ganglioside knockout tissue with 
the exogenous application of gangliosides should make it possible to obtain every 
single combination of gangliosides in the presynaptic membrane. Valaperta and 
colleagues (2007) reported that gangliosides added to culture medium under proper 
conditions are taken up by the cells and are inserted as monomers in the membrane 
bilayer, becoming virtually indistinguishable from the endogenous compounds. Thus, 
treatment with exogenous gangliosides is an efficient way to change the ganglioside 
content of the plasma membrane. Thereafter it would be even more interesting to 
obtain living mice with certain ganglioside compositions not only based on gene 
knockout, but also on addition of gangliosides via for example the food. It has already 
been shown that dietary gangliosides can change ganglioside compositions in brain 
cell membranes in living rats (Park et al., 2005). If there is a particular combination of 
gangliosides that induces vulnerability for certain types of GBS, such a manipulation 
of ganglioside expression might be a way to reveal this. However caution must be 
taken as there might need to be drawn a distinction “between intrinsic functions of 
gangliosides as naturally expressed by the cell, and activities created by application of 
exogenous ganglioside(s) that may or may not reflect the natural function” (Ledeen 
and Wu, 2002). This can be complex, as was for example shown by Wang and 
colleagues (2006), describing a feedback mechanism for sialic acid expression by the 
enzyme UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase 
(GNE). GNE catalyzes the rate limiting step in ganglioside sialic acid biosynthesis, 
but is itself regulated by gangliosides GM3 and GD3, which demonstrates a 
reciprocating feedback mechanism where gangliosides regulate an upstream 
biosynthetic enzyme. And as it turned out, also exogenous GM3 and GD3 were able 
to change the expression of GNE, meaning that addition of gangliosides can lead to 





Complement inhibition in neuropathies 
Current treatment of GBS is not optimal yet. For one part this is because the aetiology 
of the disease is not completely elucidated and for another part because the onset of 
the disease is so acute. Generally, this acute phase is followed by a long recovery 




period. To make this period shorter and easier, accurate action already in the acute 
phase is required. It is likely that the complement cascade is involved in GBS 
neuropathy (Hartung et al., 1987; Halstead et al., 2004). Post mortem studies of fatal 
cases of AMAN and AIDP revealed activation and binding of complement at motor 
nerves (Hafer-Macko et al., 1996a; Hafer-Macko et al., 1996b), and cytotoxicity 
assays demonstrated that neuronal cell lysis caused by serum from GBS patients is 
complement dependent (Zhang et al., 2004). In this thesis the mechanism of injury in 
experimental MFS/GBS is inhibited by the application of complement inhibitors: the 
monoclonal antibody eculizumab and the recombinant tick factor rEV576. When 
applied in the MFS mouse model, both therapeutics prevented splicing of component 
C5 and thereby the initial phase of the formation of membrane attack complex (MAC) 
as a final step in the complement cascade, which resulted in preservation of neuronal 
membrane integrity and neuromuscular transmission. Of outmost importance for these 
complement inhibitors to be effective in GBS patients will be administration early in 
the course of the disease. The deterioration in GBS happens within the first four 
weeks, when MAC is disintegrating nerve membranes and macrophages are attracted 
by the complement components, causing neuronal and glial injury, and nerves are 
degenerating (Hughes and Cornblath, 2005). When this deterioration phase comes to 
an end, no more injury will be initiated and regeneration will be the main process. 
This means that the effectiveness of the complement inhibitors will most probably be 
highest in the initial phase. Obviously, when the complement activity is inhibited 
early, less neuronal damage will occur. Complete nerve protection will not be 
possible, because the clinical presentation of the disease will almost certainly be 
preceded by complement activation. However, swift reduction of severity of the peak 
symptoms of the disease and amelioration of nerve injury is very desirable, because 
this likely positively influences long-term outcome. The complement inhibitors are a 
promising class of therapeutics for autoimmune neuropathies like GBS, but also for 
other complement-mediated autoimmune diseases like systemic lupus erythematosus 
and myasthenia gravis. For paroxysmal nocturnal haemoglobinuria (PNH), a genetic 
disease in which complement-mediated lysis of erythrocytes occurs, the complement 
inhibitor eculizumab has already been proven effective in human clinical trials 
(Hillmen et al., 2004; Hillmen et al., 2006) and since 2007 it has been approved by the 
Food and Drug Administration in the USA for the treatment of PNH patients 
(Brodsky, 2009). Clinical trials for eculizumab with autoimmune neuropathy patients 
are underway. The next experimental step could be to define where in the time path of 
the development of symptoms in the MFS/GBS mouse model, application of 
complement inhibitors are most effective and supportive for (long-term) protection 
and/or regeneration of the affected nerves. 
 
Neuroprotective therapeutics 
In addition to the complement system there are more candidate therapeutic targets in 
anti-ganglioside antibody-mediated neuropathies. For example, inhibition of the 
cytoplasmic protease calpain was found to protect against axonal degeneration. 
Calpain is activated via Ca
2+
 and elevated levels can impair neuromuscular 
transmission by disrupting motor axons. Several studies in animal models have shown 
that treatment with calpain inhibitors in (experimental) neuropathies improves 
neuronal survival (O’Hanlon et al., 2003; Kieran and Greensmith, 2004; Groshong et 
al., 2007). To my knowledge, calpain inhibitors are not yet applied in human patients, 
but they have been applied safely and successfully in animal models of 





may be found in axonal protection by blocking the well-known inhibitory effects of 
myelin-associated glycoprotein (MAG) on neurite outgrowth in regenerating tissue, 
but also in exploitation of recently found beneficial effects of MAG, as were reported 
by Nguyen and colleagues (2009): in normal healthy tissue MAG supports axonal 
stability and survival by discouraging either longitudinal or collateral outgrowth, and 
by promoting maximal radial calibre of the axon. Enhancement of his feature could 
play a positive role when degeneration should be prevented. In an animal model for 
multiple sclerosis axonal loss was 52% more severe in mice that lacked MAG. This 
shows therapeutic possibilities that deserve further exploration.  
 
Anti-ganglioside complex antibodies in GBS and MFS patients 
It was first described by Kaida and colleagues (2004b) that not only single 
gangliosides can serve as antibody targets, but also complexes of two different types 
of gangliosides can together form a new, recognizable epitope for the anti-ganglioside 
antibodies. This implies that even in the ~40% of GBS patients in which no “classic” 
anti-ganglioside antibodies can be detected, antibodies against complexes might be 
present. Since these novel antibodies were reported, sera from patients have been 
screened and several antibodies against different complexes have been found. Anti-
GM1/GalNac-GD1a complex antibodies are considered to be a target antigen in pure 
motor forms of GBS (Kaida et al., 2008b). Antibodies against GD1a/GD1b and 
GD1b/GT1b complexes were found to be associated with severe GBS requiring 
artificial ventilation (Kusunoki et al., 2007). Also in MFS patients, antibodies against 
GM1/GQ1b and/or GD1a/GQ1b complexes were detected (Kaida et al., 2006; 
Kusunoki et al., 2007). In addition, antibodies against ganglioside complexes 
(GM1/GD1a and GQ1b/GD1a) were shown to cross-react with lipooligosaccharides-
epitopes on the membrane of C. jejuni (Kuijf et al., 2007), indicating again the 
possibility of molecular mimicry as the initiator of GBS. In this thesis we investigated 
17 GBS sera with anti-GM1/GD1a complex activity and 10 GBS sera with anti-
GM1/GQ1b complex activity, for their ability to induce complement-mediated 
neuropathophysiological effects at mouse NMJs. The effects of anti-GM1/GD1a sera 
were highly variable: after addition of a source of complement, 8 out of 17 sera 
induced increased spontaneous transmitter release. This effect was exclusively seen in 
NMJs of GD3s-KO mice (which have upregulated GM1 and GD1a), indicating the 
requirement of a high level of antigen density. The results were not unambiguous, 
though, because many sera were not antibody-complex specific, but also had some 
remaining activity against one or both of the individual gangliosides, which 
complicates analysis. Therefore, further study is required to unravel the exact 
neuropathic actions of this special antibody category. However, the discovery of these 
new antibodies may already be very helpful for aetiological understanding of GBS 
and it enhances the value of anti-ganglioside antibodies as diagnostic markers.  
 
Ganglioside profile as a predisposing factor for GBS 
It remains unclear why most people do not get GBS, but a small group does. In this 
thesis it is described that ganglioside knockout mice that have subsets of gangliosides 
upregulated are more vulnerable for antibodies directed against these particular 
gangliosides. For example, synapses from GD3s-KO mice did not exhibit 
pathophysiological effects when a particular anti-ganglioside antibody directed 
against GM1 was applied, but GD3s-KO mice synapses that were treated with 
neuraminidase (increasing the membrane density and absolute amount of GM1) 
showed enhanced vulnerability for development of an increase in spontaneous 




transmitter release and asynchronous muscle fibre twitching after incubation with this 
same antibody (in combination with a source of complement). This indicates that high 
density of antigenic ganglioside may form a predisposing factor in GBS. Hence, 
conditions that temporarily or locally result in increased ganglioside level may 
predispose to GBS. An example of variable ganglioside expression was encountered 
in a study by Kato and colleagues (2008) who found an increase of endogenous 
hippocampal GQ1b following several kindled-seizures in a mouse model for human 
temporal lobe epilepsy. This is an indication that ganglioside expression can 
temporarily be altered by factors other than normal growth and development, which 





On the basis of the synaptic studies performed at various ganglioside-deficient mice, it 
can be concluded that gangliosides are not crucially involved in neurotransmitter 
release at the NMJ. Rather, gangliosides seem to play a role in temperature- and use-
dependent fine-tuning of transmitter output. Given that the NMJ is considered a model 
synapse, it may well be that also at central synapses gangliosides only play marginal 
roles in synapse function. On the other hand, subtle changes may have profound 
effects on synaptic integration in central neurons and may thus considerably affect 
neuronal network function. The absence of an absolute role of gangliosides in 
synaptic transmission is surprising in view of the existence of such an elaborate 
ganglioside family, the enriched synaptic presence, and older studies showing 
synaptic effects of bath-applied gangliosides. It may be that gangliosides are more 
important in non-standard conditions, e.g. regeneration, extremely intense use, or in 
certain developmental stages. Or maybe the conclusion should be drawn that with all 
the present knowledge there seems to be no direct role for any of the gangliosides in 
the process of neurotransmitter release at the motor nerve terminal. In the end, 
gangliosides are not a universal feature of presynaptic motor nerve terminals, as 
Drosophila melanogaster has functional neuromuscular synapses, but does not 
express gangliosides (Roth et al., 1992; Chen et al., 2007a). 
This thesis furthermore describes the protective properties of complement C5 
inhibitors, eculizumab and rEV576, against the deleterious effects of anti-GQ1b 
antibodies and complement at the mouse NMJ. They were found to be very effective 
inhibitors of the pathophysiological effects in both the in vitro and the in vivo model 
for MFS. These studies indicate that complement inhibitors can restrict experimental 
neuropathophysiological damage, which suggests that these compounds may be 
clinically useful in limiting peak symptoms and speeding up recovery of GBS and 
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De rol van gangliosiden en anti-ganglioside 









Het syndroom van Guillain-Barré (GBS) is een acute, postinfectieuze neuropathie met 
een monofasisch verloop. De ziekte kent verscheidene klinische vormen, maar 
algemeen zijn de symptomen van symmetrische spierzwakte en afwezigheid van 
reflexen. Een van de mildere klinische varianten van GBS is het Miller Fisher 
syndroom, welk gekenmerkt wordt door ataxie, areflexie en verlamming of 
verzwakking van de externe oogspieren. In meer dan de helft van de GBS patiënten 
kan in het serum de aanwezigheid worden aangetoond van antistoffen tegen 
gangliosiden. Gangliosiden behoren tot de glycosphingolipiden en bevatten één of 
meer siaalzuren. Ze vormen een onderdeel van de buitenste laag van de 
celmembranen en komen voor in elk celtype. Echter, in de membranen van 
zenuwcellen en dan in het bijzonder in het presynaptische membraan aan het uiteinde 
van axonale zenuwceluitlopers zijn gangliosiden in verhoogde mate aanwezig. De 
grote familie van gangliosiden kent een specifieke stapsgewijze synthese, waarbij 
ceramide de basisstructuur vormt en door toevoeging van suikergroepen en siaalzuren 
de verschillende familieleden opgebouwd worden. Gangliosiden spelen een rol in cel-
cel herkenning en communicatie. Bovendien beïnvloeden ze allerlei processen in het 
gehele lichaam, waaronder apoptose en spermatogenese. Mede omdat gangliosiden zo 
geconcentreerd zijn in het presynaptische membraan, wordt verondersteld dat zij 
betrokken zijn in synaptische transmissie en dan in het bijzonder in het proces van 
neurotransmitter afgifte. In dit proefschrift is met behulp van onder andere 
elektrofysiologie de fysiologische rol die deze gangliosiden spelen in neurotransmitter 
afgifte onderzocht in neuromusculaire synapsen van muizen. Daarnaast zijn in deze 
synapsen ook de pathofysiologische effecten bestudeerd van antistoffen tegen deze 
gangliosiden zoals die worden gevonden in serum van GBS patiënten. 
 
In het eerste deel van dit proefschrift is gekeken naar de functie van gangliosiden in 
het proces van neurotransmitter afgifte in de neuromusculaire synaps van de muis. In 
hoofdstuk 2.1 zijn synapsen van twee verschillende ganglioside knock-out muizen 
met behulp van elektrofysiologische technieken onderzocht. Bij deze muizen 
ontbreekt een deel van de synthases die nodig zijn om de familie van gangliosiden op 
te bouwen en hierdoor is een subset van die familie afwezig. Bovendien zijn de 
gangliosiden die wel geproduceerd kunnen worden als gevolg van accumulatie of 
“opregulatie” in hogere concentratie aanwezig. De geteste muizen misten hetzij de b- 
en c-series van de gangliosiden, hetzij de b- en c-series en alle complexe gangliosiden 
waardoor ze alleen ganglioside GM3 in hun celmembranen hadden (zie Figuur 1.3). 
We vonden dat neuromusculaire synapsen van deze ganglioside mutanten alleen 
subtiele verschillen vertonen in de afgifte van neurotransmitter in vergelijking met 
wildtype controles, zoals een subklinisch lager steady-state niveau bij hoogfrequente 
zenuwstimulatie (dit is de plateaufase in transmitter afgifte die optreedt na een initiële 
inzakking). Dit suggereert dat gangliosiden wel degelijk een modulerende invloed 
hebben, maar dat er geen cruciale, onmisbare rol is die om de aanwezigheid van de 
complete familie van gangliosiden vraagt. Zelfs wanneer alleen het eenvoudige 
ganglioside GM3 nog aanwezig was, vertoonde de neurotransmitter afgifte slechts een 
geringe reductie ten opzichte van het wildtype en was de synaps nog steeds succesvol 
in het overbrengen van impulsen van zenuw- naar spiercel. Omdat deze experimenten 
uitgevoerd werden in relatief jonge muizen (jonger dan drie maanden) en gangliosiden 
mogelijk niet zozeer een rol spelen in de vroege (embryonale en postnatale) 
levensfase, maar wellicht belangrijker zijn voor onderhoud later in het leven, hebben 
we in hoofdstuk 2.2 synapsen van transgene muizen ouder dan negen maanden nader 






knock-out muizen functioneert op oudere leeftijd, wanneer herstel, onderhoud en 
regeneratie van belang zijn. Ook bij deze oude muizen was de afwezigheid van 
subsets van de familie (alle complexe gangliosiden of de b- en c-series gangliosiden) 
geen belemmering voor het functioneren van de synaps: opnieuw waren er alleen 
subtiele veranderingen meetbaar die geen gevolgen hadden voor de impulsoverdracht. 
Dit impliceert dat ofwel gangliosiden geen cruciale rol hebben in het proces van 
transmitter afgifte, ofwel dat de verschillende gangliosiden elkaars functie kunnen 
compenseren en dat het overblijven van bijvoorbeeld alleen ganglioside GM3 daarom 
voldoende is om de synaps werkend te houden. Om dit verder te onderzoeken hebben 
we, zoals beschreven in hoofdstuk 2.3, dit laatste ganglioside in een in vitro 
experiment “verwijderd” uit het weefsel van een transgene muis die alleen ganglioside 
GM3 tot expressie kon brengen. Met behulp van het enzym neuraminidase werd van 
dit laatste ganglioside het siaalzuur afgeknipt, waarmee het onderscheidende kenmerk 
van de ganglioside-familie verdwenen was. Hierbij vonden we wel enkele grotere 
veranderingen in de afgifte van neurotransmitter, zoals een steady-state niveau bij 
hoogfrequente zenuwstimulatie dat 20% lager lag dan in een wildtype synaps, 
waardoor de “compensatie theorie” enigszins lijkt te worden ondersteund. Maar nog 
steeds was dit effect onvoldoende om de impulstransmissie in de neuromusculaire 
synaps te blokkeren. Dit onderstreept nog eens dat gangliosiden geen essentiële en 
fundamentele rol spelen in de afgifte van neurotransmitter, zelfs niet op oudere 
leeftijd, maar dat ze wel enige modulerende invloed hebben.  
 
Het tweede deel van dit proefschrift focust op de neuropathofysiologische effecten 
van antistoffen tegen gangliosiden en de therapeutische werking van complement-
remmers hierop. Hoofdstuk 3.1 beschrijft het veronderstelde werkingsmechanisme 
van de antistoffen die na binding aan de gangliosiden in het celmembraan in staat zijn 
om complement te activeren. Deze reactie lijdt tot beschadiging van het 
presynaptische motor-zenuwuiteinde en heeft tot gevolg dat Ca
2+
-ionen vrij het 
uiteinde van de zenuw in kunnen diffunderen. Omdat Ca
2+
-ionen de afgifte van 
neurotransmitter stimuleren, is het resultaat een ongecontroleerde, massale afgifte van 
neurotransmitter wat uiteindelijk lijdt tot uitputting van de zenuw en verlamming van 
de spier door blokkade van neuromusculaire transmissie. Omdat dit neuropatho-
fysiologische proces complement afhankelijk is, lijkt het blokkeren van het 
complementsysteem een doeltreffende manier om in te grijpen en het schadelijke 
effect tot stilstand te brengen. In de hoofdstukken 3.2 en 3.3 zijn twee remmers van 
het complement systeem getest op hun effectiviteit om het presynaptische membraan 
te beschermen tegen de beschadigende effecten van de anti-ganglioside antistoffen. 
De eerste remmer is een gehumaniseerd muizenmonoklonaal antilichaam, 
eculizumab, en de tweede is een recombinant eiwit gebaseerd op een eiwit dat is 
geïsoleerd uit het speeksel van de zachte teek Ornithodoros moubata. Beide blokkers 
remmen de splitsing van complement component C5 in C5a en C5b. C5b is de eerste 
component van het membrane attack complex (MAC), dat samen met C6-C9 wordt 
gevormd. MAC is een moleculair complex dat gaten maakt in het celmembraan met 
lysis van de cel tot gevolg. Dit is een cruciale stap in het beschadigende effect dat 
optreedt als gevolg van de binding van antistoffen aan de gangliosiden. Door de 
formatie van MAC te voorkomen waren beide complement remmers in staat om de 
neuropathologische effecten van de antistoffen te remmen in zowel een in vitro als 
een in vivo muismodel voor het Miller Fisher syndroom. Deze stoffen zijn daarom 
interessante kandidaten om in neuropathie patiënten te testen. Naast effecten als 






we ook gekeken naar de verschillende typen antistoffen die deze immuunreactie op 
gang kunnen brengen (hoofdstuk 3.4). Enkele jaren geleden is ontdekt dat er niet 
alleen antistoffen bestaan die binden aan epitopen op de individuele gangliosiden, 
maar ook antistoffen die binden aan combinaties van twee verschillende gangliosiden, 
die kennelijk samen één, geheel nieuwe bindingsplaats vormen voor antistoffen (een 
ganglioside complex). In een oriënterende studie hebben wij een aantal 
serummonsters met anti-complex antilichamen getest op hun potentie om 
neuropathofysiologische effecten te veroorzaken in de neuromusculaire synaps van de 
muis, zoals eerder aangetoond met sera met antistoffen tegen individuele 
gangliosiden. Ongeveer de helft van de 27 onderzochte monsters had een 
beschadigend effect, blijkend uit elektrofysiologische experimenten. Echter, de mate 
waarin de monsters effecten sorteerden was zeer gevarieerd en bovendien werd de 
interpretatie bemoeilijkt door het feit dat veel sera ook in meer of mindere mate 
additionele antistoffen bevatten tegen individuele gangliosiden. De ontwikkeling van 
monoclonale antistoffen met monospecificiteit tegen ganglioside complexen zal 
verder onderzoek naar de exacte rol van anti-ganglioside complex antistoffen 
faciliteren.  
Tenslotte is in hoofdstuk 3.5 nader gekeken naar de condities waaronder anti-
ganglioside GM1 antistoffen in staat zijn om aan ganglioside GM1 te binden. Het is al 
eerder gebleken dat het niet alleen belangrijk is dat de gangliosiden aanwezig zijn in 
het membraan, maar ook in welke confirmatie ze aanwezig zijn en welke interacties 
ze aangegaan zijn met naburige moleculen. Deze studie laat zien dat een ganglioside 
in staat is om de bindingsplaats voor antistoffen bij een naburig GM1 ganglioside te 
maskeren. Het is afhankelijk van de structuur van de antistof of deze vervolgens nog 
kan binden of niet. Als gevolg van deze interactie tussen naburige gangliosiden kan de 
activiteit van verschillende antistoffen gericht tegen eenzelfde ganglioside drastisch 
variëren. Tevens werden in deze studie voor het eerst neuropathofysiologische 
effecten van (patiënten- en muizen-) anti-GM1 antistoffen op de neuromusculaire 
synaps aangetoond. 
 
Concluderend laten de studies in dit proefschrift zien dat gangliosiden niet essentieel 
lijken te zijn voor het functioneren van de neuromusculaire synaps met betrekking tot 
transmitter afgifte, maar wel een modulerende rol hebben. Daarnaast blijkt het 
blokkeren van het complement systeem met behulp van C5-remmers een effectieve 
methode om zenuwmembranen te beschermen tegen de beschadigende effecten van 
complement activatie na binding van anti-ganglioside antistoffen. In het laatste 
hoofdstuk worden deze en andere experimentele bevindingen in dit proefschrift 
bediscussieerd in het licht van de bestaande literatuur en de pathogenese en 






List of Abbreviations 
 
 
αBTx   α-bungarotoxin 
αLTx   α-latrotoxin 
ACh   acetylcholine 
AChR   acetylcholine receptor 
AIDP   acute inflammatory demyelinating polyradiculoneuropathy 
AMAN   acute motor axonal neuropathy 
AMSAN   acute motor-sensory neuropathy 
BBE   Bickerstaff’s brainstem encephalitis 
BSA   bovine serum albumin 
C   complement  
Cav1   voltage-gated calcium channel type 1 (L-type calcium channel) 
Cav2.1   voltage-gated calcium channel type 2.1 (P/Q-type calcium channel) 
CFP   cyan fluorescent protein 
C. jejuni   Campylobacter jejuni 
CIDP   chronic inflammatory demyelinating polyradiculoneuropathy 
CMV   cytamegalovirus 
CNS   central nervous system 
Crry   complement receptor-1 related gene/protein Y 
CTB   cholera toxin B-subunit 
DAF1   decay accelerating factor 1 (also: CD55) 
(d)KO   (double) knockout 
EAN   experimental autoimmune neuritis 
EC50   half maximal effective concentration 
EM   electron microscopy 
EPP   endplate potential 
EthD-1 / EthD-2  ethidium homodimer-1 / 2 
fH   Factor H 
GalNAc(-T)  β1,4-N-acetylgalactosaminyl(transferase) 
GBS   Guillain-Barré syndrome 
GD3synthase  α2,8sialyltransferase 
GFP   green fluorescent protein 
GM2synthase  see: GalNAc-T (also: GM2/GD2synthase) 
IgG / IgM  immunoglobulin type G / type M 
IVIg   intravenous immunoglobulin 
KDO   3-deoxy-D-manno-2-octulosonic acid 
LacCer   lactosylceramide 
LOS   lipooligosaccharide 
LPS   lipopolysaccharide 
(m)Ab   (monoclonal) antibody 
MAC   membrane attack complex; complement components C5b to C9 
MAG   myelin-associated glycoprotein 
MASP   MBL-associated serine protease 
MBL   mannose-binding lectin 
MEPP   miniature endplate potential 
MFS   Miller Fisher syndrome 
nAChR   nicotinic acetylcholine receptor 
NeuAc   N-acetylneuraminic acid 
NeuGc   N-glycoloyl-neuraminic acid  
NF   neurofilament 
NHS   normal human serum 
NMDA   N-methyl-D-asparaginezuur 
NMJ   neuromuscular junction 
PBS   phosphate-buffered saline 
PNS   peripheral nervous system 
pSC   perisynaptic Schwann cell 
PVDF   polyvinylidine difluoride 
RRP   readily releasable pool 
SNAP25   synaptosomal-associated protein of 25kDa 
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
VGCC   voltage-gated Ca2+ channel 
WT   wildtype 
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